

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
14 April 2005 (14.04.2005)

PCT

(10) International Publication Number
WO 2005/033100 A1

(51) International Patent Classification⁷: **C07D 405/04**,
C07H 15/00, C07D 205/08

(74) Agent: **CARRIERA, Andrea**; Isler & Pedrazzini AG,
Gotthardstrasse 53, Postfach 6940, CH-8023 Zürich (CH).

(21) International Application Number:
PCT/CH2004/000584

(22) International Filing Date:
15 September 2004 (15.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03405719.0 7 October 2003 (07.10.2003) EP

(71) Applicant (for all designated States except US): **LIPI-
DEON BIOTECHNOLOGY AG** [CH/CH]; Her-
mann-Hiltbrunner-Weg 25, CH-8713 Uerikon (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CARREIRA, Erick**
[US/CH]; Chapfstrasse 73, CH-8126 Zumikon (CH).
HAUSER, Helmut [AT/CH]; Hermann-Hiltbrunner-
weg 25, CH-8713 Uerikon (CH). **KVAERNO, Lisbet**
[DK/CH]; Kronenstrasse 37, App. 16, CH-8006 Zürich
(CH). **RITTER, Tobias** [DE/CH]; Neugasse 52, CH-8005
Zürich (CH). **WERDER, Moritz** [CH/CH]; Marktgas-
se 16, CH-5620 Bremgarten (CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: NOVEL HYPOCHOLESTEROLEMIC COMPOUNDS



(57) Abstract: The present invention relates to novel hypocholesterolemic compounds of formula (I) useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels as well as to pharmaceutical compositions comprising said compounds alone or in combination with other active agents.

Novel hypocholesterolemic compounds

The present invention relates to novel hypocholesterolemic compounds useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels as well as to pharmaceutical compositions comprising said compounds alone or in combination with other active agents.

Atherosclerotic coronary heart disease represents the major cause for death and cardiovascular morbidity in the western world. Risk factors for atherosclerotic coronary heart disease include hypertension, diabetes mellitus, family history, male gender, cigarette smoke as well as serum cholesterol. Elevated concentrations of serum cholesterol have been demonstrated by a number of clinical studies to be a major contributing factor in the development and progression of atherosclerosis, which is characterized by the formation of cholesterol-containing plaques in the aorta and lesser arteries.

In mammals, 1/3 of the serum cholesterol is derived from exogenous dietary sources which enters the body through absorption in the intestine and 2/3 of the serum cholesterol are derived through endogenous de novo synthesis in the liver involving a complex set of enzyme-catalyzed reactions and regulatory mechanisms.

Recently it has been shown that intestinal cholesterol absorption is an energy-independent, protein-mediated process (Hauser, H. et al, *Biochemistry* **1998**, *37*, 17843-17850; Schulthess, G. et al, *Biochemistry* **2000**, *39*, 12623-12631; Werder, M. et al, *Biochemistry* **2001**, *40*, 11643-11650) rather than a passive diffusion process. The proteins facilitating intestinal cholesterol absorption were identified as two brush border membrane-resident scavenger receptors (Hauser, H. et al, *Biochemistry* **1998**, *37*,

17843-17850; Werder, M. et al, *Biochemistry* **2001**, *40*, 11643-11650). Both *in vitro* and *in vivo* animal experiments confirmed the presence of these two scavenger receptors in the intestinal BBM and proved that they are responsible for the protein-mediated cholesterol uptake.

Various 2-azetidinone compounds have been reported as being useful in lowering cholesterol and/or in inhibiting the formation of cholesterol-containing lesions in mammalian arterial walls: For example WO 93/02048, WO 94/17038, WO 95/08532, PCT/US95/03196, U.S. Pat. No. 5,633,246 describe 2-azetidinone compounds with different substituents at the 3-position, and U.S. Pat. No. 5,756,470 discloses 2-azetidinones having varying substituents at the 4 position. Other azetidinone derivatives include for example elastase inhibitory substituted azetidinones disclosed in European Patent 199,630B1 and European Patent Application 337,549A1. The most prominent representative of these 2-azetidinones, Ezetimibe (also known under trade names ZetiaTM and Ezetrol[®]), has been in use as a cholesterol-lowering drug in monotherapy and in dual therapy combined with a statin. It is the first representative of the new class of cholesterol-lowering drugs that inhibit intestinal cholesterol absorption by targeting the two scavenger receptors in the intestinal brush border membrane described above.


However, it has been shown that the 2-azetidinones upon administration are readily absorbed and extensively metabolized into the pharmacologically active glucuronide of which over 95% remained in the intestinal wall upon direct administration as the glucuronide (van Heek, M. et al. *Br. J. Pharmacol.* **2000**, *129*, 1748-1754). In addition side effects such as allergic reactions including rash and angiodema have been reported.

Applicants have now discovered that the compounds of the present invention with the structural characteristics as depicted in

formula I and in particular formulas II and III are able to inhibit the protein-mediated process mentioned above by which cholesterol absorption is mediated, while overcoming the above described disadvantages of compounds known in the art. Thus the compounds of the present invention are particularly useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels.

In a first aspect, the present invention thus relates to novel hypocholesterolemic compounds of formula I, and in particular to compounds of formulas II and III having a four- or five-membered ring, respectively.

In one embodiment, the present invention is directed to a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof,



wherein

P represents $-N<$ or $-C=$,

X represents independently of each other $-CH_2-$, CR_1 (sp_2 -hybridised), O, $-NH-$, $=N-$, $-CO-$ or $-CS-$, wherein R_1 represents H or NR_2 , wherein R_2 represents H or lower alkyl, which optionally is linked to Z such that a bicyclic structure is formed;





n represents 1 or 2,

R_a represents H, lower alkyl, $-OR_3$, $-O(CO)R_3$, $-O(CO)OR_3$, $-O(CO)NR_3R_4$, $-NR_3R_4$, $-NR_3(CO)R_4$, $-COOR_3$, $-CONR_3R_4$, -

$\text{CH}=\text{CHCOOR}_3$, $-\text{CF}_3$, $-\text{CN}$, $-\text{NO}_2$, SO_3H , PO_3H or halogen, wherein R_3 and R_4 represent H or lower alkyl,

R_b represents H, OH, $-\text{OSO}_2\text{Me}$, $-\text{OSO}_2\text{W}$ wherein W represents optionally substituted aryl or heteroaryl, $-\text{OCO}(\text{CHOH})_2\text{COOR}_5$ wherein R_5 represents H or lower alkyl; or represents the formula $-\text{Sp}_3-\text{R}_6$,

wherein Sp_3 represents a covalent bond, $-\text{O}-$, $-\text{OCH}_2-$, $-\text{OSO}_2\text{CH}_2-$, $-\text{OSO}_2-$, $-\text{OSO}_2-(p)\text{C}_6\text{H}_4\text{O}-$ and R_6 represents one of carbohydrate structures A-D:

**A****B****C****D**

wherein

R_7 , R_8 , R_9 , R_{11} , R_{12} , R_{13} and R_{14} represent independently of each other H, lower alkyl, aryl(lower alkyl), $-\text{CO}$ -lower alkyl, $-\text{CO}$ -aryl, $-\text{SO}_3^-$ or $-\text{PO}_3^-$,

R_{10} represents $-\text{CH}_2\text{OR}_{16}$ or $-\text{COOR}_{17}$, and

R_{15} represents $-\text{CH}_2\text{OR}_{16}$, $-\text{COOR}_{17}$, $-\text{CH}_2\text{NH}_2$, $-\text{CH}_2\text{OPO}_3^-$ or $-\text{CH}_2\text{OSO}_3^-$, wherein R_{16} and R_{17} independently of each other represent H, lower alkyl, aryl(lower alkyl), $-\text{CO}$ -lower alkyl, $-\text{CO}$ -aryl, $-\text{SO}_3^-$ or $-\text{PO}_3^-$,

- Z represents optionally substituted aryl or heteroaryl,
- Sp₁ represents a spacer unit, such as a straight-chain or branched lower alkyl group $-(CH_2)_p-$, wherein p is from 2-6, which is unsubstituted, mono or poly-substituted by -OH, -OR₁₈, halogen or cyano group, wherein one or more -CH₂- groups may independently be replaced by -O-, -CO-, -CO-O-, -O-CO-, -NR₁₉-, -NR₁₉-CO-, -CO-NR₁₉-, -CH=CH-, -C≡C- and wherein R₁₈ and R₁₉ represent a hydrogen atom or lower alkyl;
- Sp₂ represents an optional spacer unit, such as a covalent bond or a straight-chain or branched lower alkyl group $-(CH_2)_q-$, wherein q is from 1-6, which is unsubstituted, mono or poly-substituted by -OH, -OR₂₀, halogen or cyano group, wherein one or more -CH₂- groups may independently be replaced by -O-, -CO-, -CO-O-, -O-CO-, -NR₂₁-, -NR₂₁-CO-, -CO-NR₂₁-, -CH=CH-, -C≡C- and wherein R₂₀ and R₂₁ represents a hydrogen atom or lower alkyl;


Y represents optionally substituted aryl or heteroaryl,

with the proviso, that if P = -N<, n=1, X = -CO- and Sp₂ represents a covalent bond, R₆ may not represent carbohydrate structures A or D for Sp₃ = -O- and R₆ may not represent carbohydrate B for Sp₃ = -OCH₂-.


Preferably, if P = -N<, n=1, X = -CO- and Sp₂ represents a covalent bond, R_b may not represent H or OH and Sp₃ may not represent a covalent bond, -O- or -OCH₂-.

In a preferred embodiment, the present invention is directed towards compounds of formula I wherein P = -N<, n = 1 and X = -CO-, -CS-, -CH₂- or -NH-.


Thus, the present invention is preferably directed towards compounds of formula IIa-d




IIa



IIb



IIc









IIId

or a pharmaceutically acceptable salt or solvate thereof,
wherein the groups R_a , R_b , Sp_1 , Sp_2 , Y and Z are as defined above.

In another preferred embodiment, the present invention is directed towards compounds of formula I wherein for $P = -N<$, $-(X)_n-$ represents $-OOC-$, $-COO-$, $-CONH-$, $-CH=N-$, and for $P = -C=$, $-(X)_n-$ represents $-NH-N=$ or $-O-N=$.



Thus, the present invention is directed towards compounds of formula IIIa-f:



or a pharmaceutically acceptable salt or solvate thereof,
wherein the groups R_a , R_b , SP_1 , SP_2 , Y and Z are as defined above.

In a further preferred embodiment, the present invention is directed towards compounds of formula I with $P = -N<$ where $-(X)_n-$ represents $-CH-C=NR-$ or $-CH-NH-CR-$ or wherein ring Z is coupled to $-(X)_n-$ to form bicyclic compounds.

Thus, the present invention is further directed towards compounds of formula IIIg-h:



R_a preferably represents H, lower alkyl, -OR₃, -NR₃R₄, -COOR₃, -CONR₃R₄, -CH=CHCOOR₃, -CF₃, -CN, -NO₂, SO₃H, PO₃H or halogen, more preferably H, lower alkyl, -OR₃, -NR₃R₄, -COOR₃, -CONR₃R₄ or halogen, most preferably H, lower alkyl, -OR₁₉ or halogen, wherein R₃ and R₄ represent independently of each other H or lower alkyl.

R_b preferably represents H, OH, -OSO₂Me, -OSO₂W wherein W represents Phenyl (Ph) or isomers of salicylic acid (all combinations of disubstituted phenyl with OH and COOH substituents); or the formula -Sp₃-R₆, wherein Sp₃ preferably represents a covalent bond, -O-, -OCH₂- or -OSO₂CH₂- and R₆ represents one of carbohydrate structures A-D, preferably carbohydrate structures A, B or D. More preferably R_b represents H, OH, -OSO₂Me, -OSO₂Ph; or the formula -Sp₃-R₆, wherein Sp₃ preferably represents a covalent bond, -O-, -OCH₂- or -OSO₂CH₂- and R₆ represents one of carbohydrate structures A-D, preferably carbohydrate structures A, B or D.

Sp₁ preferably represents a straight-chain or branched -(CH₂)_m-group, which is unsubstituted, mono or poly-substituted by -OH, -OR₁₈, halogen or cyano group, wherein R₁₈ represents hydrogen or lower alkyl and m is 1 to 3. More preferably Sp₁ represents a -(CH₂)₃-, which is unsubstituted or substituted by -OH or halogen.

Sp₂ preferably represents a straight-chain or branched -(CH₂)_p-group, which is unsubstituted, mono or poly-substituted by -OH, -OR₂₀, halogen or cyano group, wherein R₂₀ represents hydrogen or lower alkyl and p is 1 to 3. More preferably Sp₁ represents an unsubstituted -(CH₂)_p-, wherein p is 1 to 3, most preferably a covalent bond.

R₁₅ preferably represents -CH₂OR₁₆, -COOR₁₇ or -CH₂NH₂, wherein R₁₆ and R₁₇ independently of each other represent H, lower alkyl, aryl(lower alkyl), -CO-lower alkyl, -CO-aryl, -SO₃⁻ or -PO₃⁻, preferably H, acetyl or benzyl.

R₇, R₈, R₉, R₁₁, R₁₂, R₁₃, and R₁₄ preferably represent independently of each other H, lower alkyl, aryl-lower alkyl, -CO-lower alkyl, -CO-aryl, more preferably, H, acetyl or benzyl.

The term "optionally substituted aryl group" should be understood to include an aromatic ring system having 4 to 10, preferably 5, 6 or 10 ring atoms. The aryl group can be substituted with one or more substituents, which may be the same or different, and are selected from a group as defined hereinafter. Non-limiting examples of suitable aryl groups include phenyl, naphthalene or tetraline groups, most preferably phenyl groups substituted by halogeno, preferably fluoro.

The term "optionally substituted heteroaryl" should be understood to include an aromatic ring system of 5 to 14, preferably 5 to 10, more preferably 5 to 6 or 10 ring atoms, in which one or more of the atoms in the ring system is/are atoms other than carbon, for example nitrogen, oxygen or sulfur. The heteroaryl can be optionally substituted by one or more substituents, which may be the same or different, and are selected from a group as defined hereinafter. Examples of suitable 6-membered heteroaryl groups include pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl and the like. Examples of useful 5-membered heteroaryl rings include furyl, thienyl, pyrrolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxazolyl and isoxazolyl. Useful bicyclic groups are benzo-fused ring systems derived from the heteroaryl groups named above, e.g., quinolyl, phthalazinyl, quinazolinyl, benzofuranyl, benzothienyl and indolyl.

The term "lower alkyl" should be understood to include straight chain and branched hydrocarbon groups having from 1 to 8, preferably 1 to 6, more preferably from 1 to 3 carbon atoms, which may be optionally substituted. Non-limiting examples of suitable lower alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, fluoromethyl and trifluoromethyl.

The term "branched" should be understood to represent a linear straight chain hydrocarbon group having one or more lower alkyl groups such as methyl, ethyl or propyl, attached to it.

The term "lower alkoxy" should be understood to include "lower alkyl-O-" groups, wherein the lower alkyl groups are as described above and have from 1 to 8, preferably 1 to 6, more preferably from 1 to 3 carbon atoms. Methoxy, ethoxy and isopropoxy groups are especially preferred.

The term "aryl(lower alkyl)" should be understood to include an aryl(lower alkyl) group in which the aryl and lower alkyl are as previously described. Non-limiting examples of suitable aryl(lower alkyl) groups include benzyl, phenethyl and naphth-1-ylmethyl.

If not otherwise indicated, the term "optionally substituted" should be understood to represent substituents independently selected from the group consisting of aryl, heteroaryl, aryl(lower alkyl), (lower alkyl)aryl, aralkenyl, heteroaralkyl, alkylheteroaryl, heteroaralkenyl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halogen, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, aminoalkyl, alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, preferably lower alkyl, hydroxy, lower alkoxy, cyano, alkylthio, amino, -NH(lower alkyl), -N(lower alkyl)₂ (which alkyls can be the same or different), carboxy, -C(O)O-(lower alkyl) and halogen. Those skilled in the art will recognize that the size and nature of the substituent(s) will affect the number of substituents which can be present.


The term "halogen" should be understood to include fluoro, chloro, bromo, iodo, preferably, fluoro and chloro, most preferably, fluoro.

It is understood that all isomers, including enantiomers,

stereoisomers, rotamers, tautomers and racemates of the compounds of formula I and in particular the compounds of formulas II and III are contemplated as being part of this invention. The invention includes stereoisomers in optically pure form and in admixture, including racemic mixtures. Isomers can be prepared using conventional techniques, either by reacting optically pure or optically enriched starting materials or by separating isomers of a compound of formula I and in particular the compounds of formulas II and III. In a preferred embodiment the stereochemistry in the central ring is such that the substituents at the 3- and 4-position are in trans configuration to each other.

In yet a further embodiment, preferred combinations of groups R_a and R_b include combinations wherein R_b is as defined hereinabove and is in para-position (in relation to the linker Sp_2) and R_a is as defined hereinabove, most preferably H, and is in meta-position.

Thus in a further preferred embodiment the present invention is directed towards a compound of formula IVa,



IVa


wherein R_a , R_b , Sp_1 , Sp_2 , P, X, Y, Z and n are as defined hereinabove.

Such preferred combinations are thus compounds of formulas IIa-f and IIIa-h wherein R_b is as defined hereinabove and is in para-position (in relation to the linker Sp_2) and R_a is as defined

hereinabove, most preferably H, and is in meta-position.

Further preferred embodiments include combinations, wherein Sp_2 is a covalent bond and Y and Z represent optionally substituted phenyl rings.

Thus in a further preferred embodiment the present invention is directed towards a compound of formula IVb,



IVb

wherein R_a , R_b , Sp_1 , P and X are as defined hereinabove and wherein R_{21} and R_{22} preferably represent H, lower alkyl, lower alkoxy or halogen, most preferably in para-position.

Such combinations are thus compounds of formulas IIa-f and IIIa-h wherein Sp_2 is a covalent bond and Y and Z represent optionally substituted phenyl rings.

Compounds of formula I and in particular compounds of formulas II and III may be prepared using methods of preparation known in the art and are described in the following paragraphs:

The 2-azetidinone portions of the compounds of formula II can be prepared by known methods, such as are disclosed in U.S. Pat. Nos. 5,631,365, 5,756,470, 5,767,115, 5,846,966, 6,207,822, U.S. Provisional Patent Application No. 60/279,288 filed Mar. 28, 2001, and PCT Patent Application WO 93/02048, each of which is incorporated herein by reference. Compounds of formula IIa according to the invention may then be obtained by further linkage


to appropriate carbohydrate structures using literature procedures as illustrated by the Examples.

Compounds of formula IIb may be obtained through conversion of β -lactams to thiolactams, most commonly performed with Lawesson's reagent (Verkoyen, C. and Rademacher, P. *Chem. Ber.* **1985**, *118*, 653-660; Yde, B. et al. *Tetrahedron* **1984**, *40*, 2047-2052; Steliou, K.; Mrani, M. *J. Am. Chem. Soc.* **1982**, *104*, 3104-3106; Clader, J. W. et al. *J. Med. Chem.* **1996**, *39*, 3684-3693).

Compounds of formula IIc may be obtained through conversion of β -lactams to azetidines, which may be achieved by a number of wellknown methods in the art, such as (1) direct one-step reduction with reducing agents of the composition AlH_xCl_{3-x} , such as chlorodihydroalane or alane (Jackson, M. B. et al. *Aust. J. Chem.* **1983**, *36*, 779), or diborane (Jackson, M. B. et al.; *Aust. J. Chem.* **1983**, *36*, 779-788), $AlHCl_2$ and DIBAL-H (Yamashita, M. and Ojima, I. *J. Am. Chem. Soc.* **1983**, *105*, 6339-6342; Ojima, I. et al. *J. Org. Chem.* **1991**, *56*, 5263-5277); and (2) cyclodehydration of 1,3-amino alcohols using various methods (Sohar, P. et al. *Chem. Soc. Perkin Trans. 2* **2000**, 287-293; Suga, H. et al. *S. J. Am. Chem. Soc.* **1994**, *116*, 11197-11198; Barluenga, J. et al. *Tetrahedron* **1996**, *52*, 3095-3106; Obika, S. et al. *Tetrahedron Lett.* **2003**, *44*, 5267-5270) as also outlined in the Examples.


The preparation of compounds of formula IIIa is effected as outlined in Scheme I through initial Sharpless asymmetric amino hydroxylation reaction of the desired trans-1,2-disubstituted alkenes (Demko, Z. P. et al. *Org. Lett.* **2000**, *2*, 2221-2223; O'Brien, P. *Angew. Chem. Int. Edit. Engl.* **1999**, *38*, 326-329; Bodkin, J. A.; McLeod, M. D. *J. Chem. Soc. Perkin Trans. 1* **2002**, 2733-2746), followed by chromatographic separation to obtain the desired regioisomeric product. Subsequent cleavage of the *para*-toluene sulfonamide group furnishes a primary amine which upon Buchwald-Hartwig arylation reaction (Hartwig, J. F. *Acc. Chem. Res.* **1998**, *31*, 852-860; Wolfe, J. P.; Wagaw, S.; Marcoux, J. F.;

Buchwald, S. L. *Acc. Chem. Res.* **1998**, 31, 805-818) and subsequent exposure to triphosgene eventually leads to the formation of the desired oxazolidinones of formula IIIa. Alternatively, they can be accessed as outlined in the Examples.




Scheme 1

Compounds of formula IIIe may be obtained e.g. as illustrated in Scheme II using known methods in the art (Mish, M. R. et al. *J. Am. Chem. Soc.* **1997**, 119, 8379-8380; Guerra, F. M. et al. *Org. Lett.* **2000**, 2, 4265-4267). Alternatively, compounds in which sp₂ is not a covalent bond can be synthesized as demonstrated in the Examples.



Scheme II

The preparation of pyrazolidinones of formula IIIc proceeds in an analogous strategy to that reported in the literature as illustrated in Scheme III (Lou, B. S. et al. *J. Org. Chem.* **1995**, *60*, 5509-5514; Tomkinson, N. C. O. *Rodd's Chemistry of Carbon Compounds (2nd Edition)*, *Asymmetric Catalysis*, Ed. M. Sainsbury **2001**, *5*, 199-258).



Scheme III

It has been found that the use of sulfonate linkages in e.g. the Rb or Sp³ group, i.e. linking carbohydrates to the phenylene ring is particularly beneficial in that the S=O double bonds in the linkages may function as hydrogen bond acceptors compared to the more non-polar nature of a C-glycoside linkage. Such linkages have not yet been reported to link carbohydrates to other kinds of molecules. Furthermore the linkages are non-hydrolyzable, i.e. the carbohydrates are not hydrolyzed off.

It has further been shown that the compounds of the invention display superior pharmacological activities and are able to overcome the drawbacks of known cholesterol-lowering agents using well-established methods in the art, e.g. evaluation of their IC₅₀ value for cholesterol uptake in rabbit brush border membrane vesicles (BBMV) as well as in Caco-2 cells (Hauser, H. et al, *Biochemistry* **1998**, *37*, 17843-17850; Schulthess, G. et al, *Biochemistry* **2000**, *39*, 12623-12631; Werder, M. et al, *Biochemistry* **2001**, *40*, 11643-11650; Boffelli, D. et al. *FEBS Lett.* **1997**,

411, 7-11) (see also Table I).

Thus, the compounds of the invention, e.g. compounds of formula I and their pharmaceutically acceptable acid addition salts, exhibit pharmacological activity and are, therefore, useful as pharmaceuticals. The compounds of the invention have been shown to effectively inhibit cholesterol absorption and are therefore useful in the treatment and/or prevention of atherosclerosis and of the reduction of cholesterol levels.

Thus in yet a further aspect, the present invention is directed to a method of treatment and/or prevention of atherosclerosis, of the reduction of cholesterol levels and of treating or preventing a vascular condition, comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I and in particular a compound of formulas II and III.

The novel compounds of formula I can be used, for example, in the form of pharmaceutical compositions containing a therapeutically effective amount of the active ingredient, if appropriate together with inorganic or organic, solid or liquid, pharmaceutically acceptable carriers suitable for enteral, e.g. oral, or parenteral administration. Accordingly, tablets or gelatin capsules are used that contain the active ingredient together with diluents, typically lactose, dextrose, saccharose, mannitol, sorbitol, cellulose and/or lubricants, e.g. diatomaceous earth, talcum, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol. Tablets may also contain binders, typically magnesium aluminium silicate, starches, typically corn starch, wheat starch, rice starch or arrow root starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and, if desired, disintegrators, typically starches, agar, alginic acid or a salt thereof, e.g. sodium alginate, and/or effervescent mixtures, or absorbents, colourants, flavourings and

sweeteners.

Thus in another aspect, the invention relates to a pharmaceutical composition comprising a compound of formula I, and in particular a compound of formulas II and III (and optionally other therapeutically effective agents), and a pharmaceutically acceptable carrier for the treatment or prevention of arteriosclerosis or for the reduction of cholesterol levels.

The terms "effective amount" and "therapeutically effective amount" mean that amount of a compound of formula I and in particular compounds of formulas II and III (and optionally other therapeutically effective agents), that will elicit a biological or medical response of a tissue, system, animal or mammal, which includes alleviation of the symptoms of the condition or disease being treated and the prevention, slowing or halting of progression of one or more conditions, for example atherosclerosis, hypercholesterolemia.

The pharmaceutical compositions so obtained which, if desired, contain further pharmacologically active substances, are prepared in a manner known per se by conventional mixing, granulating, sugar-coating, solution or lyophilising methods and contain from about 0.1% to 100%, preferably from about 1% to about 50%, lyophilisate to about 100%, of active ingredient.

The compounds, compositions and treatments of the present invention can be administered by any suitable means which produce contact of these compounds with the site of action in the body, for example in the plasma, liver or small intestine of a mammal or human. Thus the novel compounds of formula I may also be used in the form of compositions for parenteral, oral, transdermal administration or infusion solutions. Such solutions are preferably isotonic aqueous solutions or suspension which, e.g. in the case of lyophilised compositions that contain the active ingredient by itself or together with a carrier, such as manni-

tol, can be prepared before use. The pharmaceutical compositions can be sterilised and/or can contain excipients, typically preservatives, stabilisers, wetting agents and/or emulsifiers, solubilisers, salts for regulating the osmotic pressure and/or buffers.


In yet a further aspect, the invention relates to a kit comprising an effective amount of a compound of formula I and in particular a compound of formulas II and III in a pharmaceutically acceptable carrier (and optionally an effective amount of another therapeutically effective agent), optionally in separate compartments.

The following non-limiting Examples illustrate the above-described invention in more detail.

EXAMPLES

Materials and Methods: Reactions in anhydrous solvents were all performed using oven dried glassware under an atmosphere of argon. Reagent grade solvents were all purchased from chemical companies and used without prior purification. For chromatographic purification, technical grade solvents were distilled prior to use. TLC was performed using Machery-Nagel Alugram Sil G/UV₂₅₄ TLC plates and visualized with ultraviolet light at 254 nm and 12 g phosphor molybdic acid in 250 mL EtOH or 10% H₂SO₄ in MeOH (v/v). Chromatographic purification of products was accomplished using dry column vacuum chromatography on Merck Silica Gel 60 (15 - 40 µm) according to literature procedures (Pedersen, D. S. and Rosenbohm, C. *Synthesis* **2001**, 2431-2434); fractions containing product were pooled, the solvents were evaporated under reduced pressure and the residue was dried under high vacuum to give the product. NMR spectra were recorded on a Varian Mercury 300MHz apparatus operating at 300 MHz and 75 MHz for ¹H and ¹³C,

respectively, and chemical shifts (δ) were referenced to the internal solvent signals. IR-Spectra were recorded in CHCl_3 on a Perkin Elmer Spectrum RX I FT-IR apparatus (thin films on NaCl plates) and are reported as absorption maxima in cm^{-1} . Elemental analysis was performed by the Mikroelementaranalytisches Laboratorium at the ETH, Zürich. High resolution matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) was recorded in positive ion mode.


Example 1**V**

LiAlH₄ (114 mg, 3.0 mmol) and AlCl₃ (390 mg, 2.9 mmol) were suspended in anhydrous ether (15 mL) and refluxed for 30 min. Trans-1-(4-fluorophenyl)-3-[(3-phenyl)propyl]-4-phenyl-2-azetidinone (361 mg, 1.00 mmol; prepared according to Browne, M. et al. *Tetrahedron Lett.* **1995**, 36, 2555-2558) dissolved in anhydrous ether (15 mL) was added and after stirring at reflux for 30 min, the suspension was cooled and H₂O (5 mL) was added dropwise followed by addition of 50% sat. aq. NaHCO₃ (30 mL). The layers were separated, the aqueous layer was extracted with EtOAc/hexane and ether and the combined organic layer was washed successively with sat. aq. NaHCO₃ (20 mL) and H₂O (20 mL), evaporated on celite and purified by dry column vacuum chromatography (3.7 x 3.3 cm) on silica gel eluting with a gradient of 0-10% EtOAc in hexane (v/v) to give the desired compound **V** (281 mg, 81%) as a colourless oil.

¹H-NMR (300 MHz, CDCl₃) δ: 7.51-7.14 (10H, m), 6.87 (2H, t, *J* = 8.7 Hz), 6.38 (2H, dd, *J* = 4.7, 9.0 Hz), 4.46 (1H, d, *J* = 6.8 Hz), 4.17 (1H, t, *J* = 6.8 Hz), 3.35 (1H, dd, *J* = 6.8, 7.5 Hz), 2.69-2.58 (3H, m), 1.85-1.56 (4H, m). ¹³C-NMR (75 MHz, CDCl₃) δ: 157.64, 154.52, 148.53, 142.69, 141.95 (C), 128.66, 128.25, 127.47, 125.99, 125.73, 115.41, 115.12, 113.04, 112.94 (CH), 74.37 (CH), 56.05 (CH₂), 42.09 (CH), 35.85, 33.52, 28.92 (CH₂). IR (cm⁻¹): 3026, 2933, 2852, 1603, 1508, 1473, 1453, 1321, 1222, 1120, 823, 773, 747, 699. MALDI-MS (C₂₄H₂₄FN): [MH]⁺ 346.1982 (calcd. 346.1971). Anal. Calcd for C₂₄H₂₄FN: C, 83.44; H, 7.00; N,


4.05. Found: C, 83.45; H, 7.06; N, 4.27.

Example 2



VI

a)



VIa

Ezetimibe (commercially obtained or synthesized according to Wu, G. Z. et al., *J. Org. Chem.* **1999**, *64*, 3714-3718) (5.530 g, 13.5 mmol) was suspended in 2-propanol (70 mL), aq. NaOH (2M, 15 mL) followed by Ac₂O (3.0 mL, 32 mmol) were added and the solution was stirred for 5 h followed by addition of sat. aq. NaHCO₃ (200 mL). After extraction with EtOAc (4 x 50 mL), the combined organic layer was washed successively with sat. aq. NaHCO₃ (50 mL) and H₂O (50 mL), evaporated on celite and purified by dry column vacuum chromatography (5.2 x 5.5 cm) on silica gel eluting with a gradient of 0-100% EtOAc in hexane (v/v) to give the corresponding azetidinone acetate (5.930 g, 97%) as a white foam.

¹H-NMR (300 MHz, CDCl₃) δ: 7.31 (2H, d, *J* = 8.7 Hz), 7.29-7.18

(4H, m), 7.09 (2H, d, $J = 8.7$ Hz), 6.99 (2H, t, $J = 8.7$ Hz), 6.92 (2H, t, $J = 8.7$ Hz), 4.67 (1H, bs), 4.61 (1H, d, $J = 2.5$ Hz), 3.08-3.04 (1H, m), 2.75 (1H, bs), 2.29 (3H, s), 1.97-1.85 (4H, m). ^{13}C -NMR (75 MHz, CDCl_3) δ : 169.16, 167.23, 163.56, 160.46, 160.32, 157.24, 150.58, 139.94, 139.90, 134.85, 133.53, 133.50 (C), 127.32, 127.21, 126.78, 122.38, 118.34, 118.23, 115.95, 115.65, 115.35, 115.07 (CH), 72.95, 60.81, 60.33 (CH), 36.61, 25.07 (CH_2), 21.19 (CH_3). IR (cm^{-1}): 3443, 3019, 2936, 2862, 1747, 1605, 1509, 1427, 1388, 1370, 1221, 1198, 1157, 1016, 835, 757, 668. MALDI-MS ($\text{C}_{26}\text{H}_{23}\text{F}_2\text{NO}_4$): $[\text{MH}-\text{H}_2\text{O}]^+$ 434.1556 (calcd. 434.1568); $[\text{MNa}]^+$ 474.1485 (calcd. 474.1493))

Subsequently the acetate (1.864 g, 4.13 mmol) was dissolved in anhydrous DMF (25 mL), imidazole (939 mg, 13.8 mmol) and TBDMSCl (1.853 g, 12.3 mmol) were added sequentially and the solution was stirred for 3 h followed by addition of 50% sat. aq. NaHCO_3 (150 mL). After extraction with EtOAc (4 x 40 mL), the combined organic layer was washed successively with sat. aq. NaHCO_3 (40 mL) and H_2O (40 mL), evaporated on celite and purified by dry column vacuum chromatography (4.2 x 5.5 cm) on silica gel eluting with a gradient of 0-30% EtOAc in hexane (v/v) to give the corresponding silylated azetidinone acetate (2.137 g, 91%) as a colourless oil.


^1H -NMR (300 MHz, CDCl_3) δ : 7.31 (2H, d, $J = 8.7$ Hz), 7.26-7.20 (4H, m), 7.10 (2H, d, $J = 8.7$ Hz), 6.98 (2H, t, $J = 8.7$ Hz), 6.91 (2H, t, $J = 8.7$ Hz), 4.67 (1H, t, $J = 5.3$ Hz), 4.58 (1H, d, $J = 1.9$ Hz), 3.06-3.02 (1H, m), 2.28 (3H, s), 1.96-1.80 (4H, m), 0.88 (9H, s), 0.02 (3H, s), -0.16 (3H, s). ^{13}C -NMR (75 MHz, CDCl_3) δ : 169.16, 167.06, 163.42, 160.47, 160.16, 157.23, 150.62, 140.50, 135.10, 133.74, 133.70 (C), 127.26, 127.14, 126.77, 122.37, 118.27, 118.16, 115.89, 115.58, 115.03, 114.76 (CH), 73.74, 60.67, 60.53 (CH), 37.94 (CH_2), 25.73 (CH_3), 24.55 (CH_2), 20.99 (CH_3), 18.07 (C), -4.74, -5.05 (CH_3). IR (cm^{-1}): 2953, 2930, 2857, 1752, 1606, 1510, 1472, 1426, 1385, 1370, 1252, 1219,

1197, 1166, 1140, 1102, 1086, 1015, 912, 835, 777, 736. MALDI-MS: $[\text{MH-TBDMSOH}]^+$ 434.1556 (calcd. 434.1568); $[\text{MNa}]^+$ 588.2347 (calcd. 588.2358). Anal. Calcd for $\text{C}_{32}\text{H}_{37}\text{F}_2\text{NO}_4\text{Si}$: C, 67.94; H, 6.59; N, 2.48. Found: C, 67.94; H, 6.64; N, 2.37)

The silylated azetidinone acetate (5.123 g, 9.06 mmol) was dissolved in CH_2Cl_2 (200 mL), neutral alumina (50 g) was added and the suspension was evaporated to dryness. The coated alumina was dried shortly under vacuum and then heated to 70°C for 5.5 h. After cooling, the alumina was extracted with 10% MeOH in CH_2Cl_2 (8 x 50 mL) and the combined organic extracts were evaporated on celite and purified by dry column vacuum chromatography (5.4 x 5.5 cm) on silica gel eluting with a gradient of 0-30% EtOAc in hexane (v/v) to give the silylated azetidinone phenol **VIa** (3.919 g, 83%) as a white foam.

^1H -NMR (300 MHz, CDCl_3) δ : 7.26-7.14 (6H, m), 6.99-6.83 (6H, m), 6.16 (1H, bs), 4.65 (1H, t, J = 5.3 Hz), 4.52 (1H, d, J = 1.9 Hz), 3.04-2.98 (1H, m), 1.92-1.76 (4H, m), 0.86 (9H, s), 0.00 (3H, s), -0.17 (3H, s). ^{13}C -NMR (75 MHz, CDCl_3) δ : 167.82, 163.28, 160.42, 156.12, 140.50, 140.45, 133.57 (C), 128.92, 127.19, 127.15, 127.08, 118.43, 118.32, 116.05, 115.85, 115.55, 115.01, 114.72 (CH), 73.82, 61.17, 60.35 (CH), 38.07 (CH_2), 25.89 (CH_3), 24.68 (CH_2), 18.25 (C), -4.54, -4.84 (CH_3). IR (cm^{-1}): 3351, 2953, 2938, 2857, 1722, 1615, 1604, 1510, 1450, 1391, 1361, 1252, 1223, 1156, 1103, 1087, 863, 834, 776, 760. MALDI-MS: $[\text{MH-TBDMSOH}]^+$ 392.1451 (calcd. 392.1462); $[\text{MH}]^+$ 524.2409 (calcd. 524.2433); $[\text{MNa}]^+$ 546.2242 (calcd. 546.2252). Anal. Calcd for $\text{C}_{30}\text{H}_{35}\text{F}_2\text{NO}_3\text{Si}$: C, 68.81; H, 6.74; N, 2.67. Found: C, 68.61; H, 6.82; N, 2.66.

b)

**VIb**


The silylated azetidinone phenol **VIa** (176 mg, 0.336 mmol) was dissolved in anhydrous CH_2Cl_2 (10 mL), anhydrous pyridine (0.5 mL) followed by MsCl (0.1 mL, 1.29 mmol) were added and the solution was stirred for 22 h, diluted with EtOAc (50 mL) and washed sequentially with sat. aq. NaHCO_3 (20 mL) and H_2O (20 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (4.2x3.3 cm) on silica gel eluting with a gradient of 0-50% EtOAc in hexane (v/v) to give the intermediate mesylate **VIb** (195.5 mg, 92%) as a colourless oil.

$^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 7.35 (2H, d, $J = 8.7$ Hz), 7.28 (2H, d, $J = 8.7$ Hz), 7.26-7.18 (4H, m), 6.98 (2H, t, $J = 8.7$ Hz), 6.93 (2H, t, $J = 8.7$ Hz), 4.67 (1H, dd, $J = 4.4, 6.2$ Hz), 4.59 (1H, d, $J = 1.9$ Hz), 3.16 (3H, s), 3.04-3.00 (1H, m), 1.93-1.79 (4H, m), 0.87 (9H, s), 0.01 (3H, s), -0.16 (3H, s). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ : 166.83, 163.46, 160.57, 160.21, 157.34, 148.88, 140.53, 140.49, 137.07, 133.59, 133.56 (C), 127.36, 127.28, 127.18, 122.94, 118.26, 118.16, 116.04, 115.73, 115.10, 114.81 (CH), 73.79, 60.67, 60.41 (CH), 37.97 (CH_2), 37.59, 25.76 (CH_3), 24.60 (CH_2), 18.11 (C), -4.71, -5.02 (CH_3). IR (cm^{-1}): 2952, 2931, 2857, 1752, 1605, 1509, 1371, 1252, 1220, 1176, 1153, 1102, 1086, 971, 871, 835, 777. MALDI-MS: $[\text{MH-TBDMSOH}]^+$ 470.1228 (calcd. 470.12376); $[\text{MNa}]^+$ 624.2029 (calcd. 624.2027). Anal. Calcd for $\text{C}_{31}\text{H}_{37}\text{F}_2\text{NO}_5\text{SiS}$: C, 61.87; H, 6.20; N, 2.33. Found: C, 61.69; H, 6.19; N, 2.15).

c)

The intermediate mesylate received in the previous step (67.7 mg, 0.112 mmol) was dissolved in THF (2 mL), TBAF (0.2 mL, 1M in THF) was added and the solution was stirred for 1.5 h, diluted with EtOAc (20 mL) and washed successively with sat. aq. NaHCO₃ (10 mL) and H₂O (10 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (4.2 x 2.0 cm) on silica gel eluting with a gradient of 0-90% EtOAc in hexane (v/v) to give the desired mesylated azetidinone **VI** (37.0 mg, 68%) as a white solid after coevaporation with hexane (10 mL).

¹H-NMR (300 MHz, CDCl₃) δ: 7.37-7.17 (8H, m), 7.03-6.91 (4H, m), 4.69 (1H, t, *J* = 5.9 Hz), 4.65 (1H, d, *J* = 1.9 Hz), 3.16 (3H, s), 3.07-3.01 (1H, m), 2.63 (1H, bs), 2.03-1.84 (4H, m). ¹³C-NMR (75 MHz, CDCl₃) δ: 167.11, 163.76, 160.68, 160.50, 157.44, 148.89, 139.92, 136.86, 133.41 (C), 127.40, 127.27, 122.98, 118.35, 118.24, 116.10, 115.79, 115.45, 115.18, 115.11 (CH), 73.03, 60.48, 60.41 (CH), 37.63 (CH₃), 36.48, 25.00 (CH₂). IR (cm⁻¹): 3428, 2937, 1744, 1604, 1510, 1426, 1369, 1221, 1176, 1152, 1103, 1016, 971, 912, 872, 835, 788, 734. MALDI-MS: [MH-H₂O]⁺ 470.1239 (calcd. 470.1238); [MNa]⁺ 510.1164 (calcd. 510.1163). Anal. Calcd for C₂₅H₂₃F₂NO₅S: C, 61.59; H, 4.75; N, 2.87. Found: C, 61.79; H, 4.89; N, 2.76.

Example 3**VII**

LiAlH₄ (58 mg, 1.5 mmol) and AlCl₃ (202 mg, 1.5 mmol) were suspended in anhydrous ether (15 mL), refluxed for 30 min and cooled to 0°C. The mesylate **VIb** obtained in step 2b) (195.5 mg, 0.325 mmol) dissolved in anhydrous ether (5 mL) was added and after stirring at 0°C for 15 min, sat. aq. NaHCO₃ (1 mL) was added dropwise. The suspension was evaporated on celite and purified by dry column vacuum chromatography (4.6 x 3.3 cm) on silica gel eluting with a gradient of 0-50% EtOAc in hexane (v/v) to give the intermediate silylated azetidine (146.4 mg, 77%) as a colourless oil.


¹H-NMR (300 MHz, CDCl₃) δ: 7.49 (2H, d, *J* = 8.7 Hz), 7.30 (2H, d, *J* = 8.7 Hz), 7.18 (2H, dd, *J* = 5.0, 8.7 Hz), 6.98 (2H, t, *J* = 8.7 Hz), 6.85 (2H, t, *J* = 8.7 Hz), 6.31 (2H, dd, *J* = 4.4, 9.3 Hz), 4.58 (1H, t, *J* = 5.3 Hz), 4.40 (1H, d, *J* = 6.8 Hz), 4.11 (1H, t, *J* = 7.2 Hz), 3.28 (1H, t, *J* = 7.2 Hz), 3.17 (3H, s), 2.56-2.49 (1H, m), 1.77-1.50 (4H, m), 0.88 (9H, s), 0.01 (3H, s), -0.15 (3H, s). ¹³C-NMR (75 MHz, CDCl₃) δ: 163.22, 159.99, 157.69, 154.57, 148.23, 148.07, 141.97, 140.62 (C), 127.41, 127.13, 127.03, 122.25, 115.43, 115.13, 114.96, 114.68, 113.00, 112.90 (CH), 73.86, 73.29 (CH), 55.88 (CH₂), 41.88 (CH), 37.90 (CH₂), 37.43 (CH₃), 29.43 (CH₂), 25.85 (CH₃), 18.24 (C), -4.53, -4.88 (CH₃). IR (cm⁻¹): 2932, 2856, 1605, 1509, 1473, 1372, 1331, 1252, 1222, 1198, 1171, 1151, 1090, 970, 870, 836, 776. MALDI-MS: [MH-TBDMSOH]⁺ 456.1442 (calcd. 456.14449); [MNa]⁺ 610.2236 (calcd. 610.22348). Anal. Calcd for C₃₁H₃₉F₂NO₄SiS: C, 63.34; H, 6.69; N, 2.38. Found: C, 63.49; H, 6.87; N, 2.33.

This intermediate silylated azetidine (146.3 mg, 0.249 mmol) was dissolved in anhydrous THF (5.0 mL, teflon bottle) at 0°C, anhydrous pyridine (1.0 mL) followed by HF·pyridine complex (1.0 mL) were added and the solution was stirred at 0°C for 1 h and at room temperature for 7 h, diluted with ether (30 mL) and washed with sat. aq. NaHCO₃ (3 x 10 mL). The organic layer was evapo-

rated on celite and purified by dry column vacuum chromatography (4.2 x 2.0 cm) on silica gel eluting with a gradient of 0-90% EtOAc in hexane (v/v) to give the desired mesylated azetidine **VII** (100.0 mg, 85%) as a white foam.

$^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 7.50 (2H, d, $J = 8.7$ Hz), 7.28 (2H, d, $J = 8.7$ Hz), 7.22 (2H, dd, $J = 5.6, 8.7$ Hz), 7.01 (2H, t, $J = 8.7$ Hz), 6.84 (2H, t, $J = 8.7$ Hz), 6.30 (2H, dd, $J = 4.3, 9.3$ Hz), 4.57 (1H, t, $J = 5.6$ Hz), 4.41 (1H, d, $J = 6.8$ Hz), 4.12 (1H, t, $J = 6.8$ Hz), 3.30 (1H, dd, $J = 6.8, 7.5$ Hz), 3.16 (3H, s), 2.55 (1H, dt, $J = 6.8, 7.5$ Hz), 1.93 (1H, bs), 1.88-1.53 (4H, m). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ : 163.62, 160.37, 157.74, 154.61, 148.22, 148.01, 141.89, 139.95, 139.91 (C), 127.46, 127.28, 127.17, 122.29, 115.46, 115.42, 115.13, 113.02, 112.92 (CH), 73.43, 73.28 (CH), 55.92 (CH_2), 41.81 (CH), 37.49 (CH_3), 36.28, 29.85 (CH_2). IR (cm^{-1}): 3416, 2938, 2853, 1508, 1367, 1221, 1196, 1171, 1149, 970, 871, 823. MALDI-MS ($\text{C}_{25}\text{H}_{25}\text{F}_2\text{NO}_4\text{S}$): $[\text{MH}-\text{H}_2\text{O}]^+$ 456.1447 (calcd. 456.1445); $[\text{M}]^+$ 473.1481 (calcd. 473.1472); $[\text{MNa}]^+$ 496.1380 (calcd. 496.1370).

Example 4



VIII

The silylated azetidinone phenol **VIa** obtained in step 2a) (143 mg, 0.273 mmol) and C-(hydroxymethyl)-2,3,4,6-tetra-O-benzyl- β -D-

glucopyranoside (prepared according to RajanBabu, T. V. and Reddy, G. S. *J. Org. Chem.* **1986**, *51*, 5458-5461; 180 mg, 0.325 mmol) were dissolved in anhydrous THF (10 mL) at 0°C, Bu₃P (0.20 mL, 0.80 mmol) and 1,1'-(azodicarbonyl)dipiperdine (206 mg, 0.82 mmol) were added sequentially and the suspension was allowed to warm to ambient temperature over several hours and stirred for 24 h. EtOAc/hexane (1:4 (v/v), 20 mL) was added, the suspension was filtered through celite (2 x 10 mL EtOAc/hexane (1:4 (v/v)) washings) and the filtrate was evaporated on celite and purified by dry column vacuum chromatography (4.1 x 3.3 cm) on silica gel eluting with a gradient of 0-50% EtOAc in hexane (v/v) to give the corresponding C-glycoside (60.1 mg, 21%) as a colourless oil.

¹H-NMR (300 MHz, CDCl₃) δ: 7.37-7.17 (26H, m), 7.04-6.89 (6H, m), 4.96 (2H, bs), 4.89 (1H, d, *J* = 9.3 Hz), 4.86 (1H, d, *J* = 8.7 Hz), 4.69 (1H, t, *J* = 5.3 Hz), 4.63-4.53 (5H, m), 4.21 (1H, d, *J* = 10.6 Hz), 4.10 (1H, dd, *J* = 5.0, 10.6 Hz), 3.85-3.52 (7H, m), 3.07-3.02 (1H, m), 2.01-1.78 (4H, m), 0.91 (9H, s), 0.05 (3H, s), -0.13 (3H, s). ¹³C-NMR (75 MHz, CDCl₃) δ: 167.25, 158.74, 140.53, 140.49, 138.29, 137.85, 137.79, 137.65, 133.81 (C), 129.53, 128.32, 128.28, 128.18, 127.96, 127.81, 127.78, 127.74, 127.66, 127.54, 127.48, 127.18, 127.08, 126.90, 118.22, 118.12, 115.77, 115.47, 115.30, 114.98, 114.70 (CH), 87.12, 79.14, 78.25, 77.87, 77.71 (CH), 75.56, 75.11, 75.03 (CH₂), 73.82 (CH), 73.44, 68.93, 67.23 (CH₂), 61.02, 60.47 (CH), 38.10 (CH₂), 25.89 (CH₃), 24.71 (CH₂), 18.24 (C), -4.54, -4.83 (CH₃). IR (cm⁻¹): 2951, 2929, 2858, 1749, 1608, 1510, 1454, 1386, 1361, 1250, 1223, 1156, 1141, 1101, 1028, 911, 835, 777, 735, 699. MALDI-MS (C₆₅H₇₁F₂NO₈Si): [MNa]⁺ 1082.4831 (calcd. 1082.4815).


This C-Glycoside (72 mg, 0.068 mmol) was subsequently dissolved in EtOH (5 mL), Pd(OH)₂/C (20% (w/w), 40 mg) was added and the suspension was evacuated 4 times with H₂ and stirred under an H₂-atmosphere for 17 h. The suspension was evaporated on celite and

purified by dry column vacuum chromatography (3.8 x 2.0 cm) on silica gel eluting with a gradient of 0-100% EtOAc in hexane followed by 10% MeOH in CH₂Cl₂ (v/v) to give the debenzylated C-glycoside (28 mg, 59%) as colourless oil.


¹³C-NMR (75 MHz, CDCl₃) δ: 167.22, 163.28, 160.05, 158.36, 157.03, 140.57, 133.75, 130.30, 129.52, 127.22, 127.11, 118.23, 115.83, 115.54, 116.35, 115.05, 114.91, 114.76, 79.16, 78.33, 77.70, 73.88, 70.18, 69.52, 67.75, 61.54, 60.79, 60.57, 38.14, 25.91, 24.81, 18.27, -4.51, -4.80. IR (cm⁻¹): 3391, 2930, 2858, 1747, 1609, 1510, 1387, 1362, 1223, 1140, 1086, 1043, 1014, 835, 758. MALDI-MS (C₃₇H₄₇F₂NO₈Si): [MH-TBDMSOH]⁺ 568.2132 (calcd. 568.2147); [MNa]⁺ 722.2939 (calcd. 722.2937).

Subsequently, the debenzylated C-Glycoside (27.0 mg, 0.039 mmol) was dissolved in THF (1.0 mL), TBAF (0.2 mL, 1M in THF) was added and the solution was stirred for 15 h, diluted with CH₂Cl₂, evaporated on celite and purified by dry column vacuum chromatography (3.5 x 2.0 cm) on silica gel eluting with a gradient of 0-18% MeOH in CH₂Cl₂ (v/v) to give the desired C-glycoside **VIII** (14.0 mg, 62%) as a white solid after coevaporation with hexane (10 mL).

¹H-NMR (300 MHz, CD₃OD) δ: 7.33-7.23 (6H, m), 7.05-6.94 (6H, m), 4.78 (1H, d, *J* = 1.9 Hz), 4.59 (1H, t, *J* = 5.3 Hz), 4.29 (1H, dd, *J* = 1.5, 10.3 Hz), 4.13 (1H, dd, *J* = 5.6, 10.6 Hz), 3.85 (1H, d, *J* = 11.2 Hz), 3.67-3.61 (1H, m), 3.57-3.51 (1H, m), 3.44-3.37 (2H, m), 3.31-3.28 (2H, m), 3.11-3.06 (1H, m), 1.97-1.81 (4H, m). ¹³C-NMR (75 MHz, CD₃OD) δ: 169.20, 160.12, 130.69, 128.36, 128.25, 128.14, 119.52, 119.41, 116.35, 116.04, 115.93, 115.63, 115.35, 81.55, 79.49, 79.39, 73.35, 71.30, 71.23, 68.77, 62.66, 61.74, 60.86, 37.22, 25.84. MALDI-MS (C₃₁H₃₃F₂NO₈): [MH-TBDMSOH]⁺ 568.2143 (calcd. 568.2147); [MNa]⁺ 608.2073 (calcd. 608.2072).

Example 5**IX**

a)

**IXa**

Methyl 2,3,4-Tri-O-benzyl- α -D-glucopyranoside (prepared according to Jaramillo, C. et al; Chiara, J. L.; Martinlomas, M. J. *Org. Chem.* **1994**, 59, 3135-3141; 1.181 g, 2.54 mmol) was dissolved in anhydrous CH_2Cl_2 (25 mL) at 0°C , anhydrous pyridine (3.0 mL) followed by MsCl (0.50 mL, 6.4 mmol) were added and the solution was stirred at 0°C for 1 h and at room temperature for 7 h followed by addition of sat. aq. NaHCO_3 (50 mL). The layers were separated and the aqueous layer extracted with EtOAc (3 x 25 mL). The combined organic layer was washed successively with sat. aq. NaHCO_3 (25 mL) and H_2O (25 mL), evaporated on celite and purified by dry column vacuum chromatography (4.1 x 3.3 cm) on silica gel eluting with a gradient of 0-100% CH_2Cl_2 in hexane (v/v) followed by 0.25-1.0% MeOH in CH_2Cl_2 (v/v) to give the corresponding mesylate (1.303 g, 94%) as a colourless oil after coevaporation with acetonitrile (3 x 10 mL).

^1H -NMR (300 MHz, CDCl_3) δ : 7.39-7.26 (15H, m), 5.02 (1H, d, J = 10.6 Hz), 4.92 (1H, d, J = 10.6 Hz), 4.84 (1H, d, J = 10.6 Hz), 4.80 (1H, d, J = 12.5 Hz), 4.66 (1H, d, J = 11.8 Hz), 4.63 (1H, d, J = 10.6 Hz), 4.60 (1H, d, J = 3.7 Hz), 4.41-4.32 (2H, m), 4.02 (1H, t, J = 9.3 Hz), 3.85 (1H, dt, J = 3.7, 10.0 Hz), 3.52 (1H, dt, J = 3.7, 6.2 Hz), 3.50 (1H, bs), 3.39 (3H, s), 2.98 (3H, s). ^{13}C -NMR (75 MHz, CDCl_3) δ : 138.30, 137.75, 137.56 (C), 128.36, 128.30, 127.94, 127.84, 127.76, 127.57 (CH), 98.06, 81.73, 79.69, 76.86 (CH), 75.73, 75.09, 73.44 (CH_2), 68.59 (CH), 68.36 (CH_2), 55.46, 37.54 (CH_3). IR (cm^{-1}): 3031, 2913, 1497, 1454, 1359, 1177, 1089, 1074, 1046, 1003, 965, 931, 813, 739, 699. MALDI-MS: $[\text{MNa}]^+$ 565.1873 (calcd. 565.1872). Anal. Calcd for $\text{C}_{29}\text{H}_{34}\text{O}_8\text{S}$: C, 64.19; H, 6.32. Found: C, 63.99; H, 6.27.

Subsequently, this mesylate (1.290 g, 2.38 mmol) was dissolved in EtOH (25 mL), KOSMe (869 mg, 7.61 mmol) was added and the unclear solution was stirred at reflux for 4 h (orange precipitate). After cooling, 50% sat. aq. NaHCO_3 (100 mL) was added and the suspension was extracted with EtOAc (3 x 50 mL). The combined organic layer was washed successively with sat. aq. NaHCO_3 (50 mL) and H_2O (50 mL), evaporated on celite and purified by dry column vacuum chromatography (4.1 x 3.3 cm) on silica gel eluting with a gradient of 0-30% EtOAc in hexane (v/v) to give the corresponding thioacetate (1.189 g, 96%) as a light orange solid.

^1H -NMR (300 MHz, CDCl_3) δ : 7.41-7.32 (15H, m), 5.03 (1H, d, J = 10.6 Hz), 4.94 (1H, d, J = 10.6 Hz), 4.86 (1H, d, J = 10.6 Hz), 4.82 (1H, d, J = 11.8 Hz), 4.69 (1H, d, J = 11.8 Hz), 4.66 (1H, d, J = 10.6 Hz), 4.58 (1H, d, J = 3.1 Hz), 4.02 (1H, t, J = 9.0 Hz), 3.81 (1H, dt, J = 2.5, 7.5 Hz), 3.55 (1H, dd, J = 3.7, 9.3 Hz), 3.48 (1H, dd, J = 3.1, 13.7 Hz), 3.40 (3H, s), 3.35 (1H, t, J = 9.5 Hz), 3.08 (1H, dd, J = 7.5, 13.7 Hz), 2.36 (3H, s). ^{13}C -NMR (75 MHz, CDCl_3) δ : 194.67, 138.46, 137.90, 137.78 (C), 128.33, 128.29, 128.03, 127.94, 127.85, 127.81, 127.74, 127.53

(CH), 97.72, 81.69, 80.36, 79.78 (CH), 75.64, 75.04, 73.22 (CH₂), 69.23 (CH), 55.02 (CH₃), 30.73 (CH₂), 30.39 (CH₃). IR (cm⁻¹): 3063, 3031, 2908, 1694, 1497, 1454, 1358, 1201, 1156, 1136, 1092, 1072, 1050, 1029, 999, 955, 737, 698, 630. MALDI-MS: [MNa]⁺ 545.1974 (calcd. 545.1974). Anal. Calcd for C₃₀H₃₄O₆S: C, 68.94; H, 6.56. Found: C, 68.77; H, 6.63.

The thioacetate received above (1.180 g, 2.26 mmol) was then dissolved in AcOH (25 mL), KOAc (4.082 g, 41.6 mmol) followed by Oxone (2KHSO₅·KHSO₄·K₂SO₄, 4.019 g, 8.69 mmol) were added and after stirring for 15 h, sat. aq. NaHCO₃ (100 mL), H₂O (50 mL) and sat. aq. Na₂CO₃ (50 mL) were carefully added. After extraction with EtOAc (4 x 40 mL), the combined organic layer was washed with sat. aq. Na₂CO₃ (50 mL), evaporated on celite and purified by dry column vacuum chromatography (4.0 x 3.3 cm) on silica gel eluting with a gradient of 0-90% EtOAc in hexane (v/v) followed by 0-50% MeOH in EtOAc (v/v) to give the corresponding sulfonate salt (1.116 g, 90%) as a white solid.


¹H-NMR (300 MHz, CD₃OD) δ: 7.37-7.21 (15H, m), 4.90 (1H, d, *J* = 11.2 Hz), 4.86 (1H, d, *J* = 10.6 Hz), 4.84 (1H, d, *J* = 11.2 Hz), 4.73 (1H, d, *J* = 3.1 Hz), 4.72 (1H, d, *J* = 11.2 Hz), 4.64 (1H, d, *J* = 12.5 Hz), 4.60 (1H, d, *J* = 11.2 Hz), 4.16 (1H, t, *J* = 9.2 Hz), 3.90 (1H, t, *J* = 9.3 Hz), 3.55 (1H, dd, *J* = 3.4, 9.3 Hz), 3.48 (3H, s), 3.30-3.22 (2H, m), 2.92 (1H, dd, *J* = 10.0, 14.3 Hz). ¹³C-NMR (75 MHz, CD₃OD) δ: 140.03, 139.57, 139.55 (C), 129.42, 129.31, 129.15, 128.93, 128.89, 128.84, 128.67, 128.59 (CH), 98.53, 83.03, 81.65, 81.52 (CH), 76.44, 75.83, 73.85 (CH₂), 68.52 (CH), 55.95 (CH₃), 53.65 (CH₂). IR (cm⁻¹): 3484, 3030, 2922, 1497, 1454, 1360, 1230, 1198, 1177, 1156, 1093, 1058, 1028, 736, 696. MALDI-MS (C₂₈H₃₁NaO₈S): [MNa]⁺ 573.1536 (calcd. 573.1535).

Finally, the obtained sulfonate salt (696 mg, 1.26 mmol) was suspended in anhydrous acetonitrile/CH₂Cl₂ (10 mL, 1:1 (v/v)) at 0°C, Ph₃P (1.002 g, 3.8 mmol) and thionyl chloride (0.40 mL, 5.5

mmol) were added sequentially and the suspension was stirred at room temperature for 13 h. EtOAc/hexane (1:4 (v/v), 100 mL) was added, the suspension was filtered through celite (4 x 15 mL EtOAc/hexane (1:3 (v/v)) washings) and the filtrate was evaporated and dried shortly under vacuum to give the desired sulfonyl chloride **IXa** (657 mg, 95%) as a yellowish oil.

$^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 7.42-7.28 (15H, m), 5.05 (1H, d, J = 10.6 Hz), 4.96 (1H, d, J = 11.8 Hz), 4.85 (1H, d, J = 10.6 Hz), 4.83 (1H, d, J = 11.8 Hz), 4.67 (1H, d, J = 12.5 Hz), 4.60 (1H, d, J = 11.2 Hz), 4.60 (1H, d, J = 3.1 Hz), 4.33 (1H, t, J = 9.6 Hz), 4.07 (1H, t, J = 9.0 Hz), 3.85 (1H, dd, J = 1.2, 13.7 Hz), 3.55 (1H, d, J = 9.3 Hz), 3.52 (1H, t, J = 10.0 Hz), 3.46 (3H, s), 3.26 (1H, t, J = 9.5 Hz). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ : 138.02, 137.57, 137.06 (C), 128.58, 128.36, 128.30, 128.23, 128.12, 127.92, 127.66 (CH), 98.00, 81.56, 79.41, 78.49 (CH), 75.85, 74.76, 73.38, 66.75 (CH_2), 65.93 (CH), 55.90 (CH_3). MALDI-MS ($\text{C}_{28}\text{H}_{31}\text{ClO}_7\text{S}$): $[\text{MNa}]^+$ 569.1378 (calcd. 569.1377).

b)



IXb

The sulfonyl chloride **IXa** obtained in step 5a) (197 mg, 0.36 mmol) was suspended in anhydrous CH_2Cl_2 (5 mL), anhydrous pyri-

dine (0.5 mL) followed by the silylated azetidinone phenol **Via** obtained in step 2a) (70.0 mg, 0.13 mmol) were added and the solution was stirred for 22 h, diluted with EtOAc (25 mL) and washed sequentially with sat. aq. NaHCO₃ (10 mL) and H₂O (10 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (4.3 x 2.0 cm) on silica gel eluting with a gradient of 0-35% EtOAc in hexane (v/v) to give the corresponding glycosylated azetidinone (125.5 mg, 91%) as a colourless oil/glass.

¹H-NMR (300 MHz, CDCl₃) δ: 7.37-7.14 (23H, m), 7.00 (2H, t, *J* = 8.7 Hz), 6.95 (2H, t, *J* = 8.7 Hz), 5.05 (1H, d, *J* = 11.2 Hz), 4.97 (1H, d, *J* = 11.2 Hz), 4.84 (1H, d, *J* = 11.8 Hz), 4.82 (1H, d, *J* = 10.6 Hz), 4.69 (1H, t, *J* = 6.8 Hz), 4.67 (1H, d, *J* = 12.5 Hz), 4.60 (1H, d, *J* = 3.7 Hz), 4.56 (1H, d, *J* = 12.5 Hz), 4.54 (1H, d, *J* = 10.6 Hz), 4.29 (1H, t, *J* = 9.5 Hz), 4.06 (1H, t, *J* = 9.0 Hz), 3.57 (1H, t, *J* = 3.1 Hz), 3.53 (1H, d, *J* = 3.1 Hz), 3.46 (3H, s), 3.26 (1H, t, *J* = 9.3 Hz), 3.14 (1H, dd, *J* = 10.0, 14.3 Hz), 2.96 (1H, dt, *J* = 1.9, 6.8 Hz), 1.97-1.78 (4H, m), 0.90 (9H, s), 0.04 (3H, s), -0.13 (3H, s). ¹³C-NMR (75 MHz, CDCl₃) δ: 166.62, 163.27, 160.37, 160.03, 157.14, 148.91, 140.33, 138.05, 137.63, 137.29, 136.67, 133.45, 133.42 (C), 128.44, 128.31, 128.18, 128.04, 127.96, 127.86, 127.65, 127.15, 127.03, 126.97, 123.15, 118.13, 118.03, 115.93, 115.64, 115.02, 114.75 (CH), 97.92, 81.67, 79.60, 79.23 (CH), 75.78, 74.86 (CH₂), 73.78 (CH), 73.37 (CH₂), 65.64, 60.66, 60.48 (CH), 55.73 (CH₃), 51.63, 38.06 (CH₂), 25.85 (CH₃), 24.69 (CH₂), 18.22 (C), -4.54, -4.87 (CH₃). IR (cm⁻¹): 3032, 2930, 2858, 1750, 1605, 1510, 1455, 1386, 1252, 1220, 1153, 1086, 1073, 1048, 870, 836, 755, 699. MALDI-MS: [MNa]⁺ 1056.3969 (calcd. 1056.3964). Anal. Calcd for C₅₈H₆₅F₂NO₁₀SiS: C, 67.35; H, 6.33; N, 1.35. Found: C, 67.43; H, 6.44; N, 1.33.

Subsequently the glycosylated azetidinone (105.1 mg, 0.102 mmol) was dissolved in EtOH (5 mL), Pd(OH)₂/C (20% (w/w), 33 mg) was

added and the suspension was evacuated 4 times with H₂ and stirred under an H₂-atmosphere for 6 h. The suspension was evaporated on celite and purified by dry column vacuum chromatography (4.2 x 2.0 cm) on silica gel eluting with a gradient of 0-10% MeOH in CH₂Cl₂ (v/v) to give the debenzylated azetidinone (63.2 mg, 81%) as a colourless oil.

¹H-NMR (300 MHz, acetone-*d*₆) δ: 7.55 (2H, d, *J* = 8.7 Hz), 7.42 (2H, d, *J* = 8.7 Hz), 7.37 (2H, dd, *J* = 5.9, 8.4 Hz), 7.28 (2H, dd, *J* = 5.0, 9.3 Hz), 7.11-7.01 (4H, m), 4.96 (1H, d, *J* = 1.9 Hz), 4.84 (1H, t, *J* = 5.3 Hz), 4.69 (1H, d, *J* = 3.7 Hz), 4.61 (1H, d, *J* = 5.0 Hz), 4.35 (1H, d, *J* = 3.1 Hz), 4.16 (1H, dt, *J* = 1.2, 10.0 Hz), 3.87 (1H, dd, *J* = 1.2, 14.9 Hz), 3.79 (1H, d, *J* = 7.5 Hz), 3.65 (1H, t, *J* = 9.0 Hz), 3.56 (1H, dd, *J* = 10.0, 14.9 Hz), 3.45-3.40 (1H, m), 3.38 (3H, s), 3.27-3.14 (2H, m), 2.00-1.88 (4H, m), 0.87 (9H, s), 0.05 (3H, s), -0.15 (3H, s). ¹³C-NMR (75 MHz, acetone-*d*₆) δ: 167.25, 163.96, 160.84, 160.75, 157.65, 150.14, 141.91, 141.87, 138.13, 134.95, 134.91 (C), 128.32, 128.23, 123.84, 118.98, 118.88, 116.43, 116.12, 115.49, 115.21 (CH), 100.74, 74.77, 74.42, 73.55, 73.04, 68.01, 61.25, 60.50 (CH), 55.56 (CH₃), 52.83, 38.50 (CH₂), 26.16 (CH₃), 25.34 (CH₂), 18.65 (C), -4.47, -4.71 (CH₃). IR (cm⁻¹): 3396, 2951, 2931, 2857, 1754, 1701, 1605, 1510, 1426, 1385, 1250, 1220, 1151, 1103, 1088, 1053, 1015, 988, 872, 836, 778. MALDI-MS (C₃₇H₄₇F₂NO₁₀SSi): [MNa]⁺ 786.2559 (calcd. 786.2556).

This debenzylated azetidinone (58.9 mg, 0.077 mmol) was dissolved in anhydrous THF (2.5 mL, teflon bottle), anhydrous pyridine (0.5 mL) followed by HF·pyridine complex (0.5 mL) were added and the solution was stirred for 14.5 h, diluted with ether (20 mL) and washed with sat. aq. NaHCO₃ (3 x 5 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (4.2 x 2.0 cm) on silica gel eluting with a gradient of 0-10% MeOH in CH₂Cl₂ (v/v) to give the desired azetidinone **Ixb** (44.9 mg, 90%) as a white solid.


^1H -NMR (300 MHz, acetone- d_6) δ : 7.56 (2H, d, J = 8.7 Hz), 7.43 (2H, d, J = 8.7 Hz), 7.37 (2H, dd, J = 5.6, 8.7 Hz), 7.30 (2H, dd, J = 4.7, 9.0 Hz), 7.06 (2H, d, J = 9.3 Hz), 7.03 (2H, d, J = 8.7 Hz), 4.99 (1H, d, J = 2.5 Hz), 4.69 (1H, d, J = 3.7 Hz), 4.61 (1H, d, J = 5.0 Hz), 4.42 (1H, d, J = 3.7 Hz), 4.34 (1H, bs), 4.15 (1H, dt, J = 1.2, 8.7 Hz), 3.86 (1H, dd, J = 1.2, 14.9 Hz), 3.79 (1H, d, J = 8.1 Hz), 3.65 (1H, t, J = 8.7 Hz), 3.57 (1H, dd, J = 10.0, 14.9 Hz), 3.44-3.38 (1H, m), 3.38 (3H, s), 3.32-3.14 (2H, m), 2.08-1.86 (4H, m). ^{13}C -NMR (75 MHz, acetone- d_6) δ : 167.42, 163.87, 160.85, 157.67, 150.13, 142.52, 138.18, 134.93 (C), 128.35, 128.22, 128.13, 123.83, 119.01, 118.89, 116.44, 116.13, 115.40, 115.11 (CH), 100.74, 74.77, 73.56, 73.04, 72.77, 68.01, 61.27, 60.56 (CH), 55.56 (CH_3), 52.83, 37.54, 25.70 (CH_2). IR (cm^{-1}): 3395, 2925, 1732, 1604, 1509, 1365, 1219, 1148, 1103, 1051, 1014, 871, 834, 752. MALDI-MS: $[\text{MNa}]^+$ 672.1693 (calcd. 672.1691). Anal. Calcd for $\text{C}_{31}\text{H}_{33}\text{F}_2\text{NO}_{10}\text{S}$: C, 57.31; H, 5.12; N, 2.16. Found: C, 57.34; H, 5.26; N, 2.21.

c)


LiAlH_4 (57 mg, 1.5 mmol) and AlCl_3 (200 mg, 1.5 mmol) were suspended in anhydrous ether (15 mL), refluxed for 30 min and cooled to 0°C . The azetidinone **Ixb** obtained under step 5b) (26.8 mg, 0.041 mmol) dissolved in anhydrous THF (1 mL, 2 x 0.5 mL rinse) was added and after stirring at 0°C for 10 min, sat. aq. NaHCO_3 (1 mL) was added dropwise. The suspension was evaporated on celite and purified by dry column vacuum chromatography (4.7 x 2.0 cm) on silica gel eluting with a gradient of 0-12% MeOH in CH_2Cl_2 (v/v) to give the desired azetidine **IX** (20.4 mg, 78%) as a colourless oil.

^1H -NMR (300 MHz, acetone- d_6) δ : 7.63-7.59 (2H, m), 7.49-7.42 (2H, m), 7.36-7.29 (2H, m), 7.10-7.01 (2H, m), 6.92-6.77 (2H, m), 6.40-6.35 (2H, m), 4.72 (1H, d, J = 3.7 Hz), 4.62 (1H, d, J = 5.0 Hz), 4.61 (1H, bs), 4.52 (1H, d, J = 6.9 Hz), 4.31 (2H, t, J

= 4.4 Hz), 4.21-4.15 (2H, m), 3.90 (1H, dd, J = 1.2, 14.9 Hz), 3.76 (1H, d, J = 8.1 Hz), 3.68 (1H, dd, J = 3.7, 9.3 Hz), 3.66-3.57 (2H, m), 3.41 (3H, s, OMe), 3.38-3.31 (1H, m), 3.25 (1H, dt, J = 5.0, 13.7 Hz), 2.62 (1H, dd, J = 6.8, 14.3 Hz), 1.92-1.84 (1H, m), 1.74-1.57 (3H, m). ^{13}C -NMR (75 MHz, acetone- d_6) δ : 163.90, 160.69, 158.31, 155.22, 149.93, 149.72, 149.52, 142.90, 142.84 (C), 129.60, 129.44, 128.30, 128.24, 128.13, 123.51, 122.99, 115.95, 115.91, 115.66, 115.40, 115.11, 113.87, 113.77, 113.67, 113.57 (CH), 100.84, 74.86, 74.03, 73.68, 73.14, 72.87, 68.09 (CH), 56.67 (CH₂), 55.63 (CH₃), 52.83 (CH₂), 42.78 (CH), 37.60, 29.83 (CH₂). IR (cm⁻¹): 3390, 2935, 2850, 1605, 1508, 1474, 1366, 1221, 1147, 1052, 1015, 874, 824, 755. MALDI-MS (C₃₁H₃₅F₂NO₉S): [MH-H₂O]⁺ 618.1968 (calcd. 618.1973); [MH]⁺ 636.2045 (calcd. 636.2079); [MNa]⁺ 658.1901 (calcd. 658.1898).

Example 6

a)



The above sulfonyl chloride **Xa** was prepared according to the methods described under step 5a) using C-(Hydroxymethyl)-2,3,4,6-tetra-O-benzyl- β -D-glucopyranoside (prepared according to RajanBabu, T. V.; Reddy, G. S. *J. Org. Chem.* **1986**, *51*, 5458-5461) as the starting material.

b)

The sulfonyl chloride **Xa** obtained under step 6a) (871 mg, 1.26 mmol) was suspended in anhydrous CH_2Cl_2 (10 mL), anhydrous pyridine (1.0 mL) followed by the silylated azetidinone phenol **Via** obtained in step 2a) (334 mg, 0.634 mmol) were added and the solution was stirred for 13 h, diluted with EtOAc (50 mL) and washed sequentially with sat. aq. NaHCO_3 (20 mL) and H_2O (20 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (4.3 x 3.3 cm) on silica gel eluting with a gradient of 0-100% CH_2Cl_2 in hexane (v/v) to give the corresponding glycosylated azetidinone (657 mg, 92%) as a white foam.

^1H -NMR (300 MHz, CDCl_3) δ : 7.37-7.15 (28H, m), 7.01 (2H, t, J = 8.7 Hz), 6.96 (2H, t, J = 8.7 Hz), 5.03-4.81 (4H, m), 4.73-4.51 (6H, m), 3.95 (1H, t, J = 8.4 Hz), 3.78 (4H, bs), 3.57-3.53 (1H, m), 3.48 (1H, d, J = 1.2 Hz), 3.40 (1H, t, J = 9.0 Hz), 3.24 (1H, dd, J = 9.3, 14.9 Hz), 3.02-2.95 (1H, m), 1.97-1.80 (4H, m), 0.92 (9H, s), 0.06 (3H, s), -0.11 (3H, s). ^{13}C -NMR (75 MHz, CDCl_3) δ : 166.72, 163.24, 160.35, 160.01, 157.13, 149.25, 140.37, 140.33, 137.90, 137.65, 137.58, 137.12, 136.97, 136.52, 133.52, 133.48 (C), 128.46, 128.32, 128.28, 128.17, 128.02, 127.97, 127.81, 127.76, 127.67, 127.63, 127.52, 127.13, 127.02, 123.32, 118.13, 118.02, 115.90, 115.60, 115.01, 114.72 (CH), 86.83, 79.13, 78.83, 77.73 (CH), 75.56, 75.00, 74.85 (CH_2), 74.19, 73.77 (CH), 73.31 (CH_2), 68.36, 60.57, 60.53 (CH), 51.31, 38.03 (CH_2), 25.85 (CH_3), 24.67 (CH_2), 18.20 (C), -4.57, -4.87 (CH_3). IR (cm^{-1}): 2951, 2929, 2858, 1751, 1605, 1510, 1454, 1386, 1362, 1251,

1220, 1151, 1102, 871, 835, 776, 754, 699. MALDI-MS: $[\text{MNa}]^+$ 1146.4440 (calcd. 1146.4434). Anal. Calcd for $\text{C}_{65}\text{H}_{71}\text{F}_2\text{NO}_{10}\text{SiS}$: C, 69.43; H, 6.36; N, 1.25. Found: C, 69.27; H, 6.47; N, 1.28.

The glycosylated azetidinone obtained above (236 mg, 0.210 mmol) was then dissolved in EtOH/EtOAc (10 mL, 1:1 (v/v)), $\text{Pd}(\text{OH})_2/\text{C}$ (20% (w/w), 73 mg) was added and the suspension was evacuated 4 times with H_2 and stirred under an H_2 -atmosphere for 3.5 h. The suspension was evaporated on celite and purified by dry column vacuum chromatography (4.6 x 2.0 cm) on silica gel eluting with a gradient of 0-20% MeOH in CH_2Cl_2 (v/v) to give the debenzylated azetidinone (145 mg, 90%) as a white foam.


^1H -NMR (300 MHz, acetone- d_6) δ : 7.55 (2H, dd, $J = 6.5, 8.7$ Hz), 7.47 (2H, d, $J = 8.4$ Hz), 7.40-7.20 (4H, m), 7.11-6.98 (4H, m), 4.97 (1H, dd, $J = 2.3, 10.5$ Hz), 4.83 (1H, bs), 4.61 (1H, bs), 4.48 (1H, bs), 4.30 (1H, bs), 3.90-3.81 (3H, m), 3.71-3.64 (1H, m), 3.56-3.38 (5H, m), 3.25-3.14 (2H, m), 2.66 (1H, t, $J = 7.2$ Hz), 1.98-1.81 (4H, m), 0.88 (9H, s), 0.05 (3H, s), -0.15 (3H, s). ^{13}C -NMR (75 MHz, acetone- d_6) δ : 168.30, 161.88, 158.69, 151.25, 142.96, 139.63, 139.16, 139.13, 135.98 (C), 131.66, 131.56, 129.36, 129.28, 124.92, 120.00, 119.90, 117.46, 117.16, 116.62, 116.52 (CH), 82.13, 80.16, 76.75, 75.44, 74.46, 72.35 (CH), 63.64 (CH_2), 61.60, 61.55 (CH), 54.03, 39.52 (CH_2), 27.20 (CH_3), 26.35 (CH_2), 19.68 (C), -3.44, -3.69 (CH_3). IR (cm^{-1}): 3380, 2930, 2858, 1749, 1604, 1510, 1385, 1363, 1220, 1172, 1149, 1088, 1032, 1016, 872, 835, 757. MALDI-MS: $[\text{MNa}]^+$ 786.2563 (calcd. 786.2556). Anal. Calcd for $\text{C}_{37}\text{H}_{47}\text{F}_2\text{NO}_{10}\text{SiS}$: C, 58.17; H, 6.20; N, 1.83. Found: C, 58.02; H, 6.26; N, 1.85.

The debenzylated azetidinone (31.5 mg, 0.041 mmol) was then dissolved in anhydrous THF (2.5 mL, teflon bottle), anhydrous pyridine (0.5 mL) followed by HF-pyridine complex (0.5 mL) were added and the solution was stirred for 24 h, diluted with ether (20 mL) and washed with sat. aq. NaHCO_3 (3 x 5 mL). The organic layer

was evaporated on celite and purified by dry column vacuum chromatography (4.3 x 2.0 cm) on silica gel eluting with a gradient of 0-20% MeOH in CH₂Cl₂ (v/v) to give the desired azetidinone **X** (9.8 mg, 37%) as a white solid.

¹H-NMR (300 MHz, acetone-*d*₆) δ: 7.55 (2H, d, *J* = 8.7 Hz), 7.47 (2H, d, *J* = 8.7 Hz), 7.36 (2H, dd, *J* = 5.6, 8.7 Hz), 7.29 (2H, dd, *J* = 4.8, 9.2 Hz), 7.06 (2H, d, *J* = 8.7 Hz), 7.03 (2H, d, *J* = 9.0 Hz), 4.98 (1H, d, *J* = 2.5 Hz), 4.68 (1H, bs), 4.58 (1H, bs), 4.38 (1H, bs), 4.27 (1H, bs), 3.89-3.80 (3H, m), 3.66 (1H, d, *J* = 10.6 Hz), 3.54-3.36 (5H, m), 3.24-3.14 (2H, m), 2.00-1.86 (4H, m). ¹³C-NMR (75 MHz, acetone-*d*₆) δ: 168.48, 151.29, 143.63, 139.23, 136.09 (C), 129.37, 129.29, 129.19, 124.97, 120.05, 119.94, 117.49, 117.18, 116.46, 116.18 (CH), 82.17, 80.18, 76.78, 74.49, 73.79, 72.42 (CH), 63.67 (CH₂), 62.35, 61.63 (CH), 54.06, 38.62, 26.75 (CH₂). IR (cm⁻¹): 3364, 2924, 1734, 1509, 1388, 1220, 1148, 1102, 872, 835, 769. MALDI-MS (C₃₁H₃₃F₂NO₁₀S): [MNa]⁺ 672.1744 (calcd. 672.1691).

Example 7



XI

LiAlH₄ (57 mg, 1.5 mmol) and AlCl₃ (200 mg, 1.5 mmol) were suspended in anhydrous ether (15 mL), refluxed for 30 min and cooled to 0°C. The azetidinone **X** obtained in Example 6 (41.3 mg, 0.054 mmol) dissolved in anhydrous ether (5 mL) was added and


after stirring at 0°C for 10 min, sat. aq. NaHCO₃ (1 mL) was added dropwise. The suspension was evaporated on celite and purified by dry column vacuum chromatography (4.2 x 2.0 cm) on silica gel eluting with a gradient of 0-20% MeOH in CH₂Cl₂ (v/v) to give the corresponding azetidine (38.2 mg, 94%) as a white foam.

¹H-NMR (300 MHz, acetone-*d*₆) δ: 7.58 (2H, d, *J* = 8.7 Hz), 7.47 (2H, d, *J* = 8.7 Hz), 7.29 (2H, dd, *J* = 5.6, 8.7 Hz), 7.05 (2H, t, *J* = 8.7 Hz), 6.88 (2H, t, *J* = 9.0 Hz), 6.37 (2H, dd, *J* 4.7, 9.0 Hz), 4.71 (1H, t, *J* = 5.5 Hz), 4.61 (1H, d, *J* = 5.0 Hz), 4.49 (2H, d, *J* = 6.8 Hz), 4.30 (1H, bs), 4.17 (1H, t, *J* = 7.2 Hz), 3.92-3.83 (3H, m), 3.74-3.66 (1H, m), 3.57-3.40 (5H, m), 3.32-3.15 (2H, m), 2.63-2.56 (1H, m), 1.82-1.56 (4H, m), 0.87 (9H, s), 0.04 (3H, s), -0.17 (3H, s). ¹³C-NMR (75 MHz, acetone-*d*₆) δ: 164.97, 161.76, 159.31, 156.21, 150.76, 150.47, 150.45, 143.77, 143.11, 143.07 (C), 129.35, 129.22, 124.60, 116.95, 116.65, 116.48, 116.19, 114.86, 114.75 (CH), 82.15, 80.21, 76.81, 75.43, 74.99, 74.52, 72.41 (CH), 63.70, 57.54, 53.95 (CH₂), 43.62 (CH), 39.47, 31.22 (CH₂), 27.20 (CH₃), 19.70 (C), -3.40, -3.68 (CH₃). IR (cm⁻¹): 3377, 2930, 2856, 1605, 1508, 1472, 1361, 1252, 1222, 1147, 1090, 1015, 871, 836, 776, 760. MALDI-MS (C₃₇H₄₉F₂NO₉SSi): [MNa]⁺ 772.2767 (calcd. 772.2763).


The azetidine obtained above (34.3 mg, 0.046 mmol) was dissolved in anhydrous THF (2.5 mL, teflon bottle), anhydrous pyridine (0.5 mL) followed by HF·pyridine complex (0.5 mL) were added and the solution was stirred for 14 h, diluted with ether (20 mL) and washed with sat. aq. NaHCO₃ (3 x 5 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (4.9 x 2.0 cm) on silica gel eluting with a gradient of 0-18% MeOH in CH₂Cl₂ (v/v) to give the desired azetidine **XI** (20.2 mg, 69%) as a colourless oil.

¹H-NMR (300 MHz, acetone-*d*₆) δ: 7.61 (2H, d, *J* = 8.1 Hz), 7.48

(2H, d, $J = 8.7$ Hz), 7.30 (2H, dd, $J = 5.6, 8.7$ Hz), 7.04 (2H, t, $J = 8.7$ Hz), 6.89 (2H, m), 6.38 (2H, dd, $J = 4.4, 8.7$ Hz), 4.60 (2H, d, $J = 4.4$ Hz), 4.52 (1H, d, $J = 6.8$ Hz), 4.45 (1H, d, $J = 2.5$ Hz), 4.29 (2H, d, $J = 4.4$ Hz), 4.19 (1H, t, $J = 6.8$ Hz), 4.03-3.83 (3H, m), 3.80-3.67 (1H, m), 3.60-3.31 (6H, m), 3.25 (1H, p, $J = 4.4$ Hz), 2.62 (1H, dd, $J = 7.5, 14.3$ Hz), 1.92-1.82 (1H, m), 1.78-1.61 (3H, m). ^{13}C -NMR (75 MHz, acetone- d_6) δ : 164.04, 155.14, 149.92, 149.71, 149.47, 142.77, 129.48 (C), 128.19, 128.16, 128.05, 123.52, 123.03, 115.87, 115.58, 115.39, 115.32, 115.05, 113.78, 113.69, 113.61, 113.51 (CH), 81.09, 79.15, 75.76, 73.98, 73.46, 72.75, 71.36 (CH), 62.63, 56.60, 52.88 (CH_2), 42.68 (CH), 37.52, 29.61 (CH_2). IR (cm^{-1}): 3370, 2933, 1605, 1508, 1474, 1360, 1220, 1146, 1087, 1015, 873, 823, 771. MALDI-MS ($\text{C}_{31}\text{H}_{35}\text{F}_2\text{NO}_9\text{S}$): $[\text{MH}-\text{H}_2\text{O}]^+$ 618.1973 (calcd. 618.1973); $[\text{M}]^+$ 635.1996 (calcd. 635.2001); $[\text{MNa}]^+$ 658.1900 (calcd. 658.1898).

Example 8**XII**

a)


**XIIa**

Ezetimibe (commercially obtained or synthesized according to Wu, G. Z. et al., *J. Org. Chem.* **1999**; 279 mg, 0.681 mmol) was dissolved in anhydrous DMF (5 mL), imidazole (262 mg, 3.84 mmol) and TBDMSCl (500 mg, 3.32 mmol) were added sequentially and the solution was stirred for 5 h followed by addition of 50% sat. aq. NaHCO₃ (50 mL). After extraction with EtOAc (4 x 20 mL), the combined organic layer was washed successively with sat. aq. NaHCO₃ (20 mL) and H₂O (20 mL), evaporated on celite and purified by dry column vacuum chromatography (3.8 x 3.3 cm) on silica gel eluting with a gradient of 0-10% EtOAc in hexane (v/v) to give the fully silylated azetidinone **XIIa** (424 mg, 97%) as a colourless oil.

¹H-NMR (300 MHz, CDCl₃) δ: 7.25-7.21 (4H, m), 7.17 (2H, d, *J* = 8.1 Hz), 6.98 (2H, t, *J* = 8.7 Hz), 6.91 (2H, t, *J* = 8.7 Hz), 6.83 (2H, d, *J* = 8.1 Hz), 4.66 (1H, t, *J* = 5.6 Hz), 4.51 (1H, d, *J* = 2.5 Hz), 3.08-3.02 (1H, m), 1.96-1.78 (4H, m), 0.98 (9H, s), 0.88 (9H, s), 0.20 (6H, s), 0.02 (3H, s), -0.16 (3H, s). ¹³C-NMR (75 MHz, CDCl₃) δ: 167.27, 163.28, 160.27, 160.04, 157.06, 155.71, 140.58, 140.54, 133.89, 133.86 (C), 129.99, 127.22, 127.11, 126.94, 120.56, 118.24, 118.15, 115.74, 115.44, 114.99, 114.72 (CH), 73.84, 61.08, 60.44 (CH), 38.08 (CH₂), 25.90, 25.68 (CH₃), 24.75 (CH₂), 18.26, 18.24 (C), -4.28, -4.52, -4.83 (CH₃).

IR (cm^{-1}): 2954, 2930, 2858, 1752, 1607, 1510, 1385, 1259, 1223, 1101, 1085, 914, 834, 778. MALDI-MS: $[\text{MH}-\text{TBDMSOH}]^+$ 506.2329 (calcd. 506.2327); $[\text{MH}]^+$ 638.3289 (calcd. 638.3297); $[\text{MNa}]^+$ 660.3117 (calcd. 660.3117). Anal. Calcd for $\text{C}_{36}\text{H}_{49}\text{F}_2\text{NO}_3\text{Si}_2$: C, 67.78; H, 7.74; N, 2.20. Found: C, 67.70; H, 7.60; N, 2.02.

b)



XIIb

LiAlH_4 (57 mg, 1.5 mmol) and AlCl_3 (200 mg, 1.5 mmol) were suspended in anhydrous ether (15 mL), refluxed for 40 min and cooled to 0°C . The fully silylated azetidinone **XIIa** obtained under step 8a) (180.8 mg, 0.283 mmol) dissolved in anhydrous ether (5 mL) was added and after stirring at 0°C for 30 min, H_2O (1 mL) was added dropwise. The suspension was evaporated on celite and purified by dry column vacuum chromatography (3.5 x 3.3 cm) on silica gel eluting with a gradient of 0-50% CH_2Cl_2 in hexane (v/v) to give the desired bicyclic amine **XIIb** (110.8 mg, 63%) as a colourless oil.

^1H -NMR (300 MHz, CDCl_3) δ : 7.18-7.14 (2H, m), 6.95 (2H, t, J = 8.7 Hz), 6.88 (2H, d, J = 8.7 Hz), 6.74 (2H, d, J = 8.1 Hz), 6.68 (1H, dd, J = 2.8, 8.4 Hz), 6.44 (1H, dd, J = 6.5, 8.7 Hz), 6.38 (1H, dd, J = 2.8, 9.6 Hz), 4.48 (1H, dd, J = 5.0, 6.8 Hz), 3.78 (1H, bs), 3.61 (1H, d, J = 7.5 Hz), 3.26 (1H, dd, J = 3.1,

11.2 Hz), 2.91 (1H, dd, $J = 7.8, 11.5$ Hz), 1.91-1.85 (1H, m), 1.68-1.44 (3H, m), 1.16-1.04 (1H, m), 0.99 (9H, s), 0.80 (9H, s), 0.20 (6H, s), 0.06 (3H, s), -0.21 (3H, s). ^{13}C -NMR (75 MHz, CDCl_3) δ : 163.60, 160.36, 157.37, 154.27, 141.53, 141.01, 138.13 (C), 130.07, 127.56, 127.46, 125.58, 125.50, 120.01, 117.27, 116.98, 115.17, 114.89, 114.78, 114.08, 113.79 (CH), 74.64, 48.97 (CH), 44.52 (CH_2), 39.89 (CH), 38.67, 28.28 (CH_2), 26.00, 25.90 (CH_3), 18.38, 18.32 (C), -4.16, -4.43, -4.77 (CH_3). IR (cm^{-1}): 2955, 2930, 2858, 1607, 1506, 1472, 1408, 1361, 1258, 1222, 1170, 1144, 1085, 1006, 915, 837, 808, 779, 735, 667. MALDI-MS ($\text{C}_{36}\text{H}_{51}\text{F}_2\text{NO}_2\text{Si}_2$): $[\text{MH-TBDMSOH}]^+$ 492.2517 (calcd. 492.2534); $[\text{M}]^+$ 623.3414 (calcd. 623.3426). Anal. Calcd for $\text{C}_{36}\text{H}_{51}\text{F}_2\text{NO}_2\text{Si}_2$: C, 69.30; H, 8.24; N, 2.24. Found: C, 69.47; H, 8.32; N, 2.15.


c)

The bicyclic amine **XIIb** obtained under step 8b) (39.8 mg, 0.064 mmol) was dissolved in THF (5 mL), TBAF (0.5 mL, 1M in THF) was added and the solution was stirred for 21 h, evaporated on celite and purified by dry column vacuum chromatography (3.7 x 2.0 cm) on silica gel eluting with a gradient of 0-100% EtOAc in hexane (v/v) to give the desired amine **XII** (27.7 mg, quant.) as a yellowish solid.

^1H -NMR (300 MHz, CDCl_3) δ : 7.19-7.15 (2H, m), 6.97 (2H, t, $J = 8.7$ Hz), 6.87 (2H, d, $J = 8.4$ Hz), 6.74-6.66 (3H, m), 6.46 (1H, dd, $J = 5.0, 8.7$ Hz), 6.38 (1H, dd, $J = 2.2, 9.0$ Hz), 5.54 (1H, bs), 4.52 (1H, t, $J = 6.5$ Hz), 3.61 (1H, d, $J = 7.2$ Hz), 3.26 (1H, dd, $J = 3.4, 11.5$ Hz), 2.90 (1H, dd, $J = 7.5, 11.5$ Hz), 1.95-1.86 (1H, m), 1.78-1.68 (2H, m), 1.52-1.41 (1H, m), 1.19-1.06 (1H, m). ^{13}C -NMR (75 MHz, CDCl_3) δ : 163.55, 160.30, 157.10, 154.25, 154.00, 140.44, 139.95, 139.90, 137.07 (C), 129.90, 127.46, 127.36, 125.24, 116.99, 116.70, 115.28, 115.26, 115.21, 115.15, 115.00, 114.95, 114.84, 113.91, 113.61 (CH), 73.94, 48.53 (CH), 43.98 (CH_2), 39.73 (CH), 36.43, 27.95 (CH_2). IR (cm^{-1}): 3335, 2925, 2853, 1607, 1511, 1223, 913, 836, 744. MALDI-MS

(C₂₄H₂₃F₂NO₂): [MH-H₂O]⁺ 378.1661 (calcd. 378.1670); [M]⁺ 395.1689 (calcd. 395.1670)

Example 9



XIII

The bicyclic amine **XIIb** obtained in step 8b) (503 mg, 0.806 mmol) was dissolved in THF (15 mL) at 0°C, TBAF (1.5 mL, 1M in THF) was added and the solution was stirred at 0°C for 1.5 h, diluted with EtOAc (50 mL) and washed successively with sat. aq. NaHCO₃ (20 mL) and H₂O (20 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (3.4 x 3.3 cm) on silica gel eluting with a gradient of 0-30% EtOAc in hexane (v/v) to give the corresponding phenol (344.2 mg, 84%) as a light yellow foam.

¹H-NMR (300 MHz, CDCl₃) δ: 7.16 (2H, dd, *J* = 5.6, 8.1 Hz), 6.95 (2H, t, *J* = 8.7 Hz), 6.90 (2H, d, *J* = 8.7 Hz), 6.72 (2H, d, *J* = 8.7 Hz), 6.72-6.67 (1H, m), 6.48 (1H, dd, *J* = 4.4, 8.7 Hz), 6.39 (1H, dd, *J* = 2.7, 9.6 Hz), 4.49 (1H, dd, *J* = 5.6, 6.8 Hz), 4.40 (1H, bs), 3.61 (1H, d, *J* = 7.5 Hz), 3.28 (1H, dd, *J* = 2.7, 11.2 Hz), 2.92 (1H, dd, *J* = 8.1, 11.2 Hz), 1.93-1.87 (1H, m), 1.73-1.47 (3H, m), 1.20-1.15 (1H, m), 0.81 (9H, s), 0.06 (3H, s), -0.20 (3H, s). ¹³C-NMR (75 MHz, CDCl₃) δ: 163.16, 159.93, 157.15, 154.03, 141.13, 141.09, 140.43, 140.40, 137.05 (C), 129.95,

127.21, 127.11, 125.69, 125.62, 116.92, 116.62, 115.23, 114.98, 114.87, 114.83, 114.55, 113.83, 113.53 (CH), 74.36, 48.77 (CH), 44.49 (CH₂), 39.78 (CH), 38.46, 28.07 (CH₂), 25.81 (CH₃), 18.17 (C), -4.52, -4.90 (CH₃). IR (cm⁻¹): 3338, 2954, 2929, 2857, 1606, 1508, 1475, 1462, 1361, 1251, 1221, 1084, 836, 775, 760. MALDI-MS (C₃₀H₃₇F₂NO₂Si): [MH-TBDMSOH]⁺ 378.1657 (calcd. 378.1670); [M]⁺ 509.2553 (calcd. 509.2562).

The phenol obtained above (79 mg, 0.15 mmol) and 2,3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-O-β-D-glucopyranosyl)-α-D-glucopyranosyl 1-(2,2,2-trichloroacetimidate) (prepared according to Buijsman, R. C. et al., *Bioorg. Med. Chem.* **1999**, 7, 1881-1890; 267 mg, 0.34 mmol) were then dissolved in anhydrous CH₂Cl₂ (2 mL) at -25°C and BF₃·OEt₂ in CH₂Cl₂ (1:9 (v/v), 0.10 mL, 0.08 mmol) was added. After stirring for 2.5 h at -25 to -20°C, additional BF₃·OEt₂ (0.05 mL, 0.39 mmol) was added and after additional 1 h at -25 to -20°C, sat. aq. NH₄Cl (10 mL) and EtOAc (10 mL) were added. The layers were separated and the aqueous phase was extracted with EtOAc (3 x 10 mL). The combined organic layer was washed successively with sat. aq. NaHCO₃ (10 mL) and H₂O (10 mL), evaporated on celite and purified by dry column vacuum chromatography (4.5 x 2.0 cm) on silica gel eluting with a gradient of 0-70% EtOAc in hexane (v/v) to give the glycosylated amine (169 mg, 97%) as a white foam.

¹H-NMR (300 MHz, CDCl₃) δ: 7.12 (2H, dd, *J* = 5.6, 8.7 Hz), 6.94-6.84 (6H, m), 6.66 (1H, dt, *J* = 2.5, 8.1 Hz), 6.42 (1H, dd, *J* = 4.4, 8.7 Hz), 6.29 (1H, dd, *J* = 2.7, 9.6 Hz), 5.29-4.90 (6H, m), 4.54-4.43 (3H, m), 4.37 (1H, dd, *J* = 4.4, 12.5 Hz), 4.16-4.02 (2H, m), 3.86 (1H, t, *J* = 9.0 Hz), 3.77-3.64 (2H, m), 3.60 (1H, d, *J* = 7.5 Hz), 3.23 (1H, dd, *J* = 2.7, 11.5 Hz), 2.88 (1H, dd, *J* = 8.1, 11.2 Hz), 2.07-1.96 (21H, m), 1.87-1.75 (1H, m), 1.70-1.38 (3H, m), 1.13-0.97 (1H, m), 0.76 (9H, s), -0.10 (3H, s), -0.25 (3H, s). ¹³C-NMR (75 MHz, CDCl₃) δ: 170.38, 170.09, 169.67,


169.47, 169.20, 168.96, 163.25, 160.01, 156.95, 155.27, 153.85, 141.10, 140.73, 140.10 (C), 129.91, 127.21, 127.11, 124.80, 116.68, 114.83, 114.56, 113.62 (CH), 100.71, 98.80, 76.33, 74.20, 72.81, 72.69, 72.42, 71.89, 71.48, 71.27, 67.63 (CH), 61.84, 61.42 (CH₂), 48.71 (CH), 44.19 (CH₂), 39.61 (CH), 38.27, 27.85 (CH₂), 25.64, 20.67, 20.58, 20.43 (CH₃), 17.96 (C), -4.76, -5.14 (CH₃). IR (cm⁻¹): 2955, 2858, 1756, 1506, 1368, 1223, 1049, 837, 770. MALDI-MS (C₅₆H₇₁F₂NO₁₉Si): [MNa]⁺ 1150.4235 (calcd. 1150.4255).

The glycosylated amine obtained above (370 mg, 0.328 mmol) was then dissolved in THF (10 mL), TBAF (1.0 mL, 1M in THF) was added and the solution was stirred for 27 h, diluted with EtOAc (40 mL) and washed successively with sat. aq. NaHCO₃ (15 mL) and H₂O (15 mL). The organic layer was evaporated and the crude intermediate [MALDI-MS (C₅₀H₅₇F₂NO₁₉): [MNa]⁺ 1036.3394 (calcd. 1036.3391)] was dissolved in MeOH/Et₃N/THF (12 mL, 1:1:2 (v/v/v)), H₂O (10.5 mL) was added dropwise and the solution was stirred for 18 h. sat. aq. NaHCO₃ (1 mL) was added dropwise and the suspension was evaporated on celite and purified by dry column vacuum chromatography (4.0 x 3.3 cm) on silica gel eluting with a gradient of 0-25% MeOH in EtOAc (v/v) to give the desired bicyclic amine **XIII** (80.5 mg, 34%) as a white solid after coevaporation with hexane (20 mL).

¹H-NMR (300 MHz, CD₃OD) δ: 7.20 (2H, dd, J = 5.6, 8.7 Hz), 7.02-6.93 (6H, m), 6.65 (1H, dt, J = 2.5, 8.7 Hz), 6.54 (1H, dd, J = 5.0, 8.7 Hz), 6.23 (1H, dd, J = 2.5, 10.0 Hz), 4.94 (1H, d, J = 7.5 Hz), 4.47-4.43 (2H, m), 3.92 (2H, bs), 3.90 (1H, d, J = 10.6 Hz), 3.72-3.52 (6H, m), 3.43-3.22 (5H, m), 2.86 (1H, dd, J = 8.1, 11.8 Hz), 1.96-1.84 (1H, m), 1.80-1.68 (2H, m), 1.50-1.35 (1H, m), 1.17-1.03 (1H, m). ¹³C-NMR (75 MHz, CD₃OD) δ: 164.71, 161.49, 157.30, 155.12, 142.58, 141.98, 141.95, 140.78 (C), 130.89, 128.83, 128.72, 126.64, 126.56, 117.52, 117.36, 117.09, 115.86, 115.57 (CH), 104.44, 101.98, 80.21, 78.01, 77.76, 76.49,

76.22, 74.83, 74.58, 74.41, 71.29 (CH), 62.39, 61.63 (CH₂), 50.00 (CH), 45.09 (CH₂), 40.95 (CH), 37.38, 29.09 (CH₂). MALDI-MS (C₃₆H₄₃F₂NO₁₂): [MNa]⁺ 742.2654 (calcd. 742.2651).

Example 10



XIV


The silylated azetidinone phenol **VIa** obtained in step 2a) (104.0 mg, 0.199 mmol) was dissolved in anhydrous CH₂Cl₂ (10 mL), anhydrous pyridine (0.5 mL) followed by PhSO₂Cl (0.10 mL, 0.78 mmol) were added and the solution was stirred for 19 h. Additional PhSO₂Cl (0.10 mL, 0.78 mmol) was added and the solution was stirred for further 69 h, diluted with EtOAc (50 mL) and washed sequentially with sat. aq. NaHCO₃ (20 mL) and H₂O (20 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (4.2 x 3.3 cm) on silica gel eluting with a gradient of 0-100% CH₂Cl₂ in hexane (v/v) followed by 0.5-1.0% MeOH in CH₂Cl₂ (v/v) to give the corresponding benzene sulfonate (92.0 mg, 70%) as a colourless oil.

R_F (1% MeOH in CH₂Cl₂ (v/v)) 0.72; ¹H-NMR (300 MHz, CDCl₃) δ: 7.83 (2H, d, *J* = 7.5 Hz), 7.66 (1H, t, *J* = 7.5 Hz), 7.51 (2H, t, *J* = 7.5 Hz), 7.25-7.14 (6H, m), 7.00 (2H, d, *J* = 8.7 Hz), 6.97 (2H, d, *J* = 8.7 Hz), 6.91 (2H, t, *J* = 8.7 Hz), 4.66 (1H, dd, *J* = 4.4, 6.2 Hz), 4.55 (1H, d, *J* = 1.9 Hz), 3.02-2.96 (1H, m), 1.94-1.75 (4H, m), 0.87 (9H, s), 0.00 (3H, s), -0.16 (3H, s). ¹³C-NMR (75 MHz, CDCl₃) δ: 166.82, 163.44, 160.51, 157.29, 149.35, 140.54 (C), 136.77 (CH), 135.26, 134.32, 133.56, 129.13 (C), 128.31, 127.27, 127.17, 127.08, 123.15, 118.23, 118.12, 115.93, 115.63,

115.09, 114.82, 73.76, 60.53, 60.40 (CH), 37.92 (CH₂), 25.75 (CH₃), 24.59 (CH₂), 18.10 (C), -4.71, -5.03 (CH₃). IR (cm⁻¹): 2953, 2930, 2857, 1752, 1605, 1510, 1450, 1382, 1252, 1221, 1202, 1181, 1155, 1093, 1016, 868, 835, 776, 753, 700, 687. MALDI-MS (C₃₆H₃₉F₂NO₅SSi): [MH-TBDMSOH]⁺ 532.1395 (calcd. 532.1394); [MNa]⁺ 686.2185 (calcd. 686.2184).

This benzene sulfonate (90.0 mg, 0.136 mmol) was dissolved in anhydrous THF (2.5 mL, teflon bottle) at 0°C, anhydrous pyridine (0.5 mL) followed by HF-pyridine complex (0.5 mL) were added and the solution allowed slowly to warm to room temperature. After 14 h, the mixture was diluted with ether (20 mL) and washed with sat. aq. NaHCO₃ (3 x 5 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (5.0 x 2.0 cm) on silica gel eluting with a gradient of 0-100% CH₂Cl₂ in hexane (v/v) followed by 1-7% MeOH in CH₂Cl₂ (v/v) to give β -lactam **XIV** (69.2 mg, 93%) as a white foam.

R_F (3% MeOH in CH₂Cl₂ (v/v)) 0.33; ¹H-NMR (300 MHz, CDCl₃) δ : 7.82 (2H, dd, *J* = 1.2, 7.5 Hz), 7.67 (1H, tt, *J* = 1.2, 7.5 Hz), 7.51 (2H, t, *J* = 7.5 Hz), 7.29-7.22 (4H, m), 7.15 (2H, dd, *J* = 4.4, 8.7 Hz), 6.99 (2H, t, *J* = 8.7 Hz), 6.98 (2H, d, *J* = 8.7 Hz), 6.92 (2H, t, *J* = 8.7 Hz), 4.68 (1H, dd, *J* = 5.6, 6.2 Hz), 4.60 (1H, d, *J* = 1.9 Hz), 3.06-2.98 (1H, m), 2.55 (1H, bs), 2.04-1.84 (4H, m). ¹³C-NMR (75 MHz, CDCl₃) δ : 166.87, 163.56, 160.44, 160.31, 157.22, 149.23, 139.84, 139.79 (C), 136.46 (CH), 135.10, 134.26, 133.37 (C), 129.07, 128.22, 127.26, 127.16, 127.02, 123.07, 118.21, 118.11, 115.93, 115.62, 115.36, 115.07, 72.98, 60.50, 60.32 (CH), 36.54, 25.09 (CH₂). IR (cm⁻¹): 3440, 3069, 3017, 2927, 2862, 1747, 1604, 1510, 1450, 1426, 1378, 1221, 1201, 1180, 1154, 1094, 1016, 868, 835, 753, 700, 687, 668. MALDI-MS (C₃₀H₂₅F₂NO₅S): [MH-H₂O]⁺ 532.1388 (calcd. 532.1394); [MNa]⁺ 572.1302 (calcd. 572.1319).


Example 11**XV**

LiAlH₄ (57 mg, 1.5 mmol) and AlCl₃ (202 mg, 1.5 mmol) were suspended in anhydrous ether (15 mL), refluxed for 30 min and cooled to 0°C. β-Lactam **XIV** obtained in example 10 (62.8 mg, 0.114 mmol) dissolved in anhydrous ether (5 mL) was added and after stirring at 0°C for 20 min, sat. aq. NaHCO₃ (1 mL) was added dropwise. The suspension was evaporated on celite and purified by dry column vacuum chromatography (4.8 x 2.0 cm) on silica gel eluting with a gradient of 0-50% EtOAc in hexane (v/v) to give azetidine **XV** (24.5 mg, 40%) as a white foam.

R_f (1:1 EtOAc/hexane (v/v)) 0.46; ¹H-NMR (300 MHz, CDCl₃) δ: 7.88-7.82 (2H, m), 7.70-7.63 (1H, m), 7.55-7.47 (2H, m), 7.38-7.30 (2H, m), 7.24-7.19 (2H, m), 7.05-6.98 (4H, m), 6.83 (2H, t, *J* = 8.7 Hz), 6.26 (2H, dd, *J* = 4.4, 9.3 Hz), 4.56 (1H, dd, *J* = 5.0, 7.5 Hz), 4.36 (1H, d, *J* = 6.8 Hz), 4.09 (1H, dd, *J* = 6.8, 7.5 Hz), 3.27 (1H, dd, *J* = 6.8, 7.5 Hz), 2.79 (1H, d, *J* = 5.6 Hz), 2.52 (1H, dd, *J* = 6.8, 7.5 Hz), 1.89-1.52 (4H, m). ¹³C-NMR (75 MHz, CDCl₃) δ: 163.65, 160.40, 157.73, 154.61, 148.65, 148.07, 141.59, 139.94, 135.36 (C), 134.11, 129.24, 129.03, 128.30, 127.28, 127.17, 122.54, 115.45, 115.15, 112.99, 112.90, 73.47, 73.32 (CH), 55.89 (CH₂), 41.74 (CH), 36.30, 29.93 (CH₂). IR (cm⁻¹): 3411, 2937, 2853, 1604, 1508, 1474, 1450, 1374, 1221, 1198, 1175, 1151, 1093, 1016, 867, 823, 752, 700, 686. MALDI-MS (C₃₀H₂₇F₂NO₄S): [MH-H₂O]⁺ 518.1596 (calcd. 518.1601); [M]⁺ 535.1619 (calcd. 535.1629); [MNa]⁺ 558.1512 (calcd. 558.1527).

Example 12

52




XVI

The silylated azetidinone phenol **VIa** obtained in step 2a) (105 mg, 0.201 mmol) was dissolved in anhydrous CH_2Cl_2 (5 mL), anhydrous pyridine (0.5 mL, 5.0 mmol) and 3-carboxy-4-hydroxybenzene sulfonyl chloride (prepared according to Stewart, J. *J. Chem. Soc.* **1922**, 121, 2555-2561; 223 mg, 0.94 mmol) were added sequentially and the suspension was stirred at room temperature for 63 h. The mixture was evaporated on celite and purified by dry column vacuum chromatography (4.7 x 2.0 cm) on silica gel eluting with a gradient of 0-15% MeOH in CH_2Cl_2 (v/v) to give the corresponding silylated sulfonate (76.2 mg, 53%) as a colourless oil. R_f (20% MeOH in CH_2Cl_2 (v/v)) 0.68; $^1\text{H-NMR}$ (300 MHz, CD_3CN) δ : 10.36 (1H, bs), 8.31 (1H, bs), 7.69 (1H, bs), 7.31-7.13 (8H, m), 7.00 (2H, t, J = 7.5 Hz), 6.89 (2H, t, J = 8.1 Hz), 6.57 (1H, bs), 4.72 (1H, bs), 4.65 (1H, bs), 3.12 (1H, bs), 2.98 (1H, bs), 1.88-1.72 (4H, m), 0.84 (9H, s), 0.01 (3H, s), -0.18 (3H, s). $^{13}\text{C-NMR}$ (75 MHz, CD_3CN) δ : 168.91, 167.92, 163.57, 160.97, 157.89, 150.74, 142.17, 142.14, 137.17, 134.89 (C), 128.57, 128.45, 128.16, 123.34, 119.23, 119.17, 118.18, 116.68, 116.38, 115.71, 115.43, 74.39, 61.14, 60.64 (CH), 38.40 (CH_2), 26.12 (CH_3), 25.10 (CH_2), 18.65 (C), -4.53, -4.69 (CH_3). IR (cm^{-1}): 3450, 2954, 2930, 2858, 1751, 1696, 1606, 1585, 1510, 1478, 1386, 1339, 1293, 1220, 1194, 1126, 1103, 1087, 1063, 1042, 835, 777, 758. MALDI-MS ($\text{C}_{37}\text{H}_{39}\text{F}_2\text{NO}_8\text{SSi}$): $[\text{M-H}+2\text{Na}]^+$ 768.1851 (calcd. 768.1851).


This silylated sulfonate (74.2 mg, 62.5 mmol) was dissolved in anhydrous THF (2.5 mL, teflon bottle) at 0°C, anhydrous pyridine (0.5 mL) followed by HF·pyridine complex (0.5 mL) were added and the solution allowed slowly to warm to room temperature. After 15 h, sat. aq. NaHCO₃ (15 mL) was added and the suspension was evaporated on celite and purified by dry column vacuum chromatography (4.4 x 2.0 cm) on silica gel eluting with a gradient of 0-25% MeOH in EtOAc (v/v) to give sulfonate **XVI** (43.6 mg, 70%) as a white solid.

R_f (1:3 MeOH/EtOAc (v/v)) 0.44; ¹H-NMR (300 MHz, CD₃OD) δ: 8.53 (1H, d, *J* = 1.9 Hz), 7.99 (1H, dd, *J* = 2.5, 8.7 Hz), 7.48 (1H, d, *J* = 8.7 Hz), 7.35-7.28 (6H, m), 7.07-6.97 (5H, m), 4.93 (1H, d, *J* = 2.5 Hz), 4.62 (1H, dd, *J* = 5.0, 6.2 Hz), 3.17-3.08 (1H, m), 1.97-1.84 (4H, m). ¹³C-NMR (75 MHz, CD₃OD) δ: 169.19, 164.04, 151.43, 142.04, 142.01, 138.00 (C), 137.35 (CH), 134.92 (C), 129.46, 128.72, 128.62, 128.44, 123.54, 119.86, 119.76, 118.63, 116.82, 116.51, 115.98, 115.68 (CH), 112.37 (C), 73.73, 61.65, 61.39 (CH), 37.49, 26.18 (CH₂). MALDI-MS (C₃₁H₂₅F₂NO₈S): [M-H+2Na]⁺ 654.1000 (calcd. 654.0986).

Example 13



a)



The silylated azetidinone phenol **VIa** obtained in step 2a) (80.3 mg, 0.153 mmol) and alcohol **XVIIa** (prepared according to Spak, S. J.; Martin, O. R. *Tetrahedron* **2000**, *56*, 217-224; 101.5 mg, 0.103 mmol) were dissolved in anhydrous THF (10 mL) at 0°C, Bu₃P (50 mg, 0.20 mmol) and 1,1'-(azodicarbonyl)dipiperidine (39.5 mg, 0.17 mmol) were added sequentially and the suspension was allowed to warm to ambient temperature over several hours. After stirring at room temperature for 26 h, EtOAc/hexane (1:4 (v/v), 30 mL) was added and the suspension was filtered through celite (2 x 10 mL EtOAc/hexane (1:4 (v/v)) washings). The filtrate was evaporated on celite and purified by dry column vacuum chromatography (4.5 x 2.0 cm) on silica gel eluting with a gradient of 0-25% EtOAc in hexane (v/v) to give a 1:1 mixture of the corresponding C-glycoside and unreacted phenol **VIa** (49.7 mg) as a white foam.

R_f (1:1 EtOAc/hexane (v/v)) 0.64; ¹³C-NMR (75 MHz, CDCl₃) δ: 167.39, 163.27, 160.31, 158.82, 157.09, 140.54, 140.49, 139.05, 138.37, 138.29, 138.19, 137.85, 133.78, 133.73, 129.40, 128.96, 128.23, 128.12, 128.04, 127.94, 127.86, 127.73, 127.63, 127.57, 127.49, 127.41, 127.20, 127.10, 126.87, 118.30, 118.19, 116.01, 115.78, 115.49, 115.30, 114.99, 114.71, 102.41, 85.35, 84.84, 82.70, 79.29, 78.01, 77.82, 77.19, 75.64, 75.25, 75.10, 75.02, 74.96, 74.81, 73.84, 73.26, 68.99, 68.15, 67.49, 61.07, 60.44, 38.09, 25.90, 24.72, 18.25, -4.53, -4.83. MALDI-MS (C₉₂H₉₉F₂NO₁₃Si): [MNa]⁺ 1514.6763 (calcd. 1514.6751).

This mixture of the C-glycoside and phenol **VIa** (49.7 mg) was dissolved in EtOH/EtOAc (10 mL, 1:1 (v/v)), Pd(OH)₂/C (20% (w/w), 31 mg) was added and the suspension was evacuated 4 times with H₂ and stirred under an H₂-atmosphere for 3 h. The suspension was evaporated on celite and purified by dry column vacuum chromatography (4.6 x 2.0 cm) on silica gel eluting with a gradient of

0-20% MeOH in CH₂Cl₂ (v/v) to give the corresponding debenzylated C-glycoside (18.7 mg, 21% from **Via**) as a colourless oil.

R_f (20% MeOH in CH₂Cl₂ (v/v)) 0.44; ¹H-NMR (300 MHz, CD₃OD) δ: 7.31-7.23 (6H, m), 7.04-6.94 (6H, m), 4.71 (1H, d, *J* = 1.9 Hz), 4.41 (1H, d, *J* = 7.5 Hz), 4.12 (1H, dd, *J* = 5.3, 10.9 Hz), 3.91-3.81 (3H, m), 3.66 (1H, d, *J* = 5.6, 11.8 Hz), 3.57-3.47 (3H, m), 3.40-3.20 (7H, m), 3.07 (1H, t, *J* = 5.9 Hz), 1.92-1.78 (4H, m), 0.87 (9H, s), 0.02 (3H, s), -0.18 (3H, s). ¹³C-NMR (75 MHz, CD₃OD) δ: 169.71, 160.66, 145.96, 142.43, 131.16, 131.05, 128.89, 128.80, 128.62, 120.00, 119.89, 116.83, 116.54, 116.41, 116.02, 115.74, 115.58, 104.65, 80.78, 80.43, 79.64, 78.16, 77.90, 75.13, 74.99, 71.43, 62.50, 62.08, 61.29, 38.96, 26.38, 25.75, 19.06, -4.40. MALDI-MS (C₄₃H₅₇F₂NO₁₃Si): [MNa]⁺ 884.3668 (calcd. 884.3465).

This debenzylated C-glycoside (18.3 mg, 0.021 mmol) was dissolved in anhydrous THF (2.5 mL, teflon bottle) at 0°C, anhydrous pyridine (0.50 mL) followed by HF-pyridine complex (0.50 mL) were added and the solution was stirred for 17 h. NaHCO₃ (s) was added and the suspension was evaporated on celite and purified by dry column vacuum chromatography (4.6 x 2.0 cm) on silica gel eluting with a gradient of 0-20% MeOH in CH₂Cl₂ (v/v) to give the desired C-glycoside **XVII** (10.3 mg, 65%) as a white solid.


R_f (20% MeOH in CH₂Cl₂ (v/v)) 0.31; ¹H-NMR (300 MHz, CD₃OD) δ: 7.33-7.24 (6H, m), 7.05-6.94 (6H, m), 4.78 (1H, d, *J* = 1.9 Hz), 4.60 (1H, t, *J* = 4.4 Hz), 4.41 (1H, d, *J* = 7.5 Hz), 4.30 (1H, d, *J* = 10.0 Hz), 4.12 (1H, dd, *J* = 5.0, 10.6 Hz), 3.91-3.84 (3H, m), 3.66 (1H, d, *J* = 5.6, 11.8 Hz), 3.57-3.49 (3H, m), 3.40-3.20 (6H, m), 3.10-3.06 (1H, m), 1.97-1.82 (4H, m). ¹³C-NMR (75 MHz, CD₃OD) δ: 169.52, 164.87, 160.42, 142.07, 133.18 (C), 131.03, 130.87, 128.68, 128.59, 128.47, 123.36, 119.86, 119.74, 116.69, 116.38, 116.25, 116.22, 115.96, 115.88, 115.68, 104.54, 80.71, 80.36, 79.58, 78.11, 77.85, 74.94, 73.70, 71.38 (CH), 69.02,

56

62.47 (CH₂), 62.09 (CH₂+CH), 61.20 (CH), 37.54, 26.18 (CH₂).


MALDI-MS (C₃₇H₄₃F₂NO₁₃): [MNa]⁺ 770.2589 (calcd. 770.2600).

Example 14



XVIII

a)



XVIIIa

Alcohol **XVIIa** (prepared according to Spak, S. J.; Martin, O. R. *Tetrahedron* **2000**, *56*, 217-224; 895.3 mg, 0.907 mmol) was dissolved in anhydrous CH₂Cl₂ (10 mL), anhydrous pyridine (1.0 mL) followed by MsCl (0.20 mL, 2.6 mmol) were added and after stirring for 1 h, sat. aq. NaHCO₃ (40 mL) was added. The layers were separated and the aqueous layer extracted with EtOAc (3 x 20 mL). The combined organic layer was washed successively with sat. aq. NaHCO₃ (20 mL) and H₂O (20 mL), evaporated on celite and purified by dry column vacuum chromatography (4.2 x 3.3 cm) on silica gel eluting with a gradient of 0-50% EtOAc in hexane (v/v) to give the corresponding mesylate (830.7 mg, 86%) as a white solid.

R_f (1:1 EtOAc/hexane (v/v)) 0.67; ¹H-NMR (300 MHz, CDCl₃) δ: 7.49-7.24 (35H, m), 5.31 (1H, d, *J* = 11.2 Hz), 5.00 (1H, d, *J* =

11.2 Hz), 4.98-4.79 (6H, m), 4.66-4.36 (9H, m), 4.09 (1H, t, $J = 9.3$ Hz), 3.90 (1H, dd, $J = 2.8, 10.9$ Hz), 3.83 (1H, d, $J = 10.0$ Hz), 3.75-3.62 (5H, m), 3.55-3.39 (5H, m), 2.97 (3H, s). ^{13}C -NMR (75 MHz, CDCl_3) δ : 138.97, 138.37, 138.21, 138.04, 137.61 (C), 128.37, 128.29, 128.18, 128.08, 127.93, 127.84, 127.76, 127.38, 127.34, 127.24, 102.51, 84.86, 82.64, 78.70, 77.94, 76.84, 76.53, 76.38, 75.57 (CH), 75.22, 75.09 (CH_2), 74.96, 74.78 (CH_2 , CH), 73.21, 73.02, 69.22, 68.89, 67.76 (CH_2), 37.74 (CH_3). IR (cm^{-1}): 3063, 3030, 2867, 1497, 1454, 1358, 1277, 1209, 1174, 1150, 1092, 1071, 1028, 984, 922, 812, 737, 698, 527. MALDI-MS ($\text{C}_{63}\text{H}_{68}\text{O}_{13}\text{S}$): $[\text{MNa}]^+$ 1087.4284 (calcd. 1087.4278). Anal. Calcd for $\text{C}_{63}\text{H}_{68}\text{O}_{13}\text{S}$: C, 71.03; H, 6.43. Found: C, 70.94; H, 6.62.

Subsequently, this mesylate (825 mg, 0.774 mmol) was dissolved in EtOH (20 mL), KOSMe (278 mg, 2.43 mmol), *i*PrOH (10 mL) and THF (10 mL) were added and the orange solution was stirred at reflux for 3 h (orange precipitate). Additional KOSMe (512 mg, 4.48 mmol) was added and the suspension was stirred at reflux for 16 h. After cooling, 50% sat. aq. NaHCO_3 (100 mL) was added and the suspension was extracted with ether (4 x 30 mL). The combined organic layer was washed successively with sat. aq. NaHCO_3 (50 mL) and H_2O (50 mL), evaporated on celite and purified by dry column vacuum chromatography (4.2 x 3.3 cm) on silica gel eluting with a gradient of 0-50% EtOAc in hexane (v/v) to give the corresponding thioacetate (637 mg, 79%) as a light orange solid.

R_f (1:3 EtOAc/hexane (v/v)) 0.45; ^1H -NMR (300 MHz, CDCl_3) δ : 7.43-7.19 (35H, m), 5.22 (1H, d, $J = 11.2$ Hz), 4.92 (1H, d, $J = 11.2$ Hz), 4.88 (1H, d, $J = 11.2$ Hz), 4.87-4.71 (5H, m), 4.62 (1H, d, $J = 12.5$ Hz), 4.60-4.43 (5H, m), 4.41 (1H, d, $J = 11.8$ Hz), 4.06 (1H, t, $J = 9.3$ Hz), 3.86 (1H, dd, $J = 3.7, 11.2$ Hz), 3.75 (1H, dd, $J = 1.6, 10.9$ Hz), 3.69-3.55 (5H, m), 3.51-3.31 (6H, m), 3.05 (1H, dd, $J = 6.8, 13.7$ Hz), 2.34 (3H, s). ^{13}C -NMR

(75 MHz, CDCl_3) δ : 195.04, 139.19, 138.53, 138.30, 138.24, 138.17, 137.96 (C), 128.33, 128.26, 128.20, 128.04, 127.79, 127.71, 127.63, 127.55, 127.47, 127.29, 127.19, 102.40, 85.12, 84.88, 82.71, 79.85, 79.30, 78.05, 77.87 (CH), 75.62, 75.18 (CH_2), 75.09 (CH), 74.94, 74.81, 73.26, 73.21, 68.96, 67.86, 31.12 (CH_2), 30.49 (CH_3). IR (cm^{-1}): 3030, 2868, 1692, 1496, 1454, 1358, 1210, 1067, 1028, 773, 735, 698, 626. MALDI-MS ($\text{C}_{64}\text{H}_{68}\text{O}_{11}\text{S}$): $[\text{MNa}]^+$ 1067.4365 (calcd. 1067.4380). Anal. Calcd for $\text{C}_{64}\text{H}_{68}\text{O}_{11}\text{S}$: C, 73.54; H, 6.56. Found: C, 73.50; H, 6.60.

The thioacetate received above (631 mg, 0.604 mmol) was suspended in AcOH (10 mL), KOAc (933 mg, 9.5 mmol) followed by Oxone ($2\text{KHSO}_5 \cdot \text{KHSO}_4 \cdot \text{K}_2\text{SO}_4$, 1.179 g, 2.55 mmol) were added and after stirring for 18 h, sat. aq. Na_2CO_3 (50 mL) and H_2O (50 mL) were carefully added. After extraction with CHCl_3 (4 x 25 mL), the combined organic layer was washed with sat. aq. Na_2CO_3 (25 mL), evaporated on celite and purified by dry column vacuum chromatography (4.1 x 3.3 cm) on silica gel eluting with a gradient of 0-20% MeOH in CH_2Cl_2 (v/v) to give the corresponding sulfinate salt (622 mg, 96%) as a colourless oil.

R_f (10% MeOH in CH_2Cl_2 (v/v)) 0.29; ^1H -NMR (300 MHz, CDCl_3) δ : 7.40-7.14 (35H, m), 5.19-4.34 (15H, m), 4.17-3.22 (15H, m). ^{13}C -NMR (75 MHz, CDCl_3) δ : 138.97, 138.32, 138.21, 138.06, 137.88, 137.84, 128.70, 128.36, 128.18, 128.05, 127.86, 127.76, 127.63, 127.57, 127.44, 127.29, 127.20, 126.94, 84.53, 84.45, 82.01, 79.48, 77.96, 77.75, 76.06, 76.01, 75.46, 74.94, 74.79, 74.67, 74.57, 73.28, 73.08, 73.02, 53.42. IR (cm^{-1}): 3478, 3063, 3030, 2870, 1497, 1454, 1361, 1315, 1210, 1174, 1069, 1048, 1028, 736, 698, 621. MALDI-MS ($\text{C}_{62}\text{H}_{65}\text{NaO}_{13}\text{S}$): $[\text{MH}]^+$ 1073.4098 (calcd. 1073.4122); $[\text{MNa}]^+$ 1095.3926 (calcd. 1095.3941).

Finally, the obtained sulfinate salt (334 mg, 0.311 mmol) was dissolved in anhydrous acetonitrile/ CH_2Cl_2 (4 mL, 1:1 (v/v)) at

0°C, Ph_3P (264 mg, 1.01 mmol) and thionyl chloride (0.10 mL, 1.37 mmol) were added sequentially at 0°C and the suspension was stirred at room temperature for 6 h. EtOAc/hexane (1:4 (v/v), 30 mL) was added, the suspension was filtered through a short pad of silica gel (4 x 5 mL EtOAc/hexane (1:3 (v/v)) washings) and the filtrate was evaporated and dried shortly under vacuum to give the desired sulfonyl chloride **XVIIIa** (220 mg, 66%) as a light yellow foam.

R_f (1:3 EtOAc/hexane (v/v)) 0.38; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 7.50-7.26 (35H, m), 5.30 (1H, d, $J = 11.2$ Hz), 4.98 (1H, d, $J = 10.6$ Hz), 4.96-4.81 (5H, m), 4.79 (1H, d, $J = 10.6$ Hz), 4.67-4.50 (6H, m), 4.48 (1H, d, $J = 11.8$ Hz), 4.23-4.15 (1H, m), 3.98-3.91 (2H, m), 3.85-3.57 (8H, m), 3.51-3.38 (3H, m), 3.30 (1H, t $J = 9.0$ Hz). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ : 138.77, 138.45, 138.17, 138.11, 137.78, 137.27 (C), 128.63, 128.38, 128.31, 128.18, 128.12, 127.94, 127.78, 127.70, 127.63, 127.55, 127.42, 127.29, 102.32, 84.98, 84.80, 82.66, 79.23, 77.95, 77.82, 75.78 (CH), 75.60, 75.38 (CH_2), 75.12 (CH), 74.99, 74.78, 74.70 (CH_2), 74.21 (CH), 73.24, 68.95, 67.35, 66.79 (CH_2). IR (cm^{-1}): 3089, 3063, 3030, 2868, 1496, 1454, 1362, 1313, 1280, 1209, 1167, 1091, 1067, 1028, 913, 771, 736, 698, 601. MALDI-MS ($\text{C}_{62}\text{H}_{65}\text{ClO}_{12}\text{S}$): $[\text{MNa}]^+$ 1091.3767 (calcd. 1091.3783).

The sulfonyl chloride **XVIIIa** (271 mg, 0.253 mmol) was dissolved in anhydrous CH_2Cl_2 (3 mL), anhydrous pyridine (0.5 mL) followed by the silylated azetidinone phenol **VIa** obtained in step 2a) (75.7 mg, 0.145 mmol) were added and the solution was stirred for 38 h, diluted with EtOAc (50 mL) and washed sequentially with sat. aq. NaHCO_3 (15 mL) and H_2O (15 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (4.5 x 3.3 cm) on silica gel eluting with a gradient of 0-20% EtOAc in toluene (v/v) to give the corresponding sulfonate mixed with unreacted phenol **VIa** (166 mg, 4:1 mixture) as

a white foam.

R_f (1:1 EtOAc/hexane (v/v)) 0.73; ¹H-NMR (300 MHz, CDCl₃) δ: 7.49-7.17 (41H, m), 7.06 (2H, d, *J* = 8.7 Hz), 7.02 (2H, t, *J* = 8.1 Hz), 6.96 (2H, d, *J* = 8.7 Hz), 5.31 (1H, d, *J* = 11.2 Hz), 5.01-4.74 (7H, m), 4.65-4.45 (8H, m), 4.21 (1H, t, *J* = 9.3 Hz), 4.02-3.96 (2H, m), 3.86-3.60 (6H, m), 3.53-3.47 (4H, m), 3.33 (1H, d, *J* = 9.3 Hz), 3.26 (1H, t, *J* = 9.0 Hz), 3.19 (1H, d, *J* = 9.3 Hz), 3.06-3.00 (1H, m), 2.06-1.84 (4H, m), 0.96 (9H, s), 0.10 (3H, s), -0.07 (3H, s). ¹³C-NMR (75 MHz, CDCl₃) δ: 166.70, 160.35, 160.00, 156.27, 149.33, 140.35, 140.31, 138.63, 138.26, 138.00, 137.90, 137.59, 137.45, 137.29, 136.51, 133.47 (C), 128.82, 128.73, 128.34, 128.19, 128.08, 127.98, 127.85, 127.66, 127.56, 127.45, 127.30, 127.25, 127.12, 127.01, 125.10, 123.32, 118.11, 118.01, 115.91, 115.60, 115.00, 114.93, 114.72, 102.39, 84.93, 84.80, 82.56, 78.82, 78.55, 77.95, 75.99 (CH), 75.60, 75.31 (CH₂), 75.15 (CH), 74.96, 74.76 (CH₂), 74.23, 73.77 (CH), 73.21, 73.08, 68.97, 67.62 (CH₂), 61.02, 60.57, 60.39 (CH), 51.26, 38.02 (CH₂), 25.85 (CH₃), 24.67 (CH₂), 18.19 (C), -4.56, -4.87 (CH₃). ¹⁹F-NMR (282 MHz, CDCl₃) δ: -114.94 (1F, septet, *J* = 4.3 Hz), -117.10 (1F, septet, *J* = 4.3 Hz). MALDI-MS (C₉₂H₉₉F₂NO₁₅SiS): [MNa]⁺ 1578.6365 (calcd. 1578.6370).

Subsequently, this sulfonate (166 mg 4:1 mixture) was dissolved in EtOH (5 mL), Pd(OH)₂/C (20% (w/w), 94 mg) was added and the suspension was evacuated 4 times with H₂ and stirred under an H₂-atmosphere for 11.5 h. The suspension was evaporated on celite and purified by dry column vacuum chromatography (4.3 x 2.0 cm) on silica gel eluting with a gradient of 0-10% MeOH in CH₂Cl₂ (v/v) to give the corresponding debenzylated β-lactam (69.5 mg, 52% from phenol **VIa**) as a colourless oil.



R_f (20% MeOH in CH₂Cl₂ (v/v)) 0.46; ¹H-NMR (300 MHz, CD₃OD) δ: 7.46-7.38 (4H, m), 7.31-7.23 (4H, m), 7.04-6.95 (4H, m), 4.75-4.68 (1H, m), 4.44 (1H, d, *J* = 8.1 Hz), 3.92-3.80 (5H, m), 3.69-

3.18 (11H, m), 3.10-3.05 (1H, m), 1.95-1.75 (4H, m), 0.86 (9H, s), 0.01 (3H, s), -0.19 (3H, s). ^{13}C -NMR (75 MHz, CD_3OD) δ : 169.31, 169.21, 161.76, 158.91, 150.96, 142.28, 138.45, 135.01, 134.98, 131.06, 130.95 (C), 128.83, 124.50, 119.92, 119.83, 116.99, 116.68, 116.10, 116.04, 115.81, 115.74, 104.54, 80.33, 80.10, 78.11, 77.81, 77.72, 76.30, 75.13, 74.89, 73.61, 71.38 (CH), 62.47, 61.63 (CH_2), 61.56, 61.47 (CH), 53.26, 38.83 (CH_2), 26.38 (CH_3), 25.75 (CH_2), 19.04 (C), -4.40, -4.70 (CH_3). ^{19}F -NMR (282 MHz, CD_3OD) δ : -117.94 (1F, septet, J = 4.3 Hz), -120.10 (1F, septet, J = 4.3 Hz). MALDI-MS ($\text{C}_{43}\text{H}_{57}\text{F}_2\text{NO}_{15}\text{SiS}$): $[\text{MNa}]^+$ 948.3088 (calcd. 948.3084).

This debenzylated β -Lactam (59.5 mg, 0.073 mmol) was dissolved in anhydrous THF (2.0 mL, teflon bottle), anhydrous pyridine (0.40 mL) followed by HF-pyridine complex (0.40 mL) were added and the solution was stirred for 14 h. Sat. aq. NaHCO_3 (5 mL) was added and the suspension was evaporated on celite and purified by dry column vacuum chromatography (4.4 x 2.0 cm) on silica gel eluting with a gradient of 10-20% MeOH in CH_2Cl_2 (v/v) to give the desired β -lactam **XVIII** (38.1 mg, 64%) as a white solid.

R_f (10% MeOH in CH_2Cl_2 (v/v)) 0.17 (eluted thrice); ^1H -NMR (300 MHz, CD_3OD) δ : 7.45 (2H, t, J = 9.3 Hz), 7.40 (2H, d, J = 8.7 Hz), 7.33-7.24 (4H, m), 7.02 (2H, t, J = 8.1 Hz), 6.98 (2H, d, J = 8.7 Hz), 4.90 (1H, d, J = 1.9 Hz), 4.60 (1H, dd, J = 5.0, 6.2 Hz), 4.43 (1H, d, J = 7.5 Hz), 3.92-3.79 (5H, m), 3.69-3.49 (4H, m), 3.44-3.18 (6H, m), 3.12-3.06 (1H, m), 1.99-1.82 (4H, m). ^{13}C -NMR (75 MHz, CD_3OD) δ : 169.31, 165.08, 162.17, 161.85, 158.96, 150.98, 142.15, 138.51, 135.01 (C), 128.88, 128.76, 124.46, 119.97, 119.86, 116.99, 116.68, 116.13, 115.84, 104.54, 80.35, 80.06, 78.11, 77.81, 77.71, 76.31, 74.91, 73.77, 73.63, 71.39 (CH), 62.45, 61.50 (CH_2), 61.42 (CH), 53.26, 37.45, 26.12 (CH_2). ^{19}F -NMR (282 MHz, CD_3OD) δ : -118.08 (1F, septet, J = 4.3 Hz), -120.21 (1F, septet, J = 4.3 Hz). MALDI-MS ($\text{C}_{37}\text{H}_{43}\text{F}_2\text{NO}_{15}\text{S}$): $[\text{MNa}]^+$

834.2223 (calcd. 834.2219).

Example 15**a)**

A 50 mL Schlenk flask was charged with $\text{Zn}(\text{OTf})_2$ (12.647 g, 34.79 mmol) and heated to 120°C under high-vacuum (0.2 Torr) for 3.5 h. After cooling, (+)-*N*-methylephedrine (6.595 g, 36.79 mmol) was added and the flask was purged with Ar for 15 min. Anhydrous toluene (14 mL) followed by Et_3N (3.874 g, 38.3 mmol) were added and after 3 h stirring, benzyl propargyl ether (prepared according to Ren, X. F.; Turos, E.; Lake, C. H.; Churchill, M. R. *J. Org. Chem.* **1995**, *60*, 6468-6483; 5.556 g, 38.00 mmol) was added in one portion. After 20 min stirring, the mixture was transferred to a precooled acetone bath (8°C), stirred for 5 min and *p*- $\text{FC}_6\text{H}_4\text{CHO}$ (3.632 g, 29.26 mmol) was added in one portion. After 15 h stirring at 9 to 12°C, the suspension was diluted with EtOAc

(125 mL) and washed with sat. aq. NH_4Cl (2 x 30 mL) and brine (30 mL). The organic layer was evaporated on celite and purified by dry column vacuum chromatography (5.4 x 5.5 cm) on silica gel eluting with a gradient of 0-50% EtOAc in hexane (v/v) to give propargyl alcohol **XIXa** (5.896 g, 75%) as a light yellow oil.

Enantiomeric excess as determined by HPLC analysis: 96% ee; R_t 20 min (*R*-**XIXa**), 28 min (*S*-**XIXa**) (Chiracel OD-H 25 cm, 6% *i*PrOH in hexane, flow 1.0 mL/min, 254 nm). R_f (1:3 EtOAc/hexane (v/v)) 0.28; ; ^1H -NMR (300 MHz, CDCl_3) δ : 7.50 (2H, dd, $J = 5.6, 8.7$ Hz), 7.38-7.32 (5H, m), 7.06 (2H, t, $J = 8.7$ Hz), 5.48 (1H, s), 4.60 (2H, s), 4.26 (2H, s), 2.84 (1H, s). ^{13}C -NMR (75 MHz, CDCl_3) δ : 164.01, 160.75, 136.95, 136.04 (C), 128.30, 128.21, 127.92, 127.81, 115.43, 115.13 (CH), 86.13, 82.62 (C), 71.74 (CH_2), 63.74 (CH), 57.35 (CH_2). ^{19}F -NMR (282 MHz, CDCl_3) δ : -113.28 (1F, septet, $J = 4.3$ Hz). IR (cm^{-1}): 3390, 3066, 3032, 2859, 1604, 1508, 1455, 1413, 1386, 1355, 1224, 1158, 1121, 1096, 1072, 1028, 1014, 842, 772, 744, 699, 592, 561, 498. MALDI-MS ($\text{C}_{17}\text{H}_{15}\text{FO}_2$): $[\text{MNa}]^+$ 293.0947 (calcd. 293.0954). Anal. Calcd for $\text{C}_{17}\text{H}_{15}\text{FO}_2$: C, 75.54; H, 5.59. Found: C, 75.39; H, 5.62.

Subsequently this propargyl alcohol (4.108 g, 15.20 mmol) was dissolved in anhydrous DMF (50 mL), imidazole (2.123 g, 31.1 mmol) and TBDMSCl (3.590 mg, 23.8 mmol) were added sequentially and the solution was stirred for 3.5 h followed by addition of 50% sat. aq. NaHCO_3 (150 mL). After extraction with ether (4 x 50 mL), the combined organic layer was washed successively with sat. aq. NaHCO_3 (50 mL) and H_2O (50 mL), evaporated and dried shortly under high vacuum. The residue was dissolved in EtOH (40 mL), Na_2CO_3 (3.229 g, 30.5 mmol) and Pd/C (10% (w/w), 223 mg) were added and the suspension was evacuated 4 times with H_2 and stirred under an H_2 -atmosphere for 19 h. The suspension was diluted with 10% EtOAc/hexane (250 mL (v/v)) and filtered through a short plug of silica gel (2 x 25 mL 20% EtOAc/hexane washings

(v/v)), evaporated and dried shortly under high vacuum. The residue was dissolved in EtOH (40 mL), Pd/C (10% (w/w), 142 mg) was added and the suspension was evacuated 4 times with H₂ and stirred under an H₂-atmosphere for 1 h. Additional Pd/C (10% (w/w), 190 mg) was added and the suspension was evacuated 4 times with H₂ and stirred under an H₂-atmosphere for 1.25 h. The suspension was evaporated on celite and purified by dry column vacuum chromatography (5.2 x 5.5 cm) on silica gel eluting with a gradient of 0-25% EtOAc in hexane (v/v) to give the corresponding alcohol (3.643 g, 80%) as a light yellow oil.

R_f (1:3 EtOAc/hexane (v/v)) 0.37; ¹H-NMR (300 MHz, CDCl₃) δ: 7.24 (2H, dd, *J* = 5.6, 8.7 Hz), 6.97 (2H, t, *J* = 8.7 Hz), 4.69 (1H, dt, *J* = 1.2, 5.0 Hz), 3.59 (2H, dt, *J* = 1.2, 6.2 Hz), 2.18 (1H, bs), 1.77-1.45 (4H, m), 0.87 (9H, s), 0.02 (3H, s), -0.15 (3H, s). ¹³C-NMR (75 MHz, CDCl₃) δ: 163.37, 160.13, 140.96, 140.91 (C), 127.32, 127.23, 114.94, 114.64, 74.16 (CH), 62.76, 37.19, 28.47 (CH₂), 25.76 (CH₃), 18.15 (C), -4.71, -5.05 (CH₃). IR (cm⁻¹): 3339, 2954, 2930, 2885, 2858, 1606, 1510, 1472, 1463, 1362, 1252, 1223, 1156, 1092, 1060, 984, 890, 836, 776, 668, 560. MALDI-MS (C₁₆H₂₇FO₂Si): [MNa]⁺ 321.1643 (calcd. 321.1662). Anal. Calcd for C₁₆H₂₇FO₂Si: C, 64.39; H, 9.12. Found: C, 64.36; H, 9.15.

The alcohol obtained above was dissolved in CH₂Cl₂ (50 mL), Dess-Martin periodinane (5.658 g, 13.3 mmol) was added and the milky solution was stirred at room temperature for 1.5 h. Sat. aq. Na₂SO₃ (100 mL) was added and the layers were swirled until the solid had dissolved. The layers were separated and the aqueous phase was extracted with CH₂Cl₂ (2 x 40 mL). The combined organic phase was evaporated on celite and purified by dry column vacuum chromatography (5.1 x 5.5 cm) on silica gel eluting with a gradient of 0-10% EtOAc in hexane (v/v) to give the corresponding aldehyde **XIXb** (2.093 g, 80%) as a light yellow oil.

R_f (1:3 EtOAc/hexane (v/v)) 0.63; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 9.73 (1H, d, $J = 1.5$ Hz), 7.25 (2H, dd, $J = 5.6, 8.7$ Hz), 6.99 (2H, t, $J = 9.0$ Hz), 4.74 (1H, dt, $J = 5.0, 6.8$ Hz), 2.52-2.35 (2H, m), 2.06-1.88 (2H, m), 0.88 (9H, s), 0.02 (3H, s), -0.16 (3H, s). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ : 201.91 (CH), 163.35, 160.10, 140.13 (C), 127.20, 127.10, 115.04, 114.75, 73.03 (CH), 39.69, 33.11 (CH_2), 25.85 (CH_3), 18.21 (C), -4.61, -4.95 (CH_3). IR (cm^{-1}): 2955, 2938, 2888, 2858, 2720, 1727, 1606, 1509, 1472, 1464, 1412, 1390, 1362, 1254, 1223, 1156, 1090, 1014, 837, 776, 670, 540. Anal. Calcd for $\text{C}_{16}\text{H}_{25}\text{FO}_2\text{Si}$: C, 64.82; H, 8.50. Found: C, 64.95; H, 8.36.

LiCl (140.8 mg, 3.32 mmol) was heated shortly with a heat gun under high-vacuum and after cooling, anhydrous CH_3CN (5 mL), phosphonate **XIXc** (prepared according to Melekhov, A.; Fallis, A. G. *Tetrahedron Lett.* **1999**, 40, 7867-7870; 660 mg, 1.68 mmol) and DBU (221 mg, 1.45 mmol) were added sequentially. After 3 min stirring, the aldehyde **XIXb** (407.3 mg, 1.37 mmol) was added and the suspension was stirred at room temperature for 2.5 h followed by addition of 50% sat. aq. NaHCO_3 (60 mL). After extraction with ether/hexane (1:1 (v/v), 4 x 25 mL), the combined organic layer was washed with brine (25 mL), evaporated on celite and purified by dry column vacuum chromatography (4.6 x 3.3 cm) on silica gel eluting with a gradient of 0-20% EtOAc in hexane (v/v) to give olefin **XIXd** (520.7 mg, 71%) as a colourless oil.

R_f (1:3 EtOAc/hexane (v/v)) 0.43; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 7.25 (2H, dd, $J = 5.6, 8.7$ Hz), 7.10-6.94 (3H, m), 6.53 (1H, d, $J = 14.9$ Hz), 4.65 (1H, dd, $J = 5.0, 7.5$ Hz), 3.91 (1H, dd, $J = 5.6, 6.8$ Hz), 3.50 (1H, d, $J = 13.7$ Hz), 3.42 (1H, d, $J = 13.7$ Hz), 2.30-2.23 (2H, m), 2.09-2.02 (2H, m), 1.90-1.70 (5H, m), 1.43-1.30 (2H, m), 1.15 (3H, s), 0.95 (3H, s), 0.85 (9H, s), 0.01 (3H, s), -0.20 (3H, s). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ : 163.88, 163.39, 160.14, 150.06, 140.63 (C), 127.35, 127.26, 120.91,

114.98, 114.69, 73.24, 64.99 (CH), 53.04 (CH₂), 48.33, 47.67 (C), 44.58 (CH), 38.61, 38.39, 32.71, 28.32, 26.40 (CH₂), 25.72, 20.72, 19.78 (CH₃), 18.04 (C), -4.74, -5.10 (CH₃). IR (cm⁻¹): 2956, 2885, 2859, 1684, 1640, 1605, 1509, 1472, 1414, 1374, 1332, 1295, 1250, 1220, 1165, 1134, 1083, 1049, 995, 970, 860, 836, 774, 544. MALDI-MS (C₂₈H₄₂FNO₄SSi): [MNa]⁺ 558.2479 (calcd. 558.2486). Anal. Calcd for C₂₈H₄₂FNO₄SSi: C, 62.77; H, 7.90; N, 2.61. Found: C, 62.84; H, 7.78; N, 2.58.

Olefin **xixd** was dissolved in anhydrous toluene (2.0 mL), TMSCHN₂ (2 M in hexanes, 1.50 mL, 3.0 mmol) was added and the solution was stirred at room temperature for 64 h. After evaporation, the residue was dissolved in CH₂Cl₂ (10 mL), TFA (202 mg, 1.77 mmol) was added and the solution was stirred for 20 min. Sat. aq. NaHCO₃ (1.5 mL) was added and the mixture was evaporated on celite and purified by dry column vacuum chromatography (4.5 x 3.3 cm) on silica gel eluting with a gradient of 0-40% EtOAc in hexane (v/v) to give the corresponding pyrazoline (468 mg, 84%) as a light yellow foam.

R_f (1:3 EtOAc/hexane (v/v)) 0.25; ¹H-NMR (300 MHz, CDCl₃) δ: 7.21 (2H, dd, *J* = 5.6, 8.7 Hz), 6.95 (2H, t, *J* = 8.7 Hz), 6.60 (1H, s), 6.16 (1H, d, *J* = 5.6 Hz), 4.65 (1H, t, *J* = 5.0 Hz), 4.33 (1H, dd, *J* = 5.9, 9.7 Hz), 3.87 (1H, dd, *J* = 5.0, 7.5 Hz), 3.67-3.62 (1H, bs), 3.53 (1H, d, *J* = 13.7 Hz), 3.44 (1H, d, *J* = 13.7 Hz), 2.15-1.99 (2H, m), 1.91-1.86 (3H, m), 1.66-1.51 (3H, m), 1.47-1.21 (3H, m), 1.14 (3H, s), 0.95 (3H, s), 0.86 (9H, s), 0.01 (3H, s), -0.17 (3H, s). ¹³C-NMR (75 MHz, CDCl₃) δ: 167.96, 163.12, 159.89 (C), 146.91 (CH), 140.52, 140.49 (C), 127.15, 127.05, 114.83, 114.54, 73.37, 66.44, 65.09 (CH), 52.81 (CH₂), 48.91 (C), 48.04 (CH), 47.79 (C), 44.33 (CH), 37.98, 37.79, 32.55, 26.76, 26.45 (CH₂), 25.82, 20.68, 19.84 (CH₃), 18.16 (C), -4.64, -4.90 (CH₃). IR (cm⁻¹): 3360, 2955, 2857, 1700, 1604, 1509, 1472, 1390, 1329, 1273, 1250, 1236, 1221, 1166, 1134,

1086, 1066, 994, 939, 836, 775, 694, 542. MALDI-MS ($C_{29}H_{44}FN_3O_4SSi$): $[MNa]^+$ 600.2691 (calcd. 600.2704). Anal. Calcd for $C_{29}H_{44}FN_3O_4SSi$: C, 60.28; H, 7.67; N, 7.27. Found: C, 60.25; H, 7.83; N, 7.16.

This pyrazoline (409.8 mg, 0.709 mmol), $Cu(OAc)_2$ (296 mg, 1.63 mmol) and $(p-FC_6H_4)_3Bi$ (prepared according to Banfi, A.; Bartolletti, M.; Bellora, E.; Bignotti, M.; Turconi, M. *Synthesis* **1994**, 775-776; 950 mg, 1.92 mmol) were dissolved in anhydrous CH_2Cl_2 (5 mL), anhydrous Et_3N (165 mg, 1.63 mmol) was added and the dark green suspension was stirred at room temperature for 12.5 h. After evaporation on celite the residue was purified by dry column vacuum chromatography (4.5 x 3.3 cm) on silica gel eluting with a gradient of 0-30% EtOAc in hexane (v/v) to give *N*-arylated pyrazoline **XIXe** (320.8 mg, 63%) as a light yellow foam.

R_f (1:3 EtOAc/hexane (v/v)) 0.33; 1H -NMR (300 MHz, $CDCl_3$) δ : 7.24 (2H, dd, J = 5.3, 8.4 Hz), 7.01-6.94 (4H, m), 6.89 (2H, t, J = 8.7 Hz), 6.68 (1H, d, J = 1.9 Hz), 5.05 (1H, d, J = 3.7 Hz), 4.62 (1H, t, J = 5.3 Hz), 3.85 (1H, dd, J = 4.4, 7.5 Hz), 3.59 (1H, d, J = 14.3 Hz), 3.58 (1H, d, J = 14.3 Hz), 3.41-3.35 (1H, m), 1.98-1.78 (5H, m), 1.72-1.60 (3H, m), 1.41-1.23 (3H, m), 1.21 (3H, s), 0.98 (3H, s), 0.88 (9H, s), 0.04 (3H, s), -0.17 (3H, s). ^{13}C -NMR (75 MHz, $CDCl_3$) δ : 169.54, 163.38, 160.14, 158.46, 155.30 (C), 142.10 (CH), 140.75 (C), 127.32, 127.22, 115.71, 115.40, 114.96, 114.67, 114.22, 114.12, 73.99, 65.48, 64.93 (CH), 53.02 (CH, CH_2), 49.05, 47.77 (C), 44.31 (CH), 37.98, 36.95, 32.76, 27.79, 26.25 (CH_2), 25.75, 20.37, 19.77 (CH_3), 18.07 (C), -4.77, -5.01 (CH_3). ^{19}F (282 MHz, $CDCl_3$) δ : -116.27 (1F, m), -125.73 (1F, septet, J = 4.3 Hz). IR (cm^{-1}): 2957, 2857, 1699, 1606, 1510, 1471, 1413, 1362, 1334, 1268, 1250, 1221, 1166, 1136, 1113, 1088, 1063, 987, 836, 776, 759, 538. MALDI-MS ($C_{35}H_{47}F_2N_3O_4SSi$): $[MH-TBDMSOH]^+$ 540.2127 (calcd. 540.2132); $[MNa]^+$

694.2909 (calcd. 694.2922). Anal. Calcd for $C_{35}H_{47}F_2N_3O_4SSi$: C, 62.56; H, 7.05; N, 6.25. Found: C, 62.37; H, 7.05; N, 6.03.

The *N*-arylated pyrazoline **XIXe** (101.5 mg, 0.151 mmol) was dissolved in anhydrous THF (5 mL) $-78^{\circ}C$, $LiAlH_4$ (33 mg, 0.87 mmol) was added and the suspension was stirred at $-78^{\circ}C$ for 4.5 h. Sat. aq. $NaHCO_3$ (1 mL) was added and the mixture was evaporated on celite and purified twice by dry column vacuum chromatography (4.6 x 2.0 cm) on silica gel eluting with a gradient of 0-30% EtOAc in hexane (v/v) to give the corresponding alcohol (52.7 mg, 76%) as a light yellow oil.

R_f (1:3 EtOAc/hexane (v/v)) 0.23; 1H -NMR (300 MHz, $CDCl_3$) δ : 7.23 (2H, dd, $J = 5.6, 8.7$ Hz), 7.04-6.92 (6H, m), 6.67 (1H, d, $J = 1.2$ Hz), 4.64 (1H, t, $J = 5.9$ Hz), 3.81 (1H, dd, $J = 4.0, 11.5$ Hz), 3.68-3.58 (2H, m), 3.12 (1H, dd, $J = 6.2, 6.8$ Hz), 1.86 (1H, bs), 1.77-1.67 (2H, m), 1.58-1.48 (2H, m), 0.86 (9H, s), 0.00 (3H, s), -0.17 (3H, s). ^{13}C -NMR (75 MHz, $CDCl_3$) δ : 163.47, 160.22, 158.83, 155.68 (C), 144.84 (CH), 142.35, 140.67, 140.62 (C), 127.26, 127.16, 115.75, 115.46, 115.11, 115.06, 114.96, 114.83, 73.76, 66.81 (CH), 62.37 (CH_2), 50.05 (CH), 37.72, 28.28 (CH_2), 25.75 (CH_3), 18.12 (C), -4.67, -5.01 (CH_3). ^{19}F (282 MHz, $CDCl_3$) δ : -115.25 (1F, septet, $J = 4.3$ Hz), -124.25 (1F, septet, $J = 4.3$ Hz). IR (cm^{-1}): 3401, 2953, 2930, 2885, 2858, 1672, 1605, 1509, 1472, 1463, 1416, 1362, 1296, 1252, 1223, 1156, 1086, 1006, 979, 938, 861, 835, 776, 666, 608, 554. MALDI-MS ($C_{25}H_{34}F_2N_2O_2Si$): [MH- CH_2O] 429.2175 (calcd. 429.2174); [M-H] $^+$ 459.2279 (calcd. 459.2279).

Subsequently this alcohol (70.8 mg, 0.154 mmol) was dissolved in anhydrous CH_2Cl_2 (5 mL), anhydrous Et_3N (0.50 mL, 3.9 mmol), DMAP (6.8 mg, 0.056 mmol) and TsCl (69 mg, 0.36 mmol) were added and the solution was stirred at room temperature for 12.5 h, evaporated on celite and purified by dry column vacuum chromatography

(4.4 x 2.0 cm) on silica gel eluting with a gradient of 0-20% EtOAc in hexane (v/v) to give the corresponding tosylate (78.4 mg, 83%) as a colourless oil.

R_f (1:3 EtOAc/hexane (v/v)) 0.44; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 7.68 (2H, d, $J = 8.7$ Hz), 7.25 (4H, t, $J = 8.1$ Hz), 6.99 (2H, t, $J = 8.7$ Hz), 6.92-6.80 (4H, m), 6.64 (1H, d, $J = 1.2$ Hz), 4.65 (1H, dd, $J = 4.4, 6.8$ Hz), 4.12 (1H, dd, $J = 2.5, 9.3$ Hz), 3.92-3.81 (2H, m), 3.08-3.01 (1H, m), 2.42 (3H, s), 1.80-1.43 (4H, m), 0.87 (9H, s), 0.01 (3H, s), -0.17 (3H, s). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3) δ : 163.49, 160.24, 158.59, 155.43, 145.16 (C), 143.40 (CH), 140.54, 132.21 (C), 129.84, 127.82, 127.32, 127.21, 115.79, 115.48, 115.12, 114.83, 114.31, 114.22, 73.50 (CH), 67.45 (CH_2), 62.42, 50.74 (CH), 37.35, 27.87 (CH_2), 25.77, 21.59 (CH_3), 18.10 (C), -4.67, -5.01 (CH_3). ^{19}F (282 MHz, CDCl_3) δ : -116.01 (1F, m), -125.40 (1F, septet, $J = 4.3$ Hz). IR (cm^{-1}): 3055, 3034, 2953, 2930, 2886, 2857, 1603, 1509, 1472, 1463, 1365, 1307, 1294, 1252, 1223, 1190, 1177, 1156, 1096, 979, 862, 835, 775, 666, 608, 555. MALDI-MS ($\text{C}_{32}\text{H}_{40}\text{F}_2\text{N}_2\text{O}_4\text{SSi}$): $[\text{MH-TBDMSOH}]^+$ 483.1559 (calcd. 483.1554); $[\text{MNa}]^+$ 637.2330 (calcd. 637.2344).

The tosylate received above was dissolved in anhydrous DMF (2.5 mL), hydroquinone (263 mg, 2.39 mmol) and Cs_2CO_3 (102.1 mg, 0.313 mmol) were added and the suspension was stirred at 80°C for 12 h. EtOAc (30 mL) was added and the organic phase was washed with sat. aq. NaHCO_3 (10 mL) and H_2O (10 mL), evaporated on celite and purified by dry column vacuum chromatography (4.5 x 2.0 cm) on silica gel eluting with a gradient of 0-30% EtOAc in hexane (v/v) to give the corresponding phenol **XIXf** (70.9 mg, 86%) as a colourless oil.

R_f (1:3 EtOAc/hexane (v/v)) 0.33; $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 7.24 (2H, dd, $J = 5.3, 8.4$ Hz), 7.06-6.93 (6H, m), 6.75-6.68 (5H, m), 4.67 (1H, dd, $J = 4.4, 6.8$ Hz), 4.10-3.98 (2H, m), 3.74 (1H, dd, $J = 1.2, 7.5$ Hz), 3.17-3.11 (1H, m), 1.86-1.54 (4H, m), 0.88


(9H, s), 0.02 (3H, s), -0.15 (3H, s). ^{13}C -NMR (75 MHz, CDCl_3) δ : 163.32, 160.08, 158.48, 155.35, 152.31, 149.86 (C), 143.85 (CH), 141.52, 141.49, 140.63 (C), 127.23, 127.12, 115.99, 115.73, 115.51, 115.44, 115.04, 114.75, 114.67, 114.57, 73.78 (CH), 67.79 (CH_2), 63.88, 51.51 (CH), 37.77, 28.38 (CH_2), 25.89 (CH_3), 18.25 (C), -4.46, -4.80 (CH_3). ^{19}F (282 MHz, CDCl_3) δ : -115.31 (1F, m), -124.71 (1F, septet, $J = 4.3$ Hz). IR (cm^{-1}): 3350, 3056, 2953, 2930, 2885, 2858, 1605, 1509, 1472, 1462, 1362, 1297, 1226, 1156, 1100, 1086, 1050, 1006, 939, 828, 776, 667, 609, 553, 518. MALDI-MS ($\text{C}_{31}\text{H}_{38}\text{F}_2\text{N}_2\text{O}_3\text{Si}$): $[\text{MH-TBDMSOH}]^+$ 421.1720 (calcd. 421.1728); $[\text{MH}]^+$ 553.2677 (calcd. 553.2698); $[\text{MNa}]^+$ 575.2505 (calcd. 575.2517).

The phenol **XIXf** (18.4 mg, 0.0333 mmol) was dissolved in anhydrous THF (1.0 mL, teflon bottle) at 0°C, anhydrous pyridine (0.20 mL) followed by HF-pyridine complex (0.20 mL) were added and the solution was allowed to warm to room temperature over several h and stirred at room temperature for 22 h. Ether (20 mL) was added and the solution was washed with sat. aq. NaHCO_3 (2 x 5 mL), evaporated on celite and purified by dry column vacuum chromatography (4.5 x 2.0 cm) on silica gel eluting with a gradient of 0-60% EtOAc in hexane (v/v) to give the desired diol **XIX** (14.4 mg, 99%) as a colourless oil.

R_f (1:1 EtOAc/hexane (v/v)) 0.27; ^1H -NMR (300 MHz, CDCl_3) δ : 7.29 (2H, dd, $J = 5.3, 8.4$ Hz), 7.06-6.93 (6H, m), 6.75-6.67 (5H, m), 4.70 (1H, t, $J = 6.5$ Hz), 4.09-4.03 (2H, m), 3.72 (1H, t, $J = 10.0$ Hz), 3.18 (1H, dd, $J = 4.4, 6.2$ Hz), 1.99-1.50 (4H, m). ^{13}C -NMR (75 MHz, CDCl_3) δ : 163.72, 160.47, 155.31, 152.26, 149.95 (C), 143.53 (CH), 141.41, 139.78 (C), 127.41, 127.29, 116.01, 115.77, 115.51, 115.23, 114.54, 114.42, 73.49 (CH), 67.60 (CH_2), 63.67, 51.35 (CH), 35.89, 28.70 (CH_2). ^{19}F (282 MHz, CDCl_3) δ : -114.89 (1F, septet, $J = 4.3$ Hz), -124.64 (1F, septet, $J = 4.3$ Hz). IR (cm^{-1}): 3320, 2927, 1604, 1508, 1453, 1366, 1225, 1157,

1102, 1044, 910, 826, 733, 609. MALDI-MS ($C_{25}H_{24}F_2N_2O_3$): $[MH-H_2O]^+$ 421.1717 (calcd. 421.1728); $[M]^+$ 438.1755 (calcd. 438.1755); $[MH]^+$ 439.1825 (calcd. 439.1833); $[MNa]^+$ 461.1650 (calcd. 461.1653).

Example 16



The phenol **XIXf** obtained in step 15a) (28.4 mg, 0.0514 mmol) was dissolved in anhydrous CH_2Cl_2 (2 mL), anhydrous pyridine (0.10 mL, 1.3 mmol) and $MsCl$ (0.05 mL, 0.51 mmol) were added and the solution was stirred at room temperature for 22.5 h, evaporated on celite and purified by dry column vacuum chromatography (4.5 x 2.0 cm) on silica gel eluting with a gradient of 0-50% EtOAc in hexane (v/v) to give the corresponding mesylate (29.2 mg, 90%) as a colourless oil.


R_f (1:1 EtOAc/hexane (v/v)) 0.64; 1H -NMR (300 MHz, $CDCl_3$) δ : 7.26-7.17 (6H, m), 7.06-6.94 (6H, m), 6.83 (2H, d, J = 9.3 Hz), 6.71 (1H, d, J = 1.2 Hz), 4.66 (1H, dd, J = 4.4, 6.8 Hz), 4.11 (1H, dd, J = 4.0, 9.0 Hz), 4.04 (1H, dt, J = 4.4, 7.5 Hz), 3.81 (1H, dd, J = 7.5, 8.7 Hz), 3.11 (3H, s), 3.19-3.08 (1H, m), 1.85-1.52 (4H, m), 0.87 (9H, s), 0.01 (3H, s), -0.16 (3H, s). ^{13}C -NMR (75 MHz, $CDCl_3$) δ : 160.25, 158.65, 157.92, 157.23, 155.50 (C), 143.67 (CH), 142.93, 141.52, 140.67 (C), 127.30, 127.19, 123.18, 115.85, 115.56, 115.45, 115.14, 114.85, 114.64, 114.53, 73.76 (CH), 67.53 (CH_2), 63.54, 51.60 (CH), 37.75 (CH_2), 37.09 (CH_3), 28.29 (CH_2), 25.78 (CH_3), 18.13 (C), -4.63, -4.98 (CH_3). ^{19}F (282 MHz, $CDCl_3$) δ : -116.00 (1F, m), -125.47 (1F, septet, J = 4.3 Hz). IR (cm^{-1}): 2930, 2857, 1605, 1508, 1472, 1369, 1299, 1251, 1223, 1197, 1168, 1152, 1086, 1009, 970, 868, 836, 776,

609, 527. MALDI-MS ($C_{32}H_{40}F_2N_2O_5SSi$): $[MH-TBDMSOH]^+$ 499.1504 (calcd. 499.1503); $[MNa]^+$ 653.2298 (calcd. 653.2293).

This mesylate (29.0 mg, 0.0460 mmol) was dissolved in anhydrous THF (1.0 mL, teflon bottle) at 0°C, anhydrous pyridine (0.20 mL) followed by HF-pyridine complex (0.20 mL) were added and the solution was allowed to warm to room temperature over several h and stirred at room temperature for 10 h. Ether (20 mL) was added and the solution was washed with sat. aq. $NaHCO_3$ (2 x 5 mL), evaporated on celite and purified by dry column vacuum chromatography (4.6 x 2.0 cm) on silica gel eluting with a gradient of 0-90% EtOAc in hexane (v/v) to give the desired mesylate **XX** (23.0 mg, 97%) as a colourless oil.

R_f (1:1 EtOAc/hexane (v/v)) 0.18; 1H -NMR (300 MHz, $CDCl_3$) δ : 7.30 (2H, dd, J = 5.6, 8.7 Hz), 7.18 (2H, d, J = 9.3 Hz), 7.06-6.94 (6H, m), 6.83 (2H, d, J = 9.3 Hz), 6.73 (1H, d, J = 1.2 Hz), 4.70 (1H, dd, J = 5.6, 6.8 Hz), 4.14-4.07 (2H, m), 3.84-3.77 (1H, m), 3.19-3.14 (1H, m), 3.10 (3H, s), 1.94 (1H, bs), 1.92-1.54 (4H, m). ^{13}C -NMR (75 MHz, $CDCl_3$) δ : 163.72, 160.47, 158.50, 157.04, 155.35 (C), 143.35 (CH), 142.82, 141.30, 141.26, 139.84 (C), 127.36, 127.26, 123.11, 115.81, 115.52, 115.41, 115.25, 114.52, 114.42, 73.44 (CH), 67.37 (CH_2), 63.44, 51.43 (CH), 37.20 (CH_3), 35.97, 28.73 (CH_2). ^{19}F (282 MHz, $CDCl_3$) δ : -114.06 (1F, m), -124.49 (1F, septet, J = 4.3 Hz). IR (cm^{-1}): 3550, 3404, 2936, 1604, 1508, 1366, 1299, 1249, 1223, 1196, 1168, 1151, 1039, 970, 913, 870, 835, 743, 528. MALDI-MS ($C_{26}H_{26}F_2N_2O_5S$): $[MH-H_2O]^+$ 499.1500 (calcd. 499.1503); $[M]^+$ 516.1536 (calcd. 516.1504); $[MH]^+$ 517.1606 (calcd. 517.1609); $[MNa]^+$ 539.1428 (calcd. 539.1428).

Example 17



To a solution of acid **XXIa** (prepared according to B. A. Shinkre, V. G. Puranik, B. M. Bhawal, A. Deshmukh, *Tetrahedron: Asymmetry* **2003**, *14*, 453; 30.0 g, 102 mmol, 1.11 equiv) in CH_2Cl_2 (600 ml) is added triethylamine (64.0 ml, 461 mmol, 5.00 equiv) followed by imine **XXIb** (prepared according to T. Kambara, K. Tomioka, *J. Org. Chem.* **1999**, *64*, 9282; 28.1 g, 92.1 mmol, 1.00 equiv). The solution is cooled to $-20\text{ }^\circ\text{C}$ and triphosgene (16.4 g, 55.8 mmol, 0.600 equiv) is added in 50 ml CH_2Cl_2 over a period of 20 min. The solution is warmed to $23\text{ }^\circ\text{C}$ over a period of 8 h and stirred for additional 10 h at this temperature. The solution is poured onto 600 ml ice water and 200 ml CH_2Cl_2 . The aqueous phase is extracted with CH_2Cl_2 (3 * 100 ml). The combined organic phases are washed with brine, dried (Na_2SO_4) and concentrated in vacuo. The residue is purified by chromatography on silica gel eluting with hexane/ ethyl acetate (3/2 to 1/2 gradient) and then chromatography on silica gel eluting with EtOAc/ CH_2Cl_2 (7/1 to 3/1 gradient) to afford β -lactam **XXIc** as a colorless solid in 40 % yield along with 35 % yield of the undesired diastereomer.

mp: 132 °C. R_f = 0.38 (hexane/ ethyl acetate 1/1). α_D = +77°, (CHCl₃, c = 1.075, 30.5 °C). ¹H-NMR (300 MHz, CDCl₃): δ 7.46-7.07 (m, 16 H), 6.92-6.84 (m, 2 H), 5.34 (d, J = 5.3 Hz, 1 H), 5.06 (s, 2 H), 4.95 (d, J = 5.3 Hz, 1 H), 4.60 (d, J = 2.5 Hz), 3.23 - 3.14 (m, 1 H), 2.90 (s, 3 H), 1.70 (s, 3 H), 0.83 (d, J = 6.2 Hz). ¹³C-NMR (75 MHz, CDCl₃): δ 165.4, 165.0, 159.3 (J = 244 Hz), 159.1, 137.1 (J = 5 Hz), 133.7, 129.9, 128.9, 128.6, 128.3, 128.0, 127.7, 125.7, 119.0 (J = 8 Hz), 116.0 (J = 23 Hz), 115.1, 100.1, 76.9, 71.2, 70.1, 62.2, 59.0, 33.8, 23.6, 12.4. IR (thin film): 2938, 1756, 1667, 1612, 1511, 1382, 1223, 1177, 1112, 1092, 834, 734. HRMS (EI): Calcd' for (C₃₅H₃₃FN₂O₅⁺), 580.2374, found, 580.2369.

To a solution of β -lactam **XXIc** (17.0 g, 29.0 mmol, 1.00 equiv) in THF (242 ml) and water (48 ml) is added *p*-toluenesulfonic acid hydrate (55.7 g, 293 mmol, 10.0 equiv). The solution is heated to reflux for 5 h. The solution is concentrated to an approximate volume of 60 ml and then poured onto EtOAc (150 ml) and water (250 ml). The aqueous phase is extracted with EtOAc (4 * 100 ml). The combined organic phases are washed with brine, dried (Na₂SO₄) and concentrated in vacuo. The residue is purified by chromatography on silica gel eluting with hexane/ ethyl acetate (3/2 to 2/3 gradient) to afford the corresponding 3-hydroxy- β -lactam as a colorless solid in 51 % yield.

mp: 168 °C. R_f = 0.26 (hexane/ ethyl acetate 3/2). α_D = -129°, (acetone, c = 1.22, 29.5 °C). ¹H-NMR (300 MHz, acetone): δ 7.50-7.47 (m, 2 H), 7.42-7.29 (m, 5 H), 7.10-7.01 (m, 4 H), 5.33 (d, J = 5.3 Hz, 1 H), 5.27 (dd, J = 7.2 Hz, 5.3 Hz, 1 H), 5.11 (s, 2 H), 5.07 (d, J = 7.2 Hz, 1 H). ¹³C-NMR (75 MHz, acetone): δ 166.5, 159.2, 159.0 (J = 241 Hz), 137.7, 134.7, 129.6, 128.6, 128.0, 127.8, 118.9 (J = 8 Hz), 115.8 (J = 23 Hz), 114.8, 78.0, 69.8, 62.3. IR (thin film): 3120, 1756, 1667, 1612, 1511, 1382,

1223, 1177, 1112, 1092, 834, 734. HRMS (EI): Calcd' for ($C_{22}H_{18}FNO_3^+$), 363.1271, found, 363.1268. Anal. Calcd. for $C_{22}H_{18}FNO_3$: C, 72.72; H, 4.99; N, 3.85; found: C, 77.73; H, 5.20; N, 3.91.

To a suspension of this 3-hydroxy- β -lactam (2.00 g, 5.50 mmol, 1.00 equiv) in methanol (55.0 ml) is added sodium methoxide (1.49 g, 27.5 mmol, 5.00 equiv). The suspension is stirred at 23 °C for 2 h. To the forming solution is added $NH_4Cl_{(s)}$ and the suspension is concentrated in vacuo. To the solid is added EtOAc (50 ml) and water (50 ml). The aqueous phase is extracted with EtOAc (3 * 20 ml). The combined organic phases are washed with brine, dried (Na_2SO_4) and concentrated in vacuo. The residue is purified by chromatography on silica gel eluting with hexane/ethyl acetate (3/2 to 1/1 gradient) to afford the corresponding amino alcohol as a colorless solid in 89 % yield.

mp: 103 °C. R_f = 0.45 (hexane/ ethyl acetate 3/2). α_D = +13.9°, (CH_2Cl_2 , c = 1.10, 25.3 °C. 1H -NMR (300 MHz, $CDCl_3$): δ 7.44-7.24 (m, 4 H), 6.97-6.91 (m, 2 H), 6.84-6.76 (m, 2 H), 6.53-6.46 (m, 2 H), 5.02 (s, 2 H), 4.81 (s, 1 H), 4.60 (s, 1 H), 4.46 (m, 1 H), 3.79 (s, 3 H), 3.07 (d, J = 3.7 Hz, 1 H). ^{13}C -NMR (75 MHz, $CDCl_3$), : δ 158.2, 155.8 (J = 233 Hz), 142.5, 136.8, 131.0, 128.5, 127.9, 127.9, 127.4, 155.5 (J = 22 Hz), 114.9, 114.8, 74.6, 70.0, 59.1, 53.1, 114.8, 78.0, 69.8, 62.3. IR (thin film): 3390, 1737, 1610, 1510, 1221, 1113, 823. MS (EI): 306.1748 (2.54 %), 186.2356 (18.8 %, 91.0908 (100 %). Anal. Calcd. for $C_{23}H_{22}FNO_4$: C, 69.86; H, 5.61; N, 3.54; found: C, 69.88; H, 5.78; N, 3.54.

To a solution of the amino alcohol received above (1.92 g, 4.86 mmol, 1.00 equiv) in CH_2Cl_2 (24.0 ml) is added diisopropylethylamine (2.54 ml, 14.6 mmol, 3.00 equiv) and 4-*N,N*-dimethylaminopyridine (59.0 mg, 0.486 mmol, 0.10 equiv). The solution is cooled to -78 °C and triphosgene (1.44 g, 4.86 mmol,

1.00 equiv) in CH_2Cl_2 (4.0 ml) is added over a period of 5 min. The solution is warmed to 23 °C over 8 h and stirred at this temperature for additional 5 h. To this solution is added water (50 ml) and concentrated aqueous ammonium hydroxide solution (3 ml). The aqueous phase is extracted with CH_2Cl_2 (3 * 20 ml). The combined organic phases are washed with brine, dried (Na_2SO_4) and concentrated in vacuo. The residue is purified by chromatography on silica gel eluting with hexane/ ethyl acetate (2/1 to 1/1 gradient) to afford methyl ester **XXId** as a colourless solid in 82 % yield.

mp: 118 °C. R_f = 0.54 (hexane/ ethyl acetate 3/2). α_D = +18°, (CHCl_3 , c = 1.10, 29.3 °C). ^1H -NMR (300 MHz, CDCl_3): δ 7.40–7.32 (m, 7 H), 7.29–7.22 (m, 2 H), 6.98–6.93 (m, 4 H), 5.33 (d, J = 4.4 Hz, 1 H), 5.03 (s, 2 H), 4.73 (d, J = 4.4 Hz, 1 H), 3.89 (s, 3 H). ^{13}C -NMR (75 MHz, CDCl_3): δ 168.9, 160.1 (d, J = 244 Hz), 159.7, 154.3, 136.7, 132.7, 129.5, 128.9, 128.4, 127.8, 127.7, 123.2 (d, J = 8 Hz), 116.1 (d, J = 22 Hz), 116.0, 77.9, 70.3, 36.6, 53.5. IR (thin film): 1769, 1552, 1388, 1227, 1099, 834. HRMS (MALDI): Calcd' for $(\text{C}_{24}\text{H}_{20}\text{FNO}_5\text{Na}^+)$, 444.1224, found, 444.1224. Anal. Calcd. for $\text{C}_{24}\text{H}_{20}\text{FNO}_5$: C, 68.40; H, 4.78; N, 3.32; found: C, 68.18; H, 4.91; N, 3.38.

To a suspension of methyl ester **XXId** (1.68 g, 3.99 mmol, 1.00 equiv) in ethanol (27.0 ml) is added at 23 °C sodium cyanoborohydride (226 mg, 5.98 mmol, 1.50 equiv). The suspension is stirred for 2 h at this temperature at which point all solids were dissolved. To this solution is added $\text{NH}_4\text{Cl}_{(s)}$ and the volume is concentrated in vacuo to 5 ml. To this suspension is added water (50 ml) and EtOAc (50 ml). The aqueous phase is extracted with EtOAc. The combined organic phases are washed with brine, dried (Na_2SO_4) and concentrated in vacuo. The residue is purified by chromatography on silica gel eluting with hexane/ ethyl acetate (1/1 to 2/3 gradient) to afford the corresponding alcohol

as a colorless solid in 92 % yield.

mp: 143 °C. R_f = 0.40 (hexane/ ethyl acetate 2/3). α_D = -16°, (CHCl₃, c = 1.54, 32.4 °C). ¹H-NMR (300 MHz, CDCl₃): δ 7.42-7.19 (m, 9 H), 6.97-6.90 (m, 4 H), 5.26 (d, J = 6.5 Hz, 1 H), 5.02 (s, 2 H), 4.39 (m, 1 H), 3.99 (d, J = 12.5 Hz, 1 H), 3.74 (d, J = 12.5 Hz, 1 H), 2.77 (s, 1 H). ¹³C-NMR (75 MHz, CDCl₃),: δ 159.7 (d, J = 245 Hz), 159.0, 136.4, 132.7, 129.4, 128.5, 128.0, 127.9, 127.4, 123.6 (d, J = 8 Hz), 115.6 (d, J = 22 Hz), 115.6, 82.0, 70.1, 61.6, 61.2. IR (thin film): 3418, 2930, 2871, 1748, 1611, 1512, 1394, 1234. HRMS (EI): Calcd' for (C₂₃H₂₀FNO₄⁺), 393.1376, found, 393.1389. Anal. Calcd. for C₂₃H₂₀FNO₄: C, 70.22; H, 5.12; N, 3.56; found: C, 70.26; H, 5.21; N, 3.61.

To a solution of oxalylchloride (508 mg, 4.00 mmol, 2.00 equiv) in CH₂Cl₂ (15.0 ml) is added at -78 °C dimethylsulfoxide (0.355 ml, 5.00 mmol, 2.50 equiv). After 10 min at -78 °C is added the alcohol received above (787 mg, 2.00 mmol, 1.00 equiv) in CH₂Cl₂ (15.0 ml) over a period of 5 min. After additional 5 min at this temperature triethylamine (1.14 ml, 8.00 mmol, 8.00 equiv) is added. After 5 min 1-(4-Fluoro-phenyl)-2-(triphenyl- λ^5 -phosphanylidene)-ethanone is added and the resulting suspension is warmed to 20 °C and stirred for additional 30 min. To the solution is added saturated aqueous Na₂HCO₃ solution. The aqueous phase is extracted with CH₂Cl₂. The combined organic phases are washed with brine, dried (Na₂SO₄) and concentrated in vacuo. The residue is purified by chromatography on silica gel eluting with hexane/ ethyl acetate (2/1 to 1/1 gradient) to afford the corresponding enone as a colorless solid in 89 % yield.

mp: 152 °C. R_f = 0.56 (hexane/ ethyl acetate 3/2). α_D = +100°, (CHCl₃, c = 0.60, 25.6 °C). ¹H-NMR (300 MHz, CDCl₃): δ 8.06-7.99 (m, 2 H), 7.42-7.06 (m, 14 H), 7.00-6.92 (m, 4 H), 5.05-5.00 (m, 4 H). ¹³C-NMR (75 MHz, CDCl₃),: δ 187.1, 165.9 (d, J = 254 Hz), 159.8 (d, J = 243 Hz), 159.4, 154.8, 140.0, 136.2, 133.2, 132.3,

131.4 (*d*, *J* = 9 Hz), 128.6, 128.1, 128.1, 127.9, 127.4, 125.8, 123.5 (*d*, *J* = 9 Hz), 115.9 (*d*, *J* = 24 Hz), 115.8 (*d*, *J* = 24 Hz), 115.8, 80.5, 70.2, 66.0. IR (thin film): 1760, 1675, 1597, 1511, 1385, 1227. HRMS (MALDI): Calcd' for (C₃₁H₂₃F₂NO₄Na⁺), 534.1493, found, 534.1482. Anal. Calcd. for C₃₁H₂₃F₂NO₄: C, 72.79; H, 4.53; N, 2.74; found: C, 72.51; H, 4.78; N, 2.73.

To this enone (910 mg, 1.78 mmol, 1.00 equiv) in ethanol (15.0 ml) is added at 23 °C palladium on carbon (10 %) (100 mg). The suspension is vigorously stirred under 1 atm of hydrogen gas for 3 h. The suspension is filtered through a pad of celite eluting with EtOAc concentrated and the residue is purified by chromatography on silica gel eluting with hexane/ ethyl acetate (2/1 to 1/1 gradient). A portion of the resulting benzyl ether (310 mg, 0.604 mmol, 1.00 equiv) is dissolved in CH₂Cl₂ and cooled to -20 °C. (R)-3,3-diphenyl-1-methyltetrahydro-3H-pyrrolo-oxazaborole-2-methyl-oxazaborolidin (solution in toluene (0.5 M) 0.600 ml, 0.302 mmol, 0.50 equiv) is added followed by borane dimethylsulfide complex (0.080 ml, 0.905 mmol, 1.50 equiv). The solution is stirred at -20 °C for 2 h, then warmed to 0 °C and quenched with methanol. To the solution is added saturated aqueous Na₂HCO₃ solution and CH₂Cl₂. The aqueous phase is extracted with CH₂Cl₂. The combined organic phases are washed with brine, dried (Na₂SO₄) and concentrated in vacuo. The residue is purified by chromatography on silica gel eluting with hexane/ ethyl acetate (3/2 to 1/1 gradient). A portion of the resulting alcohol (53 mg, 0.10 mmol, 1.0 equiv) is dissolved in ethanol and palladium on carbon (10 mg) is added. The suspension is vigorously stirred under an atmosphere of hydrogen for 2.5 h. The suspension is filtered through a plug of celite eluting with EtOAc. The residue is purified by chromatography on silica gel eluting with hexane/ ethyl acetate (1/1 to 1/2 gradient) to afford the desired oxazolidinone **XXI** as a colorless solid in 57 % yield

from the starting enone.

mp: 98 °C. R_f = 0.41 (hexane/ ethyl acetate 2/3). α_D = -1°, (CHCl₃, c = 0.84, 27.6 °C). ¹H-NMR (300 MHz, acetone d₆): δ 7.47-7.35 (m, 4 H), 7.29-7.24 (m, 2 H), 7.09-6.97 (m, 4 H), 6.85-6.79 (m, 2 H), 5.15 (d, J = 6.7 Hz, 1H), 4.76-4.68 (m, 1 H), 4.43-4.34 (m, 2 H), 2.02-1.76 (m, 4 H). ¹³C-NMR (75 MHz, acetone d₆): δ 162.0 (d, J = 243 Hz), 159.5 (d, J = 242 Hz), 157.9, 155.3, 142.2 (d, J = 3 Hz), 134.3 (d, J = 2 Hz), 129.1, 128.7, 127.8 (d, J = 8 Hz), 123.8 (d, J = 9 Hz), 116.1, 115.2 (d, J = 23 Hz), 114.9 (d, J = 21 Hz), 82.4, 72.3, 65.6, 35.0, 30.3. IR (thin film): 3316, 2925, 1726, 1603, 1511, 1224, 835. HRMS (MALDI): Calcd' for (C₂₄H₂₁F₂NO₄Na⁺), 448.1337, found, 448.1326.

Example 18


The compounds of the invention and ezetimibe (commercially obtained or prepared according to Wu, G. Z. et al., *J. Org. Chem.* **1999**) together with the glucuronide (the metabolite of ezetimibe, prepared according to Vaccaro, W. D.; Davis, H. R. *Bioorg. Med. Chem. Lett.* **1998**, 8, 313-318) as appropriate reference compounds were evaluated by well-established methods to determine their inhibition of cholesterol uptake in rabbit brush border membrane vesicles (BBMV) (Table 1). Briefly, the scavenger receptor-mediated uptake of radiolabelled cholesterol ester from the loaded donor particles into the BBMV bilayer was measured in the presence of various compounds of the invention and appropriate reference compounds (Hauser, H. et al., *Biochemistry* **1998**, 37, 17843-17850; Werder, M. et al., *Biochemistry* **2001**, 40, 11643-11650; Boffelli, D. et al., *FEBS Lett.* **1997**, 411, 7-11.)

Table 1:

Compound	applied in donor SUV (9 mol%) Inhibition in (%)
Ezetimibe	16 ± 4
Glucuronide	19 ± 4
VI	30 ± 4
VII	22 ± 2
VIII	15 ± 3
IXb	20 ± 5
IX	27 ± 4
X	15 ± 3
XI	20 ± 5
XIV	26 ± 3
XV	19 ± 3
XVI	21 ± 5
XVII	28 ± 4
XVIII	41 ± 4
XXI	19 ± 2

Claims

1. A compound according to formula I



wherein

P represents $-N<$ or $-C=$,





X represents independently of each other $-CH_2-$, CR_1 (sp_2 -hybridised), O, $-NH-$, $=N-$, $-CO-$ or $-CS-$, wherein R_1 represents H or NR_2 , wherein R_2 represents H or lower alkyl, which optionally is linked to Z such that a bicyclic structure is formed;

n represents 1 or 2,

R_a represents H, lower alkyl, $-OR_3$, $-O(CO)R_3$, $-O(CO)OR_3$, $-O(CO)NR_3R_4$, $-NR_3R_4$, $-NR_3(CO)R_4$, $-COOR_3$, $-CONR_3R_4$, $-CH=CHCOOR_3$, $-CF_3$, $-CN$, $-NO_2$, SO_3H , PO_3H or halogen, wherein R_3 and R_4 represent H or lower alkyl,

R_b represents H, OH, $-OSO_2Me$, $-OSO_2W$ wherein W represents optionally substituted aryl or heteroaryl, $-OCO(CHOH)_2COOR_5$ wherein R_5 represents H or lower alkyl; or represents the formula $-Sp_3-R_6$, wherein Sp_3 represents a covalent bond, $-O-$, $-OCH_2-$, $-OSO_2CH_2-$, $-OSO_2-$, $-OSO_2-(p)C_6H_4O-$ and R_6 represents one of carbohydrate structures A-D:

82

**A****B****C****D**

wherein

R_7 , R_8 , R_9 , R_{11} , R_{12} , R_{13} and R_{14} represent independently of each other H, lower alkyl, aryl(lower alkyl), -CO-lower alkyl, -CO-aryl, -SO₃⁻ or -PO₃⁻,

R_{10} represents -CH₂OR₁₆ or -COOR₁₇, and

R_{15} represents -CH₂OR₁₆, -COOR₁₇, -CH₂NH₂, -CH₂OPO₃⁻ or -CH₂OSO₃⁻, wherein R_{16} and R_{17} independently of each other represent H, lower alkyl, aryl(lower alkyl), -CO-lower alkyl, -CO-aryl, -SO₃⁻ or -PO₃⁻,

Z represents optionally substituted aryl or heteroaryl,

Sp_1 represents a spacer unit, such as a straight-chain or branched lower alkyl group -(CH₂)_p-, wherein p is from 2-6, which is unsubstituted, mono or poly-substituted by -OH, -OR₁₈, halogen or cyano group, wherein one or more -CH₂- groups may independently be replaced by -O-, -CO-, -CO-O-, -O-CO-, -NR₁₉-, -NR₁₉-CO-, -CO-NR₁₉-, -CH=CH-, -C≡C- and wherein R_{18} and R_{19} represent a hydrogen atom or lower alkyl;

Sp_2 represents an optional spacer unit, such as a covalent bond or a straight-chain or branched lower alkyl group -

$(\text{CH}_2)_q-$, wherein q is from 1-6, which is unsubstituted, mono or poly-substituted by $-\text{OH}$, $-\text{OR}_{20}$, halogen or cyano group, wherein one or more $-\text{CH}_2-$ groups may independently be replaced by $-\text{O}-$, $-\text{CO}-$, $-\text{CO}-\text{O}-$, $-\text{O}-\text{CO}-$, $-\text{NR}_{21}-$, $-\text{NR}_{21}-\text{CO}-$, $-\text{CO}-\text{NR}_{21}-$, $-\text{CH}=\text{CH}-$, $-\text{C}\equiv\text{C}-$ and wherein R_{20} and R_{21} represents a hydrogen atom or lower alkyl;

Y represents optionally substituted aryl or heteroaryl,

with the proviso, that if $\text{P} = -\text{N}<$, $n=1$, $\text{X} = -\text{CO}-$ and Sp_2 represents a covalent bond, R_6 may not represent carbohydrate structures A or D for $\text{Sp}_3 = -\text{O}-$ and R_6 may not represent carbohydrate B for $\text{Sp}_3 = -\text{OCH}_2-$.

2. A compound according to claim 1,

with the proviso, that if $\text{P} = -\text{N}<$, $n=1$, $\text{X} = -\text{CO}-$ and Sp_2 represents a covalent bond, R_6 may not represent H or OH and Sp_3 may not represent a covalent bond, $-\text{O}-$ or $-\text{OCH}_2-$.

3. A compound according to claims 1 or 2 wherein $\text{P} = -\text{N}<$, $n = 1$ and $\text{X} = -\text{CO}-$, $-\text{CS}-$, $-\text{CH}_2-$ or $-\text{NH}-$.


4. A compound according to claims 1 or 2 wherein $\text{P} = -\text{N}<$, $n = 1$ and $\text{X} = -\text{CS}-$, $-\text{CH}_2-$ or $-\text{NH}-$.

5. A compound according to claims 1 or 2 wherein $\text{P} = -\text{N}<$ and $-(\text{X})_n = -\text{OOC}-$, $-\text{COO}-$, $-\text{CONH}-$, $-\text{CH}=\text{N}-$.

6. A compound according to claims 1 or 2 wherein $\text{P} = -\text{C}=$ and $-(\text{X})_n = -\text{NH}-\text{N}=$ or $-\text{O}-\text{N}=$.

7. A compound according to claims 1 or 2 having the formula IVa


84



IVa

wherein R_a , R_b , SP_1 , SP_2 , P , X , Y , Z and n are as defined in claims 1 or 2.

8. A compound according to claims 1 or 2 having the formula IVb,



IVb

wherein R_a , R_b , SP_1 , P , X and n are as defined hereinabove and wherein R_{21} and R_{22} represent H, lower alkyl, lower alkoxy or halogen.

9. A compound according to claims 7 or 8 wherein $P = -N<$, $n = 1$ and $X = -CO-$, $-CS-$, $-CH_2-$ or $-NH-$.
10. A compound according to claims 7 or 8 wherein $P = -N<$, $n = 1$ and $X = -CS-$, $-CH_2-$ or $-NH-$.
11. A compound according to claims 7 or 8 wherein $P = -N<$ and $-(X)_n- = -OOC-$, $-COO-$, $-CONH-$, $-CH=N-$.
12. A compound according to claims 7 or 8 wherein $P = -C=$ and $-(X)_n- = -NH-N=$ or $-O-N=$.
13. A pharmaceutical composition comprising a therapeutically

effective amount of a compound of any preceding claim with a pharmaceutically acceptable carrier.

14. A pharmaceutical composition according to claim 13 for the treatment or prevention of arteriosclerosis or for the reduction of cholesterol levels.
15. A kit comprising a pharmaceutical composition according to claim 13 for use in the treatment or prevention of arteriosclerosis or for the reduction of cholesterol levels.
16. A method for the treatment or prevention of arteriosclerosis or for the reduction of cholesterol levels comprising administering to a subject in need of such treatment an effective amount of a compound according to claims 1 to 12.
17. Use of a compound according to claims 1 to 12 for the manufacture of a medicament for the treatment or prevention of arteriosclerosis or for the reduction of cholesterol levels.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CH2004/000584

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D405/04 C07H15/00 C07D205/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D C07H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>MUKERJEE A K ET AL: "RAPID SYNTHESIS OF DEHYDROPEPTIDES CARRYING A BETA-LACTAM MOIETY"</p> <p>JOURNAL OF CHEMICAL RESEARCH. SYNOPSES, LONDON, GB, no. 7, 1993, pages 280-281, XP009027094</p> <p>ISSN: 0308-2342</p> <p>the whole document</p> <p>-----</p> <p>-/--</p>	1-3,7-9

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

28 October 2004

Date of mailing of the international search report

08/11/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Klein, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CH2004/000584

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>VAN HECK, MARGARET ET AL: "In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461"</p> <p>JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (1997), 283(1), 157-163, 1997, XP002275919</p> <p>figure 1</p> <p>-----</p>	1-3,7-9, 13-17
X	<p>WU, GEORGE GUANGZHONG: "A Concise Asymmetric Synthesis of A.beta.-Lactam-Based Cholesterol Absorption Inhibitor"</p> <p>ORGANIC PROCESS RESEARCH & DEVELOPMENT (2000), 4(4), 298-300, 2000, XP002275920</p> <p>the whole document</p> <p>-----</p>	1-3,7-9, 13-17
X	<p>UDUPI, R.H. ET AL: "Synthesis of 1-(2-carboxy-5-nitrophenyl)-3,4-substituted azetidin-2-ones as antiinflammatory and antimicrobial agents"</p> <p>INDIAN JOURNAL OF HETEROCYCLIC CHEMISTRY (1996), 6(2), 99-102, 1996, XP009027043</p> <p>the whole document</p> <p>-----</p>	1-3
X	<p>CLADER, JOHN W. ET AL: "2-Azetidinone Cholesterol Absorption Inhibitors: Structure-Activity Relationships on the Heterocyclic Nucleus"</p> <p>JOURNAL OF MEDICINAL CHEMISTRY (1996), 39(19), 3684-3693, 1996, XP002275922</p> <p>the whole document</p> <p>-----</p>	1-3,7-9, 13-17
X	<p>OTTO H-H ET AL: "STEREOCHEMIE DER DEHYDRATISIERUNG UND HALOGENIERUNG DER ALPHAR- UND ALPHAS-ISOMERE VON 3-(ALPHA-HYDROXYBENZYL)-1,4-DIPHENYL-2-AZETIDINONEN STEREOCHEMISTRY OF DEHYDRATION AND HALOGENATION OF ALPHAR AND ALPHAS ISOMERIC 3-(ALPHA-HYDROXYBENZYL)-1,4-DIPHENYL"</p> <p>LIEBIGS ANNALEN DER CHEMIE, VERLAG CHEMIE GMBH. WEINHEIM, DE, no. 7, 1983, pages 1162-1168, XP001179959</p> <p>ISSN: 0170-2041</p> <p>the whole document</p> <p>-----</p> <p style="text-align: center;">-/--</p>	1-3,7-9

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CH2004/000584

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BROWNE, MARGARET ET AL: "Trans diastereoselective synthesis of 3-alkyl substituted.beta.-lactams via the acid chloride-imine reaction of nonactivated acid chlorides" TETRAHEDRON LETTERS (1995), 36(15), 2555-8, 1995, XP004028248 the whole document -----	1-3,7-9, 13-17
X	BOSE, AJAY K. ET AL: "Studies on lactams. 101. Microwave-assisted rapid synthesis of.alpha.-amino-.beta.-lactams" TETRAHEDRON LETTERS (1996), 37(39), 6989-6992, 1996, XP004030806 the whole document -----	1-3,7-9
X	VAN LEUSEN, ALBERT M. ET AL: "Chemistry of sulfonylmethyl isocyanides. 12. Base-induced cycloaddition of sulfonylmethyl isocyanides to carbon,nitrogen double bonds. Synthesis of 1,5-disubstituted and 1,4,5-trisubstituted imidazoles from aldimines and imidoyl chlorides" JOURNAL OF ORGANIC CHEMISTRY (1977), 42(7), 1153-9, 1977, XP002275923 the whole document -----	1-3,7,9
X	BURNETT, DUANE A. ET AL: "Synthesis of 3-(1-hydroxyethyl)-2-azetidinones via ester-imine condensations" JOURNAL OF ORGANIC CHEMISTRY (1985), 50(25), 5120-3, 1985, XP002275924 the whole document -----	1-3,7-9
X	BURNETT, DUANE A. ET AL: "2-Azetidinones as Inhibitors of Cholesterol Absorption" JOURNAL OF MEDICINAL CHEMISTRY (1994), 37(12), 1733-6, 1994, XP002275925 the whole document -----	1,2,5-10
X	ROSENBLUM, STUART B. ET AL: "Synthesis of 3-arylpropenyl, 3-arylpropynyl and 3-arylpropyl 2-azetidinones as cholesterol absorption inhibitors: application of the palladium-catalyzed arylation of alkenes and alkynes" TETRAHEDRON (2000), 56(31), 5735-5742, 2000, XP004213804 the whole document -----	1-3,7-9, 13-17
	-/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CH2004/000584

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KIRKUP M P ET AL: "(-)-SCH 57939: synthesis and pharmacological properties of a potent, metabolically stable cholesterol absorption inhibitor" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 6, no. 17, 3 September 1996 (1996-09-03), pages 2069-2072, XP004135657 ISSN: 0960-894X the whole document	1-3,7-9, 13-17
X	OTTO H-H ET AL: "DARSTELLUNG UND STEREOCHEMIE VON 3-(ALPHA-HYDROXYBENZYL)-1,4-DIPHENYL-2-AZETIDINONEN SYNTHESIS AND STEREOCHEMISTRY OF 3-(ALPHA-HYDROXYBENZYL)-1,4-DIPHENYL-2-AZETIDINONES" LIEBIGS ANNALEN DER CHEMIE, VERLAG CHEMIE GMBH. WEINHEIM, DE, 1983, pages 1152-1161, XP001012817 ISSN: 0170-2041 the whole document	1-3,7-9
X	ROSENBLUM, STUART B. ET AL: "Discovery of 1-(4-Fluorophenyl)-(3R)-3-(4-fluorophenyl)-(3S)-hydroxypropyl-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption" JOURNAL OF MEDICINAL CHEMISTRY (1998), 41(6), 973-980, 1998, XP002275926 the whole document	1-3,7-9, 13-17
X	BURNETT, DUANE A. ET AL: "Synthesis of fluorescent biochemical tools related to the 2-azetidinone class of cholesterol absorption inhibitors" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2002), 12(3), 315-318, 2002, XP002275927 the whole document	1-3,7-9, 13-17
X	BURNETT, DUANE A. ET AL: "Synthesis of iodinated biochemical tools related to the 2-azetidinone class of cholesterol absorption inhibitors" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2002), 12(3), 311-314, 2002, XP002275928 the whole document	1-3,7-9, 13-17
X	US 5 631 365 A (ROSENBLUM STUART B) 20 May 1997 (1997-05-20) the whole document	1-3,7-9, 13-17
	-/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CH2004/000584

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 524 595 A (SCHERING CORP) 27 January 1993 (1993-01-27) the whole document -----	1-3, 7-9, 13-17
X	WO 00/63703 A (SCHERING CORP) 26 October 2000 (2000-10-26) the whole document -----	1-3, 7-9, 13-17
X	US 5 633 246 A (DUGAR SUNDEEP ET AL) 27 May 1997 (1997-05-27) the whole document -----	1-3, 7-9, 13-17
X	WO 02/50090 A (SCHERING CORP) 27 June 2002 (2002-06-27) the whole document -----	1-3, 7-9, 13-17
X	DE 36 20 467 A (CIBA GEIGY AG) 2 January 1987 (1987-01-02) the whole document -----	1-3, 7-9, 13-17
X	WO 03/026643 A (SCHERING CORP) 3 April 2003 (2003-04-03) * the whole document, in particular page 42 formula X, XI * -----	1-3, 7-9, 13-17
X	US 5 756 470 A (VAN HECK MARGARET ET AL) 26 May 1998 (1998-05-26) the whole document -----	1-17
X	WO 97/16455 A (SCHERING CORP) 9 May 1997 (1997-05-09) the whole document -----	1-17
X	US 2003/119428 A1 (DAVIS HARRY R ET AL) 26 June 2003 (2003-06-26) the whole document -----	1-17

INTERNATIONAL SEARCH REPORT

national application No.
PCT/CH2004/000584

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-7, 9-17
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Continuation of Box II.2

Claims Nos.: 1-7, 9-17

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty or inventive step. So many documents were retrieved that it is impossible to determine which parts of the claims may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT).

Furthermore, present claims 1-7, 9-17 relate to an extremely large number of possible compounds. In fact, the claims contain so many options, variables or possible permutations that a lack of clarity (and conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear (and concise), namely claim 8.

Nevertheless, most of the references cited are also relevant to the subject-matter of claims 1-7, 9-17.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CH2004/000584

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5631365	A	20-05-1997	AT 180249 T	15-06-1999
			AU 681445 B2	28-08-1997
			AU 7795294 A	10-04-1995
			CA 2172149 C	28-11-2000
			CN 1131416 A ,B	18-09-1996
			CZ 9600839 A3	14-08-1996
			CZ 288891 B6	12-09-2001
			DE 10399001 I1	12-06-2003
			DE 69418613 D1	24-06-1999
			DE 69418613 T2	30-09-1999
			DK 720599 T3	08-11-1999
			EP 0720599 A1	10-07-1996
			ES 2132432 T3	16-08-1999
			FI 961300 A	21-03-1996
			GR 3030312 T3	30-09-1999
			HU 73852 A2	30-09-1996
			IL 110956 A	11-01-2001
			JP 2803908 B2	24-09-1998
			JP 8509989 T	22-10-1996
			KR 186853 B1	01-05-1999
			MA 23332 A1	01-04-1995
			NL 300132 I1	01-10-2003
			NO 961133 A	20-03-1996
			NZ 274041 A	19-12-1997
			PL 313589 A1	08-07-1996
			RU 2138480 C1	27-09-1999
			SG 46208 A1	20-02-1998
			SK 35596 A3	05-02-1997
			TW 427974 B	01-04-2001
			WO 9508532 A1	30-03-1995
			US RE37721 E1	28-05-2002
			US 5767115 A	16-06-1998
			US 5846966 A	08-12-1998
			ZA 9407086 A	14-03-1995
EP 0524595	A	27-01-1993	AT 158789 T	15-10-1997
			AU 658441 B2	13-04-1995
			AU 2398092 A	23-02-1993
			BG 61118 B2	29-11-1996
			CA 2114007 A1	04-02-1993
			CN 1069024 A	17-02-1993
			CZ 9400142 A3	13-07-1994
			DE 69222532 D1	06-11-1997
			DE 69222532 T2	26-02-1998
			EE 9400342 A	15-04-1996
			EP 0524595 A1	27-01-1993
			EP 0596015 A1	11-05-1994
			ES 2107548 T3	01-12-1997
			FI 940296 A	21-01-1994
			HU 67341 A2	28-03-1995
			IE 922374 A1	27-01-1993
			JP 2525125 B2	14-08-1996
			JP 6508637 T	29-09-1994
			MX 9204327 A1	29-07-1994
			NO 940221 A	21-01-1994
			NZ 243669 A	22-12-1994
			OA 9878 A	15-09-1994
			SK 7994 A3	06-07-1994

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CH2004/000584

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0524595	A		WO 9302048 A1	04-02-1993
			US 6093812 A	25-07-2000
			US 5561227 A	01-10-1996
			US 5688785 A	18-11-1997
			US 5688787 A	18-11-1997
			US 5306817 A	26-04-1994
			ZA 9205487 A	31-03-1993
WO 0063703	A	26-10-2000	AU 4343500 A	02-11-2000
			WO 0063703 A1	26-10-2000
			US 2003215869 A1	20-11-2003
			US 6593078 B1	15-07-2003
			US 2002009714 A1	24-01-2002
US 5633246	A	27-05-1997	US 5624920 A	29-04-1997
			AT 213726 T	15-03-2002
			AU 698750 B2	05-11-1998
			AU 4140196 A	17-06-1996
			BR 9509669 A	28-10-1997
			CA 2205202 A1	30-05-1996
			CN 1174548 A ,B	25-02-1998
			CZ 9701486 A3	12-11-1997
			DE 69525643 D1	04-04-2002
			DE 69525643 T2	26-09-2002
			DK 792264 T3	22-04-2002
			EP 0792264 A1	03-09-1997
			ES 2169162 T3	01-07-2002
			FI 972099 A	16-05-1997
			HK 1002558 A1	14-06-2002
			HU 77088 A2	02-03-1998
			JP 2908031 B2	21-06-1999
			JP 9512833 T	22-12-1997
			KR 235806 B1	01-02-2000
			NO 972272 A	16-05-1997
			NZ 296720 A	29-03-1999
			PL 320092 A1	15-09-1997
			PT 792264 T	31-07-2002
			RU 2159243 C2	20-11-2000
			SK 61697 A3	10-12-1997
			WO 9616037 A1	30-05-1996
			US 5744467 A	28-04-1998
WO 0250090	A	27-06-2002	AT 279425 T	15-10-2004
			AU 3104902 A	01-07-2002
			BR 0116212 A	30-12-2003
			CA 2432798 A1	27-06-2002
			CN 1483039 T	17-03-2004
			CZ 20031674 A3	15-10-2003
			EP 1347987 A1	01-10-2003
			HU 0302269 A2	28-10-2003
			JP 2004516299 T	03-06-2004
			NO 20032806 A	19-08-2003
			SK 7702003 A3	07-10-2003
			WO 0250090 A1	27-06-2002
			US 2002137690 A1	26-09-2002
			US 2003105028 A1	05-06-2003
DE 3620467	A	02-01-1987	DE 3620467 A1	02-01-1987

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CH2004/000584

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03026643	A	03-04-2003	CA 2460340 A1 EP 1429756 A2 WO 03026643 A2 US 2003119809 A1	03-04-2003 23-06-2004 03-04-2003 26-06-2003
US 5756470	A	26-05-1998	NONE	
WO 9716455	A	09-05-1997	AT 219495 T AU 712158 B2 AU 7517996 A BR 9611401 A CA 2235943 A1 CN 1205707 A , B CZ 9801294 A3 DE 69621952 D1 DE 69621952 T2 DK 877750 T3 EP 0877750 A1 ES 2175141 T3 HK 1012507 A1 HU 9802539 A2 ID 16177 A JP 10512592 T JP 3385031 B2 JP 2001048895 A NO 981950 A NZ 321766 A PL 327987 A1 PT 877750 T SK 48398 A3 TW 448181 B WO 9716455 A1 ZA 9609089 A	15-07-2002 28-10-1999 22-05-1997 05-01-1999 09-05-1997 20-01-1999 14-10-1998 25-07-2002 16-01-2003 15-07-2002 18-11-1998 16-11-2002 18-10-2002 30-11-1998 11-09-1997 02-12-1998 10-03-2003 20-02-2001 26-06-1998 29-07-1999 04-01-1999 30-09-2002 04-11-1998 01-08-2001 09-05-1997 29-04-1997
US 2003119428	A1	26-06-2003	US 2003105028 A1 US 2003119757 A1 US 2003119796 A1	05-06-2003 26-06-2003 26-06-2003